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Abstract 
Bacteroides fragilis is the most common anaerobe isolated from clinical infections and in 
this report we demonstrate a novel feature of the species that is critical to their success as an 
opportunistic pathogen. Among the Bacteroides spp. in the gut, B. fragilis has a unique ability to 
efficiently harvest complex N-linked glycans from the glycoproteins common to serum and 
serous fluid. This activity is mediated by a Sus-like outer membrane protein complex designated 
as Don. Using the abundant serum glycoprotein transferrin as a model it was shown that B. 
fragilis alone can rapidly and efficiently deglycosylate this protein in vitro and that transferrin 
glycans can provide the sole source of carbon and energy for growth in defined media.  We 
then showed that transferrin deglycosylation occurs in vivo when B. fragilis is propagated in the 
rat tissue cage model of extraintestinal growth and that this ability provides a competitive 
advantage in vivo over strains lacking the don locus. Thus, Don functionally is an extraintestinal 
growth factor that may contribute to B. fragilis opportunistic infection.  
The regulation of don expression is controlled by two independent pathways. The first 
one was shown to be a typical ECF sigma/anti-sigma factor switch, commonly found in Sus-like 
Polysaccharide Utilization Loci (PULs), which responds to the presence of specific substrate. In 
the ECF sigma factor deletion mutant, ΔdonA, expression of the don PUL was completely 
abolished in the presence of substrate glycans, while the cognate anti-sigma deletion strain,  
ΔdonB, expressed the don genes even in the absence of substrate glycans. The donA 
overexpressing strain highly expressed the don PUL regardless of the substrate glycan presence. 
The second regulatory pathway is involved with a cis-encoded antisense sRNA which is 
associated within the don locus, DonS. DonS was shown to negatively regulate don expression. 
In contrast, expression of the don genes was induced two- to six-fold in the donS silencing 
mutant and highly repressed in the donS overexpressing strain. Notably, this sRNA controlled 
regulatory pathway is not commonly found associated with B. fragilis PULs. Only 14 of more 
than 50 PULs in B. fragilis possess DonS-like sRNAs, but at the present time their roles in 
commensal colonization and opportunistic infections is not understood. 
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CHAPTER ONE: INTRODUCTION 
                This dissertation mainly focuses on the study of a Sus-like polysaccharide utilization 
locus (PUL) in Bacteroides fragilis, named don. The impetus for studying this locus was derived 
from the fact that in the rat artificial abscess model, its expression was the most up-regulated in 
the B. fragilis transcriptome compared to in vitro growth. This indicates that the don locus may 
play a role in adaption to extraintestinal environments. Also, in an analysis of the B. fragilis 
primary transcriptome using RNA deep sequencing, a novel feature was observed of cis-
encoded small RNAs associated with 14 PULs in B. fragilis, including don. Thus, the major 
objectives of this dissertation research were: first, characterize the role of don in colonization of 
extraintestinal sites (chapter 2); second, elucidate the role of sRNAs in the regulation of the Sus-
like systems in B. fragilis, using the don locus as a model (chapter 4). Also included in this 
dissertation is a brief description of the B. fragilis primary transcriptome analysis since it led to 
the initial discovery of the sRNAs involved in the PUL regulation (chapter3). This chapter 
(chapter 1) is a general review on the current understanding of Bacteroides physiology and 
metabolism as it relates to virulence factors and the Sus-like polysaccharides utilization 
systems. 
 
1.1   Bacteroides taxonomy, structure, physiology and metabolism 
                The genus Bacteroides are Gram-negative, obligate anaerobic bacteria commonly 




microflora (1). The type species of Bacteroides is B. fragilis, so sometimes the genus is referred 
to as the Bacteroides fragilis group. This genus falls within the family Bacteroidaceae of the 
order Bacteroidales of the phylum Bacteroidetes. Together with the closely related genera 
Porphyomonas and Prevotella, they make up a major subgroup of the Cytophaga-Flavobacter-
Bacteroides group which diverged from the primary eubacterial phylogenic lineage very early in 
evolution (2) and consequently are not closely related to the Gram-negative Proteobacteria 
which are more commonly studied. 
                All Bacteroides are non-motile, non-spore formers with relatively large genomes 
ranging in size from 4.4 to 6.7 Mb and relatively low in GC content ranging from 39% to 48% (1). 
The cell morphology is short rods and the doubling time under optimal growth conditions is 
approximately 45 minutes. Bacteroides have capsules which are important for their 
colonization in the distal gut (3). B. fragilis has eight different capsule polysaccharide encoding 
loci on its genome which are different in size, composition and staining character. Coexpression 
of two capsule polysaccharides is commonly observed (4-6). On the cell surface, Bacteroides 
possess pilli- or fimbrae-like structures that serve for attachment (1). Under transmission 
electron microscopy, numerous blebs on the cell surface and detached extracellular vesicles can 
be observed (7). These vesicles have been shown to have hemagglutinin function and contain 
sialidase activity (8, 9). The lipopolysaccharide (LPS) of Bacteroides is different from the 
canonical LPS structure represented by E. coli LPS. The lipid A in Bacteroides LPS is penta-
acylated and monophosphorylated and the fatty acids chains are branched, 15 to 17 units long 
in contrast to the unbranched 12 or 14 unit length of canonical LPS (10). This structure probably 




Bacteroides also have a rare O-glycsosylation system which enables them to synthesize 
fucosylated glycoproteins (11). The model for this general O-glycsosylation proposes that the 
glycan chain is assembled on a lipid carrier on the inner side of the cytoplasmic membrane by 
the sequential action of glycosyltransferases, then the glycan is flipped to the periplasmic space 
and glycosylation of the target protein happens there. The fucosylated O-linked glycoproteins 
then are inserted into the outer membrane surface and play a role in the colonization in the gut 
(12). 
                Bacteroides are saccharolytic organisms that primarily use carbohydrates as their 
carbon/energy source (1). They can express a large number of outer membrane protein 
complexes for polysaccharide transport and utilization (13). An in-depth review of these outer 
membrane complexes in Bacteroides will be given later in this chapter. Once the 
polysaccharides have been hydrolyzed to their monosaccharide units, further carbohydrate 
catabolism proceeds through the Embden-Meyerhof pathway followed by a split TCA cycle 
composed of two opposing half-cycles termed the oxidative branch and the reductive branch 
(1, 14). A simplified schematic diagram of this split TCA cycle is shown in Fig. 1.1. Anaerobic 
respiration makes use of the reductive branch of the TCA cycle with fumarate as the terminal 
electron receptor, reduced to succinate mediated by a membrane-bound fumarate reductase 
(1). Interestingly, Bacteroides also possess a cytochrome bd oxidase which allows them to use 
oxygen as a terminal receptor when oxygen is at nanomolar levels (15). Under nanomolar 
oxygen levels (60 nM to 1000 nM), the growth benefit of this cytochrome bd oxidase can be 




However, as obligate anaerobes, Bacteroides cannot grow with oxygen levels close or above 2 
μM (15). 
                 Heme is important for Bacteroides metabolism during normal growth. However 
Bacteroides cannot synthesize heme de novo and it must be obtained from the environment 
(1). When grown in the absence of heme, their metabolism shifts from anaerobic respiration to 
strictly fermentation since heme is required as a cofactor by two critical components of the 
electron transport chains, fumarate reductase and cytochrome bd oxidase (1). Under these 
conditions, fumarate and lactate will accumulate as the metabolic byproducts instead of the 
short chain fatty acids succinate and propionate (1). During anaerobic respiration, fumarate is 
constantly consumed as the final electron receptor and reduced to succinate. The large demand 
for fumarate is provided by carboxylation of phosphoenolpyruvate to oxaloacetate, and then by 
enzymes of the reductive branch of the TCA cycle (1, 14). Carbon dioxide is required for the 
Bacteroides anaerobic respiration since it is the substrate for the carboxykinase to catalyze the 





























                As saccharolytic bacteria, Bacteroides cannot use proteins or peptides as the sole 
carbon/energy source but they can use them as the sole nitrogen source, although ammonia is 
the more preferred nitrogen source (1). Ammonia assimilation in Bacteroides is primarily 
through incorporation of ammonia into α-ketoglutarate to form glutamate catalyzed by 
glutamate dehydrogenase (1). Glutamate serves as an amino group donor for the synthesis of 
other amino acids. α-ketoglutarate biosynthesis is achieved through the reductive branch of the 
split TCA cycle in the presence of heme, alternatively, the oxidative branch in the absence of 
heme (14) (Fig. 1.1). The Bacteroides, with the possible exception of B. ovatus, synthesize all of 
their amino acids de novo (1). 
 
1.2   The mutualistic relationship between Bacteroides and their hosts 
                The human distal gut is one of the most densely populated microbial ecosystems on 
earth, exceeding numbers of 1011 per gram of wet weight, and Bacteroides is one of the 
predominant species making up to 25% of the total microbial population in this ecological niche 
(1, 7, 16). A strong mutualistic relationship between the Bacteroides and their hosts has 
developed over the course of coevolution (16, 17).  
               The human large intestine provides an ideal space for the Bacteroides to thrive: 
sufficient moisture; highly reducing environment with oxygen levels less than 1.5%; carbon 
dioxide levels of 5% - 10%; adequate amount of ammonia, heme and vitamin B12; and most 
importantly a stable source of carbon/energy from the constant influx of polysaccharides from 




important role in shaping the gut microflora composition including the Bacteroides species (18-
20, 22). 
In return for the food and shelter, Bacteroides provide multiple benefits to their host. 
The breakdown and conversion of the indigestible dietary fiber to short chain fatty acids by the 
Bacteroides provides the host an additional nutrition source which can meet up to 10% of the 
human energy requirement (1, 7, 23). Bacteroides also play important roles in the development 
of the host GI tract: their presence greatly increases the volume, surface area of and villi 
numbers in the GI tract (1). They participate in the development of gut associated lymphatic 
tissue (GALT) and gut angiogenesis (24). They prevent the attachment and colonization of 
pathogenic bacteria by occupying the mucosal surface of the gut to form a protective barrier. B. 
thetaiotaomicron can also help prevent infection by Gram-positive species by promoting 
induction of a host cell secreted bactericidal lectin named RegIIIγ, which can directly bind to the 
peptidoglycan and result in bacterial killing (25). B. thetaiotaomicron also stimulates the 
production of a certain type of immune cell in the gut crypts called Paneth cells which secrete 
an antimicrobial substance to kill specific pathogens such as Listeria monocytogenes (26). B. 
fragilis in the gut can help the host develop a healthy immune response and prevent allergies 
(27). This is mediated in part by the capsule polysaccharide, polysaccharide A (PSA), which is a 
zwitterion, unlike most other capsule polysaccharides which are only negatively charged. PSA 
can bind to major histocompatibility complex II molecules in the professional antigen 
presenting cells and be presented to the T cells. It has been show that PSA can prevent 
inflammation by triggering the IL-10 mediated anti-inflammatory response at the same time 




cell deficiency and establish Th1/Th2 balance in the gut (28, 29). The beneficial effect of PSA 
immunomodulatory properties even can be seen in the brain. A recent study using a mouse 
model shows that a subset of neurodevelopmental disorders, including autism spectrum 
disorder (ASD), could be due to dysbiosis of the gut microbiota and GI barrier impairment. 
Harmful bacterial metabolites, for example 4-ethylphenylsulfate (4EPS), can pass the tight 
junctions between intestinal epithelial cells and enter blood stream circulation. These 
metabolites can cause autism-like symptoms in the host such as abnormalities in sociability, 
communication, compulsive activity and severe stereotypic behavior. Oral treatment with B. 
fragilis can alter the gut microbial composition, restore normal GI barrier permeability and 
correct the ASD-related behavioral abnormalities (30). Bacteroides can efficiently deconjugate 
bile salts in the gut. Deconjugated bile salts have a much lower reabsorption rate and lowered 
ability to solubilize diet cholesterols. Non-reabsorbed bile will be excreted which has the 
indirect affect to reduce cholesterol levels by forcing the host to use more cholesterols for 
biosynthesis of bile salts and decrease cholesterol absorption (31). Lastly, several reports have 
shown that there is an association between the intestinal Bacteroides population and obesity. 
Obese individuals tend to have an abnormally low Bacteroides to Firmicutes ratio (32, 33). In 
some studies, it was also found that the relative abundance of Bacteroides increases as obese 
individuals lose weight (34). It is still not clear whether there is a causal relationship between 






1.3   Bacteroides as opportunistic pathogens 
                Although the Bacteroides do provide many benefits as friendly commensals, they can 
transform into dangerous threats when translocated to extraintestinal sites. Bacteroides are 
frequently isolated from clinical anaerobic infections with high mortality (1, 7). Bacteroides 
fragilis, the type species of this group, only accounts for 0.5% of the colonic flora, but it is the 
most common anaerobe isolated from infections, being found in more than 63% of Bacteroides 
associated infections (1, 7). Thus, B. fragilis is regarded as the most virulent Bacteroides species 
and has served as a model for studying Bacteroides pathogenesis. Anaerobic infections are 
usually polymicrobial, and B. fragilis associated anaerobic infections have a mortality of more 
than 19%, up to 60% if left untreated (35).  
                B. fragilis opportunistic infections generally occur when the integrity of the intestinal 
wall is disrupted. Common predisposing conditions include GI surgery, trauma, malignancy and 
perforated inflammatory disease or infections in the GI tract (1, 7). B. fragilis associated 
infections include abscesses, appendicitis, bacteremia, bone and soft tissue infections, deep 
wound ulcers and UTI infections, but the most common and dangerous are intra-abdominal 
abscesses (IAA) (1, 7). IAA caused by B. fragilis are actually a pathologic immune response in 
which the immune cells are attracted to infected sites, if unable to clear the infection, 
additional immune cells are recruited to contain the bacterial cells and necrotic host tissue by 
walling them off with fibrin and connective tissues (36, 37). Once formed, antibiotic treatment 
has little effect on IAA and surgery is usually required. Rupture of the IAA without medical 




                It is also worthy to note that some strains of B. fragilis are able to produce the 
enterotoxin fragilysin. These strains are grouped as enterotoxigenic B. fragilis (ETBF) (92). ETBF 
can cause secretory diarrhea and studies have shown they also may be linked to inflammatory 
bowel disease and colon cancer (92). 
 
1.4   Virulence Mechanisms 
                Following translocation from the gut to an extraintestinal site, Bacteroides typically 
face several challenges to the establishment of a successful infection. First, they need to attach 
at the site of infection, withstand the increased oxygen tension and resist clearing mechanisms 
from the host immune system. Next, they must persist in the new environment where the 
available nutritional resources become very limited, and where they need to shift their diet 
from a combination of dietary glycans and host glycans to host glycans only. Bacteroides need 
to coordinately express a variety of virulence factors to meet these challenges (1). 
                The Bacteroides capsule is a major factor associated with infection and pathogenesis. 
It contributes to the virulence in several ways. First, the capsule plays an important role in 
adherence. It has been shown that the ability of B. fragilis and other Bacteroides to adhere to 
rat peritoneal mesothelium depended on the presence of capsular polysaccharide, while 
acapsular strains were less adherent (39). Purified capsular polysaccharide alone can compete 
with live bacterial cells and inhibit B. fragilis adherence to rat peritoneal mesothelium (39). 
Second, the capsule can help Bacteroides withstand host clearance mechanisms due to its anti-




antigenic variation. For example, a single strain of B. fragilis has the capacity to synthesize eight 
different capsular polysaccharides, designated PSA to PSH (41), and expression of these 
capsular polysaccharides are regulated by two independent mechanisms. One is DNA inversion 
by which the promoter region of each individual locus can flip to give it an “on” or “off” status 
(42, 43). This inversion is mediated by a global DNA invertase named Mpi (42, 44, 45). The 
second mechanism involves trans locus inhibition. Within each capsule polysaccharide synthesis 
locus, there are two regulatory genes that encode UpxY and UpxZ, where x is replaced by “a” to 
“h” corresponding to PSA to PSH. UpxY is an antiterminator which is necessary for the 
transcription of the full length message of that polysaccharide synthesis locus, and UpxZ is a 
trans locus inhibitor which interacts with several other UpxYs to cause premature termination 
of the transcription of other capsule synthesis loci (46, 47). The combined effect of these two 
regulatory mechanisms allows B. fragilis to switch its capsule composition so that no more than 
two types of capsular polysaccharides are expressed at the same time. This ability to change the 
architecture on the cell surface may result in antigenicity variation and evasion of host immune 
surveillance (48). In addition to adherence and immune evasion, the capsule plays a vital role in 
abscess formation (49). Injection of capsule polysaccharide alone is sufficient to induce abscess 
formation, while systemic injection prevents abscess formation in rats, presumably due to the 
establishment of an antibody response to the capsules (49-51). It also has been demonstrated 
that the capsular polysaccharides do not contribute equally to abscess formation; rather, PSA is 
the most potent among all the eight to facilitate abscess formation (52). PSA is a zwitterionic 




contains the amino sugar acetamido-amino-2, 4, 6-trideoxygalactose (AATGal) as a component 
sugar. These two properties were thought to boost the PSA’s abscess formation ability (49, 52). 
Extraordinary aerotolerance is another important factor associated with Bacteroides 
extraintestinal infection. When translocated from the colon to the peritoneal cavity, bacteria 
have to face the challenge of increased oxygen tension up to 6% in this new environment. 
Oxidative stress will generate dramatic amounts of intracellular reactive oxygen species (ROS) 
such as hydrogen peroxide, superoxide and hydroxyl radicals, and ROS cause damage in a cell 
by peroxidation of membrane lipids, oxidation of amino acids in proteins, destruction of iron-
sulfur clusters in enzymes, modification of DNA bases and strand breaks (53). Bacteroides, as 
strict anaerobes, cannot shift to a full aerobic metabolism but they can mount a sophisticated 
oxidative stress response that allows them to survive in oxygenated environments for extended 
periods of time. The oxidative stress response in B. fragilis has been well characterized, and can 
be divided into two phases. One is an acute response in which approximately 28 gene products 
involved in detoxification, repairing, and protection are quickly up-regulated within minutes of 
oxygen exposure (1, 54, 55). These gene products include catalase, peroxidase, superoxide 
dismutase, alkyl hydroperoxide reductase, and the non-specific DNA binding protein DPS, which 
all work synergistically to minimize the effect of ROS and to restore the reduced intracellular 
environment (54, 55). If the oxidative stress remains for an extended period, B. fragilis will 
mount a prolonged oxidative stress response (POST) in which there is a shift in gene expression 
aimed at remodeling the bacterial metabolism and physiology. This metabolic response induces 
genes encoding enzymes that can supply reducing power for detoxification and restore energy-




the most aerotolerant anaerobes on earth and enhances its survival in extraintestinal sites to 
allow it to cause infection (55).  
                Besides its capsules and oxidative stress response, B. fragilis also has other virulence 
traits. These include the ability to release outer membrane vesicles containing a variety of 
hydrolases and hemagglutinases (8, 9), expression of neuraminidinases, expression of 
hemolysins (54, 60), and release of proteases and enterotoxin (enterotoixigenic strains only) 
(92).  
 
1.5   The polysaccharide utilization systems in Bacteroides 
                Bacteroides are glycan utilization experts with extraordinary enzymatic abilities to 
degrade a wide variety of polysaccharides as carbon/energy sources (21). The human distal gut 
allows Bacteroides to exert their expertise by constantly providing a broad spectrum of 
polysaccharides, mostly undigested dietary glycans such as cellulose, pectin, xylan, and host 
derived glycans in the form of glycoconjugates such as glycoproteins, glycolipids and 
glycosaminoglycans (20, 22, 61). This ability explains in part why Bacteroides are so 
predominant in the distal gut (18, 19). 
                In Bacteroides genomes, genes encoding the machinery to degrade a specific type of 
polysaccharides are organized into multiple gene clusters, known as polysaccharide utilization 




a large portion of their genomes to these PULs. For instance, 18% of B. thetaiotaomicron 
genome is composed of these PULs (62).  
                Bacteroides PULs were first characterized in B. thetaiotaomicron using the starch 
utilization system (Sus), which specifically degrades starch, as a model. The sus locus contains 
eight genes susABCDEFGR. SusA and susB encode periplasmic amylases. SusC encodes a TonB-
linked outer membrane porin which is required to transport the processed starch 
oligosaccharides from outside of the cell to the periplasmic space. The susD gene encodes an 
outer membrane protein which binds the oligosaccharides and aids its transportation through 
the channel formed by SusC porin. Downstream genes susEFG encode gene products which will 
form an outer membrane complex with SusC and SusD and are important for recognition and 
processing of large starch molecules (63-66). SusR is a transcriptional activator which responds 
to the substrate in the periplasmic space (67). A functional model of the B. thetaiotaomicron 









Fig. 1.2. Functional model of the B. thetaiotaomicron starch utilization system (Sus) (68). 
Steps involved in processing starch are sequentially illustrated and numbered. Step 1, starch 
molecules transit through the capsule layer. Step 2, starch molecules are bound by outer 
membrane complex components such as SusD. Step 3, surface bound starch molecules are 
degraded and processed by outer membrane complex component glycohydrolase such as SusG, 
generating smaller oligosaccharides through the outer membrane porin SusC. Step 4, 
oligosaccharides are further degraded into component mono- or disaccharides by periplasmic 
glycan degrading enzymes SusA and SusB. Step 5 and 6, liberated glycan components serve as 
signal molecules for the transcriptional activator SusR that activate sus operon expression. Step 
7, degraded sugar units are imported in to the cytoplasm serving as a carbon/energy source.  
This figure is originally published on Journal of Biological Chemistry. Martens, E. C.; Koropatkin, 
N. M., Smith, T. J., Gordon, J. I. Complex glycan catabolism by the human gut microbiota: the 
Bacteroidetes Sus-like paradigm. Journal of Biological Chemistry. 2009. 283 (37): 24673-24677. 











                The B. thetaiotaomicron Sus system serves as a paradigm for all the Sus-like PULs in 
Bacteroides. These PULs encode similar outer membrane protein complexes for glycan 
utilization and are identified by sequence homology. Most PULs contain the SusC and SusD 
homolog with or without the presence of other downstream genes encoding outer membrane 
complex proteins, but in limited cases, only the SusC/SusD-like protein pair is present in the 
locus (7, 13). In contrast to the archetypical B. thetaiotaomicron Sus system, the most 
frequently observed genetic regulators of the PULs in B. fragilis are not SusR homologs but 
rather they are ECF sigma factor/anti sigma pairs, and in some cases two component regulatory 
systems.  
                Although there is a wide range of glycan substrates used by the Sus-like systems, each 
system generally only has one specific type of glycan as the substrate (68), and the Sus-like 
systems are not only limited in Bacteroides species but seen in the Bacteroidetes phylum (68). A 
few well-studied Sus-like systems are listed in Table 1.1.  
               The traditional catabolite repression/activation system which allows for the select 
utilization of a preferential carbon/energy source does not function in Bacteroides as they do 
not possess cyclic AMP (69). Although multiple Sus-like systems can be induced at the same 
time when their substrates are present, a recent study showed that there is a hierarchy in the 
expression of these Sus-like systems (22). The mechanism of how Bacteriodes define the 
hierarchy is not clear. Interestingly, there also appears to be a link between the expression of 
some specific Sus-like systems and polysaccharide capsule biosynthesis, but the mechanism is 





















CHAPTER TWO: EFFICIENT UTILIZATION OF COMPLEX N-LINKED 
GLYCANS IS A SELECTIVE ADVANTAGE FOR BACTEROIDES FRAGILIS IN 
EXTRAINTESTINAL INFECTIONS 
 
2.1   Abstract 
Bacteroides fragilis is the most common anaerobe isolated from clinical infections and in 
this report we demonstrate a novel feature of the species that is critical to their success as an 
opportunistic pathogen. Among the Bacteroides spp. in the gut, B. fragilis has a unique ability to 
efficiently harvest complex N-linked glycans from the glycoproteins common to serum and 
serous fluid. This activity is mediated by a Sus-like outer membrane protein complex designated 
as Don. Using the abundant serum glycoprotein transferrin as a model it was shown that B. 
fragilis alone can rapidly and efficiently deglycosylate this protein in vitro and that transferrin 
glycans can provide the sole source of carbon and energy for growth in defined media.  We 
then showed that transferrin deglycosylation occurs in vivo when B. fragilis is propagated in the 
rat tissue cage model of extraintestinal growth and that this ability provides a competitive 







2.2   Significance 
 The human microbiota has a huge impact on health from the proper development of the 
immune system to the maintenance of normal physiological processes.  The largest 
concentration of microbes is found in the colon which is home to more than 500 bacterial 
species most of which are obligate anaerobes. This population also poses a significant threat of 
opportunistic infection and of all the species present, Bacteroides fragilis is the one most 
frequently isolated from anaerobic, extraintestinal infections. New findings presented here 
describe a unique ability of this species to efficiently deglycosylate complex N-linked glycans 
from the most abundant glycoproteins found in serum and serous fluid. This provides B. fragilis 
a competitive, nutritional advantage for extraintestinal growth. 
 
2.3   Introduction 
The genus Bacteroides are Gram-negative, obligate anaerobic bacteria that account for 
approximately 30% of the microbiota in the human large intestine (1, 17). This relationship 
benefits the host by aiding in the development of a healthy immune response and in the 
maintenance of many physiological and nutritional processes. One major factor that 
contributes to the predominance of Bacteroides is their capacity to utilize a wide spectrum of 
polysaccharides ranging from dietary compounds that cannot be digested by the host, such as 
xylans or pectins, to the host derived glycans in the form of glyco-conjugates (19, 20). 
Polysaccharide digestion in the Bacteroides is mediated in large part by novel outer membrane 




genetic organization characterized by a regulatory region followed by an operon coding for 
orthologues of the TonB-dependent transporter, SusC, and the accessory binding protein SusD. 
Additional genes in the operon are for specific substrate binding and glycohydrolase enzymes 
(68). The genes for these protein complexes are termed polysaccharide utilization loci (PULs). 
In contrast to their beneficial role in the colon, Bacteroides species also are the most 
common opportunistic pathogens isolated from clinical specimens of anaerobic infections. 
These opportunistic infections can occur when the integrity of the intestinal wall becomes 
compromised. Predisposing conditions include intestinal surgery, perforated or gangrenous 
appendix, carcinoma, diverticulitis, trauma and inflammatory bowel diseases. Peritonitis and 
intra-abdominal abscesses are the most common infections associated with Bacteroides often 
leading to bacteremia (70). Notably, Bacteroides fragilis represents only 0.5% of the gut flora 
yet it is isolated in the majority of anaerobic infections, thus it is regarded as more invasive than 
the other Bacteroides (71-73). A number of factors have been identified that may contribute to 
its enhanced extraintestinal survival. For example, there is a variable polysaccharide capsule 
which interferes with immune surveillance and there is a robust oxidative stress resistance 
system but these attributes are not exclusive to B. fragilis (43, 52, 55). Another challenge faced 
by organisms invading from the colon is the need to adapt to different nutritional sources. In 
the gut, the Bacteroides rely on dietary polysaccharides and host derived glycans as sources of 
carbon/energy but when outside of the gut environment they will have more limited choices of 
only host derived glycans. The ability to efficiently harvest glycans present on host 




In this report we describe a Sus-like PUL which is unique to B. fragilis and allows it to 
efficiently utilize complex N-linked glycans from the most abundant serum/serous fluid 
glycoproteins including transferrin. Overall the studies suggest that the ability to harvest these 
glycans is advantageous for growth at extraintestinal sites and can explain, in part, the success 
of B. fragilis as an opportunistic pathogen relative to the other Bacteroides species. 
 
2.4   Materials and methods 
2.4.1   Bacterial strains and growth. 
Bacterial strains and plasmids used in this study are listed in Table 2.1. B. fragilis 638R 
was the wild type strain used for genetic analyses. Bacteroides strains were grown in an 
anaerobic chamber in Brain Heart Infusion broth supplemented with hemin and cysteine (BHIS) 
(55). Rifampicin (20 µg/ml), gentamicin (100 µg/ml), erythromycin (10 µg/ml) and tetracycline 
(5 µg/ml) were added as indicated. Minimal defined media (DM) were prepared as described 
previously with the specific carbon/energy sources described in the text (74). Mucin glycans 
were prepared by proteolysis of porcine gastric mucin (Sigma-Aldrich, Cat. M2378) followed by 
alkaline β-elimination to release free glycans (20). In experiments using DM-transferrin, the 
transferrin was >98% iron saturated holo-transferrin and the transferrin-containing media (and 









Table 2.1 Bacterial strains and plasmids used in this study. 
Bacterial strain or plasmid a Description Reference 
or source 
Bacteroides strains   
IB101 B. fragilis, 638R, clinical isolate, Rfr (75) 
IB555  638R Δdon, BF638R3439-3443 genes replaced with a tetQ cassette, 
Tcr, Rfr 
This study 
IB114 B. fragilis, ATCC 25285, clinical isolate, Rfr (55, 76) 
   
IB116 Bacteroides thetaiotaomicron, VPI strain 2302, Rfr (77) 
BT5482R Bacteroides thetaiotaomicron, VPI strain 5482 (ATCC 29148), Rfr (77) 
IB102 Bacteroides uniformis, VPI strain 006-1 (ATCC8492), Rfr  
IB103 Bacteroides ovatus, VPI 0038 (ATCC 8483) (76) 
IB351 Bacteroides vulgatus, ATCC 8482 (76) 
BER37 Parabacteroides distasonis, clinical isolate CLA348 (78) 
Ber39 Parabacteroides merdae, ATCC 43185  
   
E. coli strains   
DH10B E. coli, F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 
endA1 araD139 Δ(ara leu) 7697 galU galK rpsL nupG λ– 
Invitrogen 
HB101::RK231 E. coli, HB101 containing RK231, Knr, Tcr, Smr (79) 
   
Plasmids   
pFD516 Bacteroides suicide vector, 7.7 kb, Spr in E. coli, Emr in Bacteroides (80) 
pFD516/omp117±2K/tetQ pFD516 containing the BF638R3439-3443 deletion construct with the 
tetQ gene cassette, 14.6 kb, Spr in E. coli, Emr and Tcr in Bacteroides.  
This study 





Table 2.2. Oligonucleotides used in this study. 
Name Sequence ( 5’ → 3’) Tag Description 
UF AGTCCTGCAGCAAACAGATGCCTTATCAGTTT PstI Designed to amplify 2 kb 
upstream of donC UR AGTCGGATCCCAGTGTCTTATCCAGAGATTCA BamHI 
DF AGTCGGATCCCTGGACAATATCGATTCAAGCA BamHI Designed to amplify 2 kb 
downstream for donG  DR AGTCGAGCTCATAGCGACCAAAACCCTTCT SacI 
Omp117rtL GGTGAAGGCATTTCCGACTT  Designed to amplify a 140 bp 
fragment of donC gene for 
quantitative PCR 
Omp117rtR TTGCCTTCCTGCCCTTTCTT  
16srL GATGCGTTCCATTAGGTTGTTG  Designed to amplify a 127 bp 
fragment of 16s ribosomal RNA 
gene for quantitative PCR 
16srR CACTGCTGCCTCCCGTAG  
PsigOKL2 AATCACAATCAGCCTTATATTCTAC  Designed to amplify a 375 bp 
fragment spanning donA and its 
potential TIS region 
PsigOKR CATTGCTCCTGATAGGTCTG  
PantisigOKL GGATATTTCGATCCGCACTG  Designed to amplify a 298 bp 
fragment spanning the 
intergenic region of donA and 
donB 
PantisigOKR TTTCCTTCCGTTTCGTTCCA  
Pomp117L AGATATCCTGAACATTATGCAGG  Designed to amplify a 339 bp 
fragment spanning the 
intergenic region of donB and 
donC 
Pomp117R GCCGTTTGTAGAATAAAACAGC  
PsusDL AATGACCTCTTCGACAGGTA     Designed to amplify a 220 bp 
fragment spanning the 
intergenic region of donC and 
donD 
PsusDR GGTTCCGGTTGATATCTTCG  
PendoSL ATTGATCGGAAACGGATACG  Designed to amplify a 240 bp 
fragment spanning the 
intergenic region of donD and 
donE 
PendosR CTACCAACAATGCTACTCCG  
PsusEL GAAGACGCATTTGAAGACGA  Designed to amplify a 261 bp 
fragment spanning the 
intergenic region of donE and 
donF 
PsusER GCTCTAAAGTGAAGTTGACGA  
PsusFL GAGACCAAAGACCTGAAAGC  Designed to amplify a 288 bp 
fragment spanning the 
intergenic region of donF and 
donG 





2.4.2   Construction of a don operon deletion mutant. 
The donCDEFG genes were replaced with a tetQ tetracycline resistance (Fig. S1). 
Chromosomal fragments of about 2 kb flanking the donC and donE genes were amplified using 
PCR primer pairs UF/UR and DF/DR respectively (Table 2.2). The amplified DNA was cloned into 
the Bacteroides suicide vector pFD516 together with the tetQ gene cassette in a three-fragment 
ligation. The recombinant plasmid was mobilized into B. fragilis 638R by conjugation and 
exconjugants were selected on BHIS plates containing rifampicin, gentamicin and tetracycline. 
Candidate mutants were screened for sensitivity to erythromycin and by PCR to identify the 
double-crossover allelic exchange. 
  
2.4.3   Animal model of infection. 
The tissue cage infection model has been described previously (60, 81). Briefly, a 
perforated, sterilized Ping-Pong ball was surgically implanted into the peritoneal cavity of an 
adult male Sprague Dawley rat and allowed to encapsulate for 4-5 weeks. The ball becomes 
encased in connective tissue, develops a blood supply, and fills with sterile serous fluids (~25ml 
per ball). B. fragilis strains grown overnight in BHIS media were diluted in PBS buffer (50 mM 
PO4, 150 mM NaCl, pH 7.4,) to 10
5 CFU/ml and 4 ml of this suspension was injected into the 
tissue cage. Samples were aspirated at the indicated time points for viable cell counts and RNA 
extraction. For viable cell counts aliquots were serially diluted in PBS buffer, plated on BHIS 
plates and incubated in an anaerobic chamber to determine CFU. Samples were also plated on 




The in vivo competition assay was performed by mixing overnight cultures of 638R and 
Δdon at a one to one ratio followed by dilution in PBS buffer to a total viable cell count of 105 
cfu/ml. Four ml of the cell mixture was injected into the tissue cage of each animal and aliquots 
were plated to determine CFU/ml. Diluted samples were plated on BHIS plates with rifampicin 
and gentamicin. After 4-5 days incubation, 100 to 300 colonies from each sample were picked 
to BHIS plates with and without tetracycline to check the resistance phenotype and determine 
the ratio of mutant to wild type.  
All procedures involving animals followed the National Institutes of Health guidelines 
and were approved by the Animal Care and Use Committee of East Carolina University. For 
each bacterial strain tested two trials of 5 animals each were performed. 
 
2.4.4   Total RNA extraction. 
RNA extraction from in vivo samples was done as described previously with a few 
modifications (60). Fluid was aspirated and immediately mixed with RNAprotect Cell Reagent 
(Qiagen, Inc.) at a 1:2 ratio. Next, 0.1% sodium deoxycholate was used to lyse host cells, then 
bacterial cells and debris were collected and washed in PBS containing RNAprotect Cell Reagent 
and sodium deoxycholate. Total RNA was extracted from the cell pellet using the hot phenol 
method described previously (82) and stored in 50% formamide at -80°C. RNA extraction from 






2.4.5   cDNA synthesis, qRT-PCR, and microarray analysis. 
Total RNA was purified using the RNeasy Mini Kit (Qiagen, Inc.) and DNA was removed 
by treatment with DNase (Ambion/Life Technologies Inc.). DNA contamination was determined 
by PCR using specific for the 16s ribosomal RNA gene (Table 2.2). First strand cDNA synthesis 
was carried out using 1 µg total RNA with random hexamer primers and Superscript III RT (Life 
Technologies, Inc.). For qRT-PCR, primer pair, omp117rtL and omp117rtR, were used to amplify 
a 140 bp fragment of the donC gene in a standard reaction mixture with SYBRR Green Supermix 
(Bio-Rad, Inc.). All sample reactions were in run in triplicate and RNA with no reverse 
transcriptase was used as a control to monitor for DNA contamination. Relative expression 
values were normalized to 16s rRNA and calculated by the method of Pfaffl (83). Results 
represent at least two independent experiments performed in triplicate. 
Expression microarray analyses were performed essentially as described previously (58). 
Double stranded cDNA was synthesized with the SuperScriptR Double-Stranded cDNA Synthesis 
Kit (Life Technologies, Inc.). One µg of purified double stranded cDNA was then labeled with 
cy3, hybridized to microarray slides, and processed by the Florida State University 
Roche/NimbleGen Microarray Facility.  For each experimental condition at least two 
independent trials were performed. Each trial consisted of a high-density-oligonucleotide whole 
genome expression microarray (Roche/NimbleGen, Madison WI) with 8 technical replicates of 
each probe per slide. RNA for each trial was pooled from five rats prior to cDNA synthesis. Raw 




Roche DEVA 1.1 software. The microarray expression data have been deposited in the NCBI 
Gene Expression Omnibus database under accession number GSE53883. 
 
2.4.6   Whole cell deglycosylation assay. 
Cultures were grown in 5 ml of DM-mucin glycan, harvested by centrifugation at mid-
logarithmic phase, washed and the cells were suspended to an OD A550 of 1.0 in PBS. 100 µL of 
the cell suspension was incubated with 100 µL of tissue cage serous fluid (1/10 diluted), purified 
human transferrin (1 mg/ml in PBS), IgG (1 mg/ml in PBS) or IgA (1 mg/ml in PBS) as described 
in the text. All proteins were from Sigma Aldrich Inc. For controls 100 µL PBS replaced the 
bacterial cell suspension. Assays were incubated anaerobically at 37°C for 3 hours or overnight, 
then samples were centrifuged, supernatants collected, mixed with loading buffer and 
electrophoresed on 12% SDS-PAGE gels. The gels were analyzed by Coomassie blue staining or 
proteins were transferd to PVDF membranes for glycan determination using Sambucus nigra 
agglutinin according to the manufacturer’s instructions (Roche, DIG Glycan Differentiation Kit). 
 
2.4.7   Glycomics analyses of B. fragilis treated human transferrin. 
Purified human transferrin was suspended in PBS to 2 mg/ml and 100 µL of this was 
used in deglycosylation assays as described above except that following incubation the assay 
supernatants were filter sterilized and frozen at -80°C. Samples were analyzed by Ezose 




(84, 85). Briefly, samples were denatured, digested with trypsin and then heat-inactivated. The 
N-glycans were then enzymatically released from the peptides by treatment with PNGase F, 
captured on chemoselective beads and then processed for MALDI-TOF mass spectrometry. 
Mass spectra were analyzed using Ezose’s proprietary bioinformatics programs. Results were 
normalized to 1 g/L of transferrin and reported as the average of two independent 
experiments.  
 
2.5   Results 
2.5.1   In vivo, extraintestinal PUL expression.  
Considerable progress has been made in understanding how the Bacteroides compete 
for and utilize limited nutrients in the gut ecosystem. In contrast, there is a paucity of 
knowledge concerning Bacteroides nutrient foraging in extraintestinal environments. As an 
initial strategy to identify significant pathways of catabolism, microarrays were used to 
measure gene expression of B. fragilis cells growing in a rat tissue cage abscess model. The 
results suggested that the organism may rely on a variety of PULs to harvest glycans from host 
proteins present in the serous fluid of the model abscess. B. fragilis has 47 putative PULs and 22 
stand-alone SusC/SusD-like protein pairs and several of these were among the most highly 
induced genes in vivo. A five gene operon, BF638R3439-43 associated with one of these PULs 
was induced from 2147- to 765-fold along the length of the 8 kb operon. These were the most 
highly induced genes in vivo and the genes in this PUL have been designated as donABCDEFG 




used as proxy for expression of the entire operon (22). This approach was validated by qRT-PCR 
which confirmed the in vivo induction of donC (Fig. 2.1A). The results from day 1, 4, and 8 
samples were compared to in vitro grown mid-logarithmic phase cultures and showed a high 
level of induction throughout the course of the experiment. 
Examination of the SusC orthologue expression data by k-means clustering revealed four 
major in vivo PUL gene induction patterns (Appendix 2, Fig. S2). The donC gene was associated 
with the most highly induced genes, Cluster 1, which consisted of 8 PULs and 5 stand-alone 
SusC/SusD orthologues. As shown in Fig. 2.1B the PULs in this cluster were rapidly induced 
more than 10-fold and the level of induction remained high throughout the 8 days. A second 
cluster of 25 SusC orthologues was induced more gradually and remained induced 1.5-5-fold for 
the 8 days (Fig. S2B).  The remaining two PUL clusters were repressed in the abscess model and 










Fig. 2.1. In vivo PUL gene expression during growth of B. fragilis in the rat tissue cage model. 
Samples for analyses were pooled from 5 animals 1, 4, and 8 days post inoculation.  A) 
Expression of donC was determined by qRT-PCR for samples from the rat tissue cage and mid-
logarithmic cultures grown in DM-glucose. The results are the average of triplicate samples and 
are presented as the in vivo/in vitro ratio. B) Induction of SusC orthologues during growth in 
vivo relative to DM-glucose. Shown are the highly induced-in vivo susC-like genes associated 
with PULs in Cluster 1. Clusters were determined from expression microarray data analyzed by 
k-means clustering using the Standard Pearson’s correlation coefficient distance metric.  All 












2.5.2   In vitro induction of the donCDEFG operon. 
The don PUL was chosen as a model for extraintestinal PUL function and it included 
several gene products that may be associated with N-linked glycan utilization such as an endo-
S-like endo-N-acetyl-β-D-glucosaminidase (DonE) and a lectin-like product with an α-N-
acetylglucosaminidase domain (DonF). In order to demonstrate a function of the PUL it was 
necessary to find an inducing substrate for in vitro expression studies. This was accomplished by 
using a crude glycan mixture prepared by alkaline β-elimination hydrolysis of porcine stomach 
mucin.  The majority of mucin glycans are O-linked glycans and 10-20% are N-linked glycans 
(20). A defined medium containing the glycan mixture as the sole carbon/energy source 
supported rapid growth of the wild type strain BF638R (Fig. 2.2). Expression analysis by qRT-PCR 
showed that donC was strongly induced in this medium in a growth phase dependent manner 
with the highest level of induction at mid-logarithmic phase. This RNA also was used for RT-PCR 
with primers pairs that spanned the intergenic regions of the PUL and the data indicated 










Fig. 2.2. Induction of donC expression during growth on mucin glycans. Strain BF638R was 
grown in defined medium containing 2% porcine gastric mucin glycans as the sole 
carbon/energy source. The induction of donC by mucin glycans relative to growth on glucose 
was determined by qRT-PCR. The results are overlaid on a typical growth curve with mucin 
glycans (OD A550, grey diamonds). The qRT-PCR results represent 2 independent experiments 




















2.5.3   Deglycosylation of transferrin is mediated by donCDEFG. 
              Don PUL function was explored by incubating serous fluid from the rat tissue cage 
(obtained prior to inoculation) with wild type or ∆donCDEFG (∆don) mutant cells grown to mid-
logarithmic phase in the inducing, mucin glycan medium. Samples were analyzed by SDS-PAGE 
and the results in Fig. 2.3A show that one of the major fluid proteins was significantly reduced 
in size in samples treated with the wild type strain but not with the deletion mutant. Analysis by 
mass spectrometry revealed that this protein was rat serum transferrin, one of the most 
abundant glycoproteins in serum. The precise size reduction of the protein suggested the 
possibility that the transferrin glycans were removed. To test this, human transferrin was 
incubated with the wild type or ∆don mutant cells. Duplicate samples were analyzed by SDS-
PAGE with either Coomassie blue or Sambucus nigra (SNA) lectin staining. As shown in Fig. 2.3B 
transferrin treated with the wild type strain was reduced in size after the 3 h incubation 
whereas the deletion strain did not have an obvious effect on transferrin size. Also, no 
degradation or reduced intensity of the protein band was observed in any of the samples. The 
SNA stained gels showed that transferrin treated with wild type cells was completely 
deglycosylated but in contrast an intense signal remained in samples treated with the deletion 
mutant and controls (Fig. 2.3B). In addition to transferrin, other serous fluid proteins were 
rapidly deglycosylated by B. fragilis. In assays using serous fluid samples the wild type strain 
had significant deglycosylation activity on many serous fluid proteins but the ∆don mutant 
activity was considerably reduced (Fig. S3). Although the mutant clearly retained some activity, 




deglycosylation of N-linked glycans on transferrin and other glycoproteins.  These genes were 
designated don for Deglycosylation Of N-linked glycans. 
The SNA lectin recognizes terminal sialic acids linked to Gal or GalNAc which is suitable 
to detect N-linked glycans but is not a definitive assay. Conceivably loss of the terminal sialic 
acids by the action of neuraminidase could result in loss of SNA staining. Therefore a 
comprehensive mass spectrometric glycomics analysis of transferrin was performed. Human 
transferrin has two glycosylation sites and there were seven distinct oligosaccharides linked to 
those sites, five of which made up 98.1% of the total transferrin glycans (Table 1). Incubation of 
transferrin with wild type cells for 3 h resulted in essentially complete deglycosylation of N-
linked glycans.  By comparison, nearly 70% of the N-linked glycans remained in samples 
incubated with the ∆don mutant. There were no new oligosaccharide structures detected in 
reactions with the wild type strain suggesting efficient cleavage of the glycan likely at the β-1,4-
di-N-acetylchitobiose core by the endo-β-N-acetylglucosaminidase S (DonE). These results 
confirm that transferrin is a substrate for the Don PUL but also indicate there is a second, less 










Fig. 2.3. Deglycosylation of transferrin is mediated by the don PUL. A) Serous fluid obtained 
from tissues cages prior to inoculation was incubated for 3 h with PBS or B. fragilis cells induced 
by growth in DM-mucin glycan medium. Samples were analyzed by 12% SDS-PAGE and 
Coomassie blue staining (Co). The arrowhead indicates the location of transferrin above the 
abundant serum albumin protein. B) Deglycosylation analysis of human transferrin. Human 
transferrin was incubated with wild type or ∆don cells induced by growth in DM-mucin glycan 
medium. Samples were analyzed by SDS-PAGE and followed by SNA glycan-staining (SNA) to 






















2.5.4   Growth on transferrin as the sole carbon and energy source. 
The ability to forage for high quality carbohydrates in extraintestinal sites would be 
advantageous to Bacteroides spp. translocated from the gut. Transferrin is the most abundant 
glycoprotein present in serum and is estimated to have a carbohydrate content of 5.8% so we 
tested if it could support the growth of B. fragilis. As shown in Fig. 2.4, 25 mg/ml of transferrin 
supported robust growth of the wild type strain but not the ∆don mutant. There was no 
significant difference in the growth rate between wild type and mutant strains grown with 
glucose (Fig. 2.4). Expression of the don operon during growth on transferrin was measured by 
qRT-PCR with donC primers and the results showed a 104 –fold induction over glucose grown 
cells. SDS-PAGE analysis of the transferrin medium after 24 or 48 hours of growth indicated 
there was no degradation of the transferrin peptide. The non-glycosylated protein, bovine 
serum albumin, did not support growth (Fig. 2.4). Interestingly, the ∆don mutant was able to 
grow in the transferrin medium albeit at a much slower rate. This confirms the presence of a 










Fig. 2.4. B. fragilis can grow with transferrin as the sole source of carbon and energy. Growth 
curves are shown for wild type or ∆don strains in defined media with different carbon/energy 
sources. An overnight inoculum of 2% was used and the OD A550 was measured at specific time 
intervals. Dashed lines are ∆don and solid lines are wild type. Squares, glucose (0.4%); triangles, 
human transferrin (25mg/ml); circles, bovine serum albumin (25 mg/ml). Each growth curve 















2.5.5   In vivo role of the don PUL. 
To investigate a potential role for the don operon in extraintestinal sites, the rat tissue 
cage model was used to measure growth in vivo. There was not a drastic difference in CFU 
counts between wild type and ∆don strains during monoculture experiments over the course of 
a 15 day period (Fig. 2.5A). There was however a small, two-fold advantage for the wild type in 
the first two days following inoculation. To determine if this difference would translate into a 
competitive advantage, mixed culture assays were performed using wild type and mutant 
strains co-inoculated into rat tissue cages. The results were clear, ∆don was quickly out-
competed and at one day post-inoculation about 85% of the total population was wild type (Fig. 
2.5B). The same trend carried through day 8 when the wild type strain reached about 97% of 
the total population. In control experiments (Fig. S4) with strains co-inoculated into glucose 
defined media there was no significant difference between the percentage of strains in the 
population through logarithmic phase and in fact the ∆don mutant had a slight advantage in 
stationary phase. These results suggest that access to novel carbohydrate nutrient sources in 
vivo can be advantageous for survival at extraintestinal sites.  
One important extraintestinal carbohydrate source for growth in vivo is transferrin 
which was rapidly deglycosylated during growth in the rat model. This was demonstrated by 
SDS-PAGE analysis of fluids removed from rat tissue cages over the course of the eight day 
experiment (Fig. 2.5C). The transferrin from uninoculated controls appeared as a single peptide 
species of about 80 kDa but by day one post-inoculation there were two transferrin peptides in 




converted to the smaller species. In contrast, samples from animals inoculated with the ∆don 
strain appeared unchanged at day one and by day two only a small portion of the transferrin 
was deglycosylated. Interestingly all of the transferrin in samples from wild type or mutant 
infected animals was deglycosylated by the end of the experiment on day eight (Fig. 2.5C). This 
result shows that the don locus plays an important role in the efficient deglycosylation of 









Fig. 2.5. Growth in vivo is enhanced by deglycosylation of transferrin. A) Growth curve for wild 
type (circles) and ∆don (squares) strains inoculated separately into rat tissue cages. B) Mixed 
culture competition assay. Mixtures of wild type (stippled bars) and ∆don (hatched marked 
bars) cells were prepared in a 1:1 ratio, inoculated into 5 rats and the CFU/ml determined. The 
percentage of wild type or ∆don cells was determined by screening the total cell counts for 
tetracycline resistant colonies. C) Coomassie blue- stained SDS-PAGE gel of serous fluid samples 
obtained following growth of strains in the rat tissue cage. Samples from the wild type (wt) and 
∆don (∆) strains were compared to uninoculated controls (un). The arrow indicates the 
migration of the glycosylated transferrin. The results are from two biological repeats and panel 











2.5.6   Efficient transferrin deglycosylation is unique to B. fragilis. 
B. fragilis is the most common Bacteroides species isolated from opportunistic 
infections at extraintestinal sites. The ability of six other intestinal Bacteroides species to 
deglycosylate human transferrin was tested by SDS-PAGE and SNA glycan staining. The results 
in Fig. 2.6 show that only the two B. fragilis strains were able to efficiently deglycosylate 
transferrin in the 3 hour assays. This was indicated by both the change in mass and the loss of 
SNA staining of the transferrin. No significant loss in SNA staining was seen for the other species 
except B. vulgatus.  In this case the transferrin band appeared as a doublet with somewhat 
decreased staining intensity in the SNA blot (Fig. 2.6, lane 7). These data indicate that B. 
vulgatus deglycosylates transferrin inefficiently and that of the intestinal Bacteroides species 












Fig. 2.6. Transferrin deglycosylation by medically important Bacteroides species. Human 
transferrin was used in standard 3 h deglycosylation assays with mid-logarithmic phase cells of 
Bacteroides species grown in DM-mucin glycan media. Samples were analyzed by SDS-PAGE 
with Coomassie blue (Co) staining and on duplicate SDS-PAGE gels followed by SNA glycan-
staining (SNA). 1, PBS; 2, B. fragilis (638R); 3, B. fragilis (ATCC 25285); 4, B. thetaiotaomicron 
(IB116); 5, B. uniformis; 6, B. ovatus; 7, B. vulgatus; 8, Parabacteroides distasonis; 9, 














2.6   Discussion 
The intestinal microbiome has a complex, symbiotic relationship with its host that is 
maintained by a series of physical barriers and immunological processes designed to keep the 
microbial populations in check. When these barriers are breached, contaminating normally 
sterile body sites, the invading organisms must rapidly adapt to an environment with a 
challenging set of new physical, chemical, and nutritional parameters. In this study, we used a 
rat tissue cage model to gain a better understanding of the nutritional sources that 
opportunists such as B. fragilis might encounter in extraintestinal habitats. Expression 
microarrays showed that PUL genes were highly induced in vivo and the Don locus was induced 
more than any other genes in vivo. The carbon/energy sources available in the abdominal cavity 
are quite varied and complex so we were not surprised to see such a robust, complex response 
in PUL expression. A recent study of B. thetaiotaomicron PUL regulation during growth on 
mixtures of dietary glycans provides some insight into this response (22). The work showed that 
there is a rapid response to the influx of new glycan sources and that multiple PULs were 
simultaneously expressed in order to prioritize utilization of the most advantageous substrates. 
This required coordinated induction and repression of multiple systems working to maximize 
utilization of certain glycans although the rationale for prioritization is not yet entirely clear. 
Similarly B. fragilis growing in the rat tissue cage elicited a broad PUL response and in this case 
it seemed to be directed toward use of N-linked glycans found on host glycoproteins. The most 
abundant glycoprotein in tissue cage serous fluid is transferrin which is a significant substrate 
for the Don PUL. Many other glycoproteins present in the fluid also were targeted by the Don 




protein signatures consistent with the utilization of N-linked host glycans: BF638R0384-92 (β-N-
1-4 acetylglucosaminidase + GH88 glycosidase); BF638R1323-30 (endo-β-N-
acetylglucosaminidase + concanavalin A-like); BF638R0444-448 has member proteins with 
fibronectin binding domains. 
A critical requirement for utilization of N-linked glycans is removal of terminal sialic acid 
residues and in a previous study it was shown that neuraminidase activity was necessary for 
robust growth in a rat pouch model similar to the tissue cage used in this report (86). An 
extensive region of the B. fragilis chromosome (BF638R1715-1740) seems to be devoted to 
sialic acid utilization and neuraminidase activity and this region has been shown to be required 
for optimal utilization of mucin (87). This gene cluster includes the nanLET operon (88), the 
nanH operon, and 5 standalone pairs of SusC/SusD orthologues. Our microarray data showed 
that regulation of these genes was complex but the entire region was induced on day 1 
following inoculation of the tissue cage and for the most part remained elevated throughout 
(Appendix 2 and Fig. S2). 
The hydrolysis of host glycoprotein glycans is an important characteristic of several 
bacterial pathogens and this has been proposed to be a mechanism for immune evasion as well 
as for nutrient acquisition. Streptococcus pyogenes secretes the archetypical GH18 family 
glycoprotein hydrolase, EndoS, which can efficiently hydrolyze the IgG glycan and significantly 
reduce IgG mediated killing of the bacteria in blood (89, 90). Streptococcus pneumoniae 
possesses several exoglycosidases that in combination deglycosylate IgA1, lactoferrin, human 




acid glycoprotein supported growth in the absence of other carbohydrates (91, 92). This ability 
may be linked to the persistence of S. pneumoniae in the nasopharynx. Likewise transferrin 
supports the growth of B. fragilis (Fig. 2.4) and is present in serum and serous fluid at 2-4 
mg/ml so this would be an excellent source of fermentable carbohydrate for extraintestinal 
growth. Glycan harvesting also seems to be important for in vivo growth of Capnocytophaga 
canimorsus a member of the Bacteroidetes phylum and a common inhabitant of the oral cavity 
of dogs (93). C. canimorsus was able to deglycosylate fetuin and IgG in vitro using a Sus-like 
system and the deglycosylation activity was necessary to sustain growth with cultured 
mammalian cells. 
A notable difference of the Don PUL and the glycosidase systems listed above is the 
inability to deglycosylate IgG or IgA. Several attempts with different sources of human IgG and 
IgA failed to demonstrate activity against these substrates (Fig. S5). This suggests that the Don 
system did not evolve for the need to inactivate immune clearance mechanisms. Further, it is 
well known that transferrin and lactoferrin also have antibacterial activity, largely due to their 
ability to sequester iron from the bacteria (94, 95). However, the glycosylation status of 
transferrin and lactoferrin has little effect on their ability to either bind iron or their receptors 
(96, 97). The Don PUL then does not seem to be designed to circumvent this element of the 
innate immune system. 
A key finding of the work presented here was that rapid, efficient deglycosylation of 
transferrin and many other glycoproteins in serous fluid is mediated by the don genetic locus 




demonstrated specifically for transferrin but may apply to the other serous proteins (Fig. 2.6, 
Fig. S3). Although not as efficient as wild type, the Δdon mutant was able to deglycosylate and 
utilize transferrin glycan at a slow rate. This was seen both in vivo and in vitro (Figs. 2.4, 2.5) 
and these results indicate a second transferrin deglycosylation system in B. fragilis. Other 
Bacteroides may have deglycosylation capabilities more similar to the Δdon mutant. For 
example, B. vulgatus showed some deglycosylation of transferrin after 3 h (Fig. 2.6) and results 
with a second strain of B. thetaiotaomicron showed some activity on transferrin after 3 h but 
failed to further deglycosylate the substrate even after overnight incubation (Fig. S6). We 
propose that the Don PUL is composed of 7 genes (Fig. S1). DonA and DonB are the regulators 
of the system encoding an ECF sigma factor and antisigma factor respectively.  DonEFG are 
outer membrane proteins that bind and cleave glycans from the target glycoproteins. DonCD 
would work in tandem to transport oligosaccharides into the periplasm where the concerted 
effort of neuraminidases and other glycohydrolases release monosaccharides from the glycan 
chains (68).  
The normal habitat for B. fragilis is the colon where it is in a persistent, mutualistic 
relationship with its host. The Don system must have evolved to provide a means by which to 
establish a specific niche in the gut or to help the organism maintain its competitive position. 
Several studies have indicated that B. fragilis are closely associated with the mucosa and that 
they penetrate the mucus layer to bind receptors deep in the crypts (98, 99). The don genes are 
significantly induced by a crude mixture of gastric mucin glycans in fact they were the most 
highly induced of all genes in mucin glycan medium (Appendix 2). One potential role for the 




about 20% of mucus glycans (100)] as cells transit through the mucus layers to the crypts.  
Other host associated N-linked glycan sources may become available to bacteria adherent in 
the crypts or the don operon may be shut down since don transcription is negligible in the 
absence of inducer. Koropatkin et al. (19) suggested that in the colon there are many “glycan 
microhabitats” and any given Bacteroides spp. has evolved to respond to a specific subset of 
these. If we define the glycan habitat of B. fragilis then we may gain further insight as to why 
















Fig. S2. Induction/repression patterns of SusC orthologues expressed during 
growth in vivo. Expression microarray data were used to determine induction 
or repression of all susC-like genes during growth of B. fragilis 638R in the rat 
tissue cage model relative to DM-glucose. Four induction patterns (Clusters) 
were identified by k-means clustering using the Standard Pearson’s 
correlation coefficient distance metric.  The four clusters are shown in panels 
A, B, C and D respectively. The fold-induction for in vivo growth relative to 
mid-logarithmic phase growth in vitro for 1, 4, and 8 days post-inoculation are 
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2.8   Addendum 
 In this chapter, it was shown that the B. fragilis don locus mediates the efficient 
deglycosylation of N-linked glycoproteins (Fig. 2.3, 2.5C, S3; Table 2. 3) both in vitro and in vivo. 
Deletion of the don locus led to a growth defect in DM with transferrin as the sole 
carbon/energy source and a selective disadvantage in the rat extraintestinal infection model 
(Fig. 2.4, 2.5). While we have shown a correlation between deglycosylation activity and growth 
advantage in the rat abscess, model, we have not proven that deglycosylation is the cause of 
this advantage in vivo.  This is especially of interest because we deleted not only donE, which 
has predicted deglycosylation activity, but also donF and donG.  These genes have unknown 
functions that might affect in vivo growth.  In the future direction, two experimental designs 
can strength the causal relation between efficient deglycosylation of N-linked glycoprotein and 
the selective advantage in extraintestional infection. First, point mutations of two active site 
residues on the endo-β-N-acetylglucoaminidase gene (donE) can abolish the deglycosylation 
activity of this enzyme (125) but keep the structure and other functions of the locus intact. If 
there is a real causal relation between the deglycosylation of N-linked glycoproteins and 
selective advantage in extraintestinal infection, the donE point mutant should show the same 
selective disadvantage phenotype as the don deletion mutant. Second, to rule out the 
possibility that the tetracycline resistant gene tetQ is responsible for the impaired in vivo 
growth/competency phenotype, a control strain will be constructed with only the tetQ gene 
inserted into the chromosome. If tetQ is not responsible for the selective disadvantage 
observed in the don deletion mutant, similar in vivo growth/competency should be observed 
between the wild type and the tetQ insertion mutant. 
CHAPTER THREE: BACTEROIDES FRAGILIS PRIMARY TRANSCRIPTOME 
ANALYSIS 
 
3.1   Introduction 
                B. fragilis has a genome of about 5.3 Mb and encodes approximately 4,300 genes. To 
gain insight not only on the gene expression profile but also the overall structure of individual 
mRNAs, differential massively parallel cDNA sequencing (dRNA-seq) was performed using RNA 
obtained from mid-logarithmic phase anaerobic B. fragilis cultures grown in rich media. The 
dRNA-seq approach was first done with the human pathogen Helicobacter pylori which has a 
small genome (101). In contrast to other RNA-seq methods, terminator-5’-phosphate-
dependent exonuclease is used to treat the RNA samples before conversion to cDNA. By adding 
this step, the processed transcripts such as mature rRNA, tRNA and partially degraded mRNAs 
which have a 5’ mono-phosphate (5’P) group are selectively degraded leaving only the RNAs 
with a 5’ tri-phosphate (5’ppp) group such as primary transcripts including most mRNAs and 
small RNAs (sRNA) (101). By comparing the exonuclease treated samples to non-treated 
samples, it was possible to generate a single-nucleotide resolution map of the primary 
transcriptome of B. fragilis, allowing us to locate the transcription initiation sites (TIS) of 
individual transcripts, distinguish potential sRNAs, and confirm the -7 promoter consensus 
sequence for the primary sigma factor. Analysis of this primary transcriptome identified 1,657 




addition, 176 putative sRNAs were discovered. These results demonstrate that the dRNA-seq 
technique is a good approach and has great potential for understanding some of the molecular 
aspects of B. fragilis gene regulation. 
 
3.2   Materials and Methods 
3.2.1   Total RNA Extraction 
                B. fragilis strain IB101 (BF638R) was grown at 37°C anaerobically in Brain Heart 
Infusion broth supplemented with hemin and cysteine (BHIS). Cells were harvested in mid-
logarithmic phase at O.D. A550 = 0.5 for RNA extraction. RNA extractions from in vitro bacterial 
cell cultures were performed on washed cell pellets using the hot phenol method as described 
previously (82). RNA quality and integrity was checked by RNA-denaturing gel (1% agarose; 
5.5% formaldehyde) electrophoresis.  
 
3.2.2   Preparation of cDNA libraries and 454 pyrosequencing 
Experiments were done by collaborator Jӧrg Vogel and lab members at University of 
Würzburg, Institute for Molecular Infection Biology, D-97080, Würzburg, Germany. The dRNA-
seq was performed as previously described (101). Total RNA was treated by DNase I to 
eliminate residual genomic DNA. Equal amounts of IB101 RNA were either incubated with 
TerminatorTM 5’-phosphate-dependent exonuclease (TEX) (Epicentre #TER51020) or in buffer 




phenol/chloroform/isoamyalcohol (25:24:1 v/v) and then precipitated overnight with 2.5 
volumes of an ethanol/0.1M sodium acetate (pH 6.5) mixture. Then the TEX treated RNA was 
incubated with 1 unit TAP (tobacco acid pyrophosphatase) (Epicentre, #T19100) for 1 hour at 
37°C to generate 5’-mono-phosphates for linker ligation, and again purified by 
phenol/chloroform extraction and precipitation as above.  
Equal amounts of TEX treated or untreated RNA were poly(A)-tailed using poly(A) 
polymerase, followed by ligation of an RNA adapter to the 5’P RNA fragment. First-strand cDNA 
was synthesized using an oligo (dT)-adapter primer and M-MLV-RNaseH- reverse transcriptase. 
The reaction mix was incubated at 42°C for 20 min followed by 55°C for 5 min. The cDNA was 
amplified by PCR to yield a concentration of 20-30 ng/μl using a high fidelity DNA polymerase. 
Sequencing was performed on Roche 454 FLX machines at the MPI for Molecular Genetics 
(Berlin, Germany), and Roche Diagnostics GmbH (Penzberg, Germany). 
 
3.2.3   Data Visualization 
                Linker and poly(A) sequences were removed from the sequencing results to reduce the 
background. cDNA inserts were mapped to the B. fragilis 638R genome using an error-tolerant 
suffix array technique (102). Graphs representing the number of mapped reads per nucleotide 
were calculated and visualized using the Integrated Genome Browser (IGB) version 4.56 





3.3   Results 
3.3.1   Identification of B. fragilis TISs at a genome wide level 
                Degradation of the processed RNA (5’P transcripts) by TEX leads to an enrichment of 
the primary RNA (5’PPP transcripts) in the total RNA sample. Because in prokaryotic cells, RNA 
processing (including degradation) often causes a loss of the 5’ region of a transcript (103), it is 
reasonable to assume that an enrichment of the primary transcripts will lead to an enrichment 
of the original (or intact) 5’ ends of the transcripts (104). This was reflected by an increased 
signal at the 5’ end of many transcripts on the TEX treated library compared to the untreated 
library. An example is shown in Fig. 3.1. Depletion of the processed RNAs by TEX leads to a 
characteristic change in the distribution of the total transcripts, as shown here for the 
BF638R_3589 mRNA. The most noticeable change is at the 5’ end of the transcript where an 
increased number of reads are concentrated compared to the untreated library. This provides a 
reliable primary transcriptome map with a resolution to the single nucleotide level and thus can 
be used to identify the TIS of any transcript present for that specific growth condition. 1,657 
primary transcripts were mapped for this growth condition (mid-logarithmic phase in rich 
medium), of which 838 were on the positive-strand and 819 were on the negative-strand. 













Fig. 3.1. The transcript signal of the BF638R_3589 gene. B. fragilis strain IB101 was grown 
anaerobically in BHIS at 37°C to mid-logarithmic phase and RNA was prepared for dRNA-seq 
analysis as described in materials and methods. A) A comparison of the mapping signal 
histogram for TEX-treated and untreated samples of BF638R_3589 sRNA. B) A schematic 
diagram of the BF638R_3589 locus aligned with its signal on the transcriptome above. The TIS 
suggested by the dRNA-seq results is indicated by the +1 arrow and the -7 promoter consensus 
















3.3.2   Confirmation of the recognition sequence for the B. fragilis primary sigma factor 
                The Bacteroidetes/Flavobacteria are known to have a primary sigma factor that 
recognizes a unique promoter structure. The Bacteroidetes equivalent to the classic 
Proteobacteria/Eubacteria -10 sequence is TAxxTTTG (105, 106). Based on the TIS identified by 
the dRNA-seq results, sequences about 50 bases upstream of the TIS were aligned. The 
conserved promoter recognition sequence “TAxxTTTG” was observed 5 to 10 bases prior the TIS 
in 1,428 of the 1,657 TISs observed (Fig. 3.2 and Appendix 3).  These results confirmed the novel 












Fig. 3.2. Logo for the promoter recognition sequence of the primary sigma factor in B. fragilis. 
Primary transcriptome data were used to identify sequence about 50 bases upstream of the TIS 



















3.3.3   Discovery of putative small non-coding RNAs in the B. fragilis genome 
                Small non-coding RNA transcripts will have the enriched 5’ signal in the TEX (+) library 
and are usually located in intergenic regions. 176 putative sRNAs were observed by these 
criteria. Interestingly, we observed a group of 14 putative sRNAs individually located in the 
intergenic region of 14 Sus-like PULs, including the don PUL described in chapter 2. The 
apparent sizes of these sRNAs range from 80 bases to 250 bases and they are divergently 
transcribed from the putative SusC-like porin of their respective PUL. Shown in Fig. 3.3 is a 
putative sRNA located in the don PUL. Characteristics of these PUL-associated sRNAs are 












Fig. 3.3. The putative sRNA in the intergenic region of the don PUL. A) The putative sRNA 
located in the don PUL visualized on the Integrated Genome Browser. The sRNA signal is 
indicated by the red arrow. The green bars are local alignment annotations for donA, donB, and 
donC respectively as indicated at the bottom. B) A schematic diagram showing the location and 
















3.4   Discussion 
                One major advantage of using the dRNA-seq technique is that it can generate a 
primary transcriptome that precisely shows TISs across the entire genome for the condition 
tested. It is considerably more efficient than other TIS identification methods such as primer 
extension or 5’ RACE. Further, based on our observation it is at least equal in accuracy 
compared to primer extension. As shown in the results, a majority of the TISs mapped from the 
primary transcriptome data have the conserved Bacteroides primary sigma factor recognition 
sequence (TAxxTTTG) 5 to 10 bases upstream. This result supports the reliability of the TIS data 
since it is reasonable to expect that for the growth condition tested (37°C, anaerobic, rich 
medium, mid-logarithmic phase), many of the genes expressed would be transcribed by the 
primary sigma factor. 
                Another important feature of the primary transcriptome map is that putative sRNAs 
are readily identified due to the enrichment of their 5’ signal and the reduced background noise 
from processed RNAs. Most interesting for this work, a group of 14 putative sRNAs were 
observed in the intergenic region of 14 PULs, including the don PUL described in chapter 2. 
Based on the locations and orientations of these putative sRNAs, they are likely to be cis-
encoded antisense sRNAs that play a role in the regulation of the PUL they are in proximity to. 
The role of these sRNAs and their regulation mechanism will be the topic of the next chapter 
(chapter 4). 
                In this study, only the primary transcriptome in one growth condition was explored: 




when the transcriptomes of different growth conditions are compared. In these cases, it is 
reasonable to expect that there will be changes in the mRNAs such as alternative TIS and 
alternative transcript termination sites. By comparing the primary transcriptomes of stressed 
and non-stressed cells, we may also detect some stress responsive sRNAs. All in all, primary 
transcriptome analysis is a useful tool and has great potential in understanding the molecular 
mechanisms of regulating B. fragilis physiology and pathogenesis. 
  
CHAPTER FOUR: CHARACTERIZATION OF THE REGULATION 
MECHANISMS FOR THE BACTEROIDES FRAGILIS POLYSACCHARIDE 
UTILIZATION LOCUS, DON 
 
4.1   Introduction 
                As one of the most abundant symbiotic bacteria in the human gut, Bacteroides species 
are well known for their extraordinary ability to utilize a wide range of diverse polysaccharides 
as their carbon/energy source. These include plant fiber glycans from dietary sources as well as 
host derived glycans in the form of glycoconjungates such as glycoproteins. This extensive 
catabolic ability is mediated by a large number of outer membrane complexes coded by 
discrete polysaccharide utilization loci (PULs). For example, one of the most abundant gut 
Bacteroides species, B. thetaiotaomicrom, dedicates about 18% of its genome to PULs (62). The 
PULs in Bacteroidetes have a unique yet well-characterized operon structure that was first 
documented for the starch utilization system (Sus) of B. thetaiotaomicron (68). This consists of 
genes for an outer membrane protein complex that involves recognition, binding, processing 
and transport of its substrate glycan molecules. This outer membrane complex contains a SusC-
like TonB-dependent transmembrane transporter and a SusD-like substrate binding protein 
while additional genes encoding specific substrate binding and processing proteins are usually 
present downstream of the SusD-like gene (62-66). Please see chapter 1 for a detailed review of 




substrate specific, for example the prototype of these systems, the B. thetaiotaomicron Sus, 
only binds, processes and transports starch into the cell (22, 68). Expression of the PULs must 
be under precise control to avoid futile energy spending and envelope stress. Most of the PULs 
have regulatory genes located upstream from the SusC-like gene in the form of a two 
component regulatory phosphorelay or an ECF (extracytoplasmic function) sigma factor/ anti-
sigma factor pair which is the most common regulatory mechanism.  The SusC-like porin, ECF 
sigma factor and anti-sigma factor form a trans-envelope signaling pathway that provides a 
positive feedback loop; when the inducing glycan substrate is present in the environment, the 
SusC-like transporter will sense the signal and cause a conformational change of the anti-sigma 
factor followed by the release of the ECF-sigma factor and specific induction of the PUL. When 
there is no inducer substrate glycan for that particular PUL, the SusC-like porin will interact with 
the anti-sigma factor so that it will sequester the sigma factor and the expression of the system 
will switch back to an “off” state (62, 68).  
                B. fragilis is typical of the Bacteroides with more than 50 PULs. Interestingly, an 
analysis of the primary transcriptome for possible sRNAs, intense signals were observed in the 
intergenic regions between the SusC-like gene and the anti-sigma factor gene of 14 PULs. 
Please review chapter 3 for a description of the transcriptome analysis. Each of these sRNAs is 
antisense to the SusC-like gene in the operon in which they were found. There are two classes 
of antisense sRNAs in the prokaryotic systems: one is the cis-encoded antisense sRNAs that are 
located in the same chromosomal region and fully complementary to their target mRNAs over a 
long sequence stretch; and another class is the trans-encoded antisense sRNAs which are 




targets and usually need the small RNA chaperone Hfq to aid the sRNA-target interaction (107-
110). Based on the location and orientation of the 14 PUL-associated sRNAs, we hypothesized 
that they are cis-encoded regulatory sRNAs that control the expression the specific PUL in 
which they were found. In this study, we used the B. fragilis don locus (please see chapter 2 for 
a detailed study on the function and characterization of don locus) as a model to understand 
PUL regulation in B. fragilis, by first elucidating the roles of the ECF-sigma factor and anti-sigma 
factor, and then by testing our hypothesis that the sRNAs play important regulatory roles in the 
B. fragilis PULs. 
 
4.2   Materials and Methods 
4.2.1   Bacterial strains and growth 
                Bacterial strains used in this study are listed in Table 4.1. Bacteroides strains were 
grown at 37°C anaerobically in Brain Heart Infusion broth supplemented with hemin and 
cysteine (BHIS) for routine cultures (55). E. coli strains were grown at 37°C aerobically in Luria-
Bertani broth for routine cultures. Ampicillin (100 µg/mL), spectinomycin (50 µg/mL), rifampicin 
(20 µg/mL), gentamycin (100 µg/mL), erythromycin (10 µg/mL), tetracycline (5 µg/mL), 
trimethoprim (100 µg/mL), thymine (50 µg/mL) were added to the media when required (74). 
Minimal defined media (DM) were prepared as described previously with the specific 
carbon/energy source as mentioned in the text. Mucin glycans were prepared from porcine 
stomach mucin (Sigma-Aldrich, Cat. M2378) according to Eric C. Martens (20). All subcultures 




4.2.2   Construction of donA and donB deletion mutants and the donA over-expression strain  
                The donA and donB mutants, IB559 and IB560 respectively, were constructed as 
unmarked and in-frame deletions to avoid potential polar effects.  Briefly, chromosomal 
fragments of about 1.2 kb flanking donA were PCR amplified using primer pairs 
sigOK+2kL/sigOK+2kR and sigOK-2kL/sigOK-2kR respectively (Table 4.3). The amplified DNA 
fragments were cloned into the B. fragilis suicide vector pYT102 (14) by three-fragment ligation. 
The plasmid was mobilized into B.fragilis ADB77 (thyA-) using the E. coli helper strain 
HB101::RK231 (79), and the exconjugates were selected on BHIS plates containing rifampicin, 
gentamicin and tetracycline. Exconjugates were then allowed to resolve in BHIS medium 
supplemented with thymine for three days and then plated on trimethoprim-containing media. 
Sensitivity to tetracycline, resistance to trimethoprim, and PCR were used to confirm the 
double-crossover allelic exchange into the ADB77 chromosome. The mutant construction was 
finalized by reversion of the strains from thyA- to thyA+ (14). The donB mutant was made in the 
same way with the primer pairs anti-sigOK+2kL/anti-sigOK+2kR and anti-sigOK-2kL/anti-sigOK-
2kR (Table 4.2). The donA over-expression strain IB558, was made by PCR amplifying the donA 
gene using primer pairs sigOK-340L/sigOK-340R. Primer sigOK-340L contains a strong ribosomal 
binding sequence from the B. fragilis ahpC gene to facilitate expression. The amplified fragment 
was inserted to the Bacteroides-E.coli expression shuttle vector pFD340 (Table 4.2) downstream 
of the constitutive IS4351 promoter sequence. The recombinant plasmid was then mobilized 





4.2.3   Construction of DonS silencing mutant (IB561) and DonS over-expression strain (IB563) 
                DonS silencing was achieved by changing its core promoter sequence “TTTG” to 
“AAAC” through site-directed mutagenesis. First a 1301bp chromosomal fragment covering the 
entire donS region was amplified and the TTTG in the core promoter sequence was replaced 
with AAAC by using overlapping PCR with the mutagenic primer pairs 
sRNA117+L/sRNA117+R(AAACmut) and sRNA117-L(AAACmut)/sRNA117-R [Table 4.2; 
sRNA117+R(AAACmut) and sRNA117-L(AAACmut) are complementary to each other]. The 
mutated fragment was cloned into the suicide vector pYT102. The allelic exchange mutation 
was selected as described above for donA except that colony-PCR followed by nucleotide 
sequencing of the PCR fragments was used to screen for the mutation after resolving the 
exconjugates in BHIS plus thymine media. The DonS over-expression strain, IB563, was 
constructed by cloning the donS gene downstream of an 82 bp 16s rRNA promoter sequence 
into a multiple copy vector. Briefly, the primer pair sRNA117-L/sRNA117-R1 was used to amplify 
the donS sequence with 36 bp of 16s rRNA promoter sequence engineered into the sRNA117-L 
primer, upstream of the donS sequence. Then this PCR product was used as a template in a PCR 
amplification performed with primer pair 16sPR-36-82/sRNA117-R1. The primer 16sPR-36-82 
includes an additional 46 bp adjacent to and upstream of the 36 bp fragment of the 16s rRNA 
promoter sequence. The final product contained the donS sequence downstream of the 82 bp 
of the 16s rRNA promoter sequence (111, 112). The final PCR product was cloned by replacing 
the DNA fragment between the SacI site and PstI site on the plasmid pFD340. The recombinant 




Exconjugates were selected on BHIS media containing rifampicin, gentamycin and 
erythromycin. 
 
4.2.4   Total RNA extraction, cDNA synthesis and qRT-PCR 
Total RNA was extracted from cell pellets using the hot phenol method described 
previously (82) and stored in 50% formamide at -80°C. Total RNA was purified using the RNeasy 
Mini Kit (Qiagen, Inc.) and DNA was removed by treatment with DNase (Ambion/Life 
Technologies Inc.). DNA contamination was determined by PCR using specific primers for the 
16s ribosomal RNA gene (Table 4.3). First strand cDNA synthesis was carried out using 1 µg total 
RNA with random hexamer primers and Superscript III RT (Life Technologies, Inc.). For qRT-PCR, 
primer pair, omp117rtL and omp117rtR, were used to amplify a 140 bp fragment of the donC 
gene in a standard reaction mixture with SYBRR Green Supermix (Bio-Rad, Inc.). All sample 
reactions were in run in triplicate and RNA with no reverse transcriptase was used as a control 
to monitor for DNA contamination. Relative expression values were normalized to 16s rRNA 
and calculated by the method of Pfaffl (83). Results represent at least two independent 
experiments performed in triplicate. 
 Expression microarray analyses were performed essentially as described previously (58). 
Double stranded cDNA was synthesized with the SuperScriptR Double-Stranded cDNA Synthesis 
Kit (Life Technologies, Inc.). One µg of purified double stranded cDNA was then labeled with 
cy3, hybridized to microarray slides, and processed by the Florida State University 




whole genome expression microarray (Roche/NimbleGen, Madison WI) with 8 technical 
replicates of each probe per slide. Raw microarray expression data were normalized by using 
the RMA algorithm implemented with the Roche DEVA 1.1 software.  
 
4.2.5   Northern blot analysis 
                Northern blot analyses were performed as described previously (113). Briefly, 10 μg of 
RNA was separated on a 10% denaturing polyamcrylamide gel containing 7 M urea and 1X TBE 
(89 mM Tris-base, 89 mM boric acid and 2 mM EDTA). The low-molecular-weight DNA ladder 
(NEB, cat. N3233S) was labeled with [γ-32P]-ATP and polynucleotide kinase, and used as the size 
standards. Following electrophoresis in 1X TBE buffer, the ladder and RNA samples were 
transferred to an Amersham HybondTM-N+ membrane (GE Healthcare, cat. RPN303B) in 1X TBE 
buffer. The samples were UV-cross-linked to the membrane, and the membrane was pre-
hybridized in hybridization buffer (ULTRAhyb®-Oligo Buffer, Ambion, cat. AM8863) for 3 h at 
43°C on a rocking shaker. The oligonucleotide probes specific for each small RNA species were 
end-labelled with [γ-32P]-ATP and polynucleotide kinase. The radiolabelled probes were 
incubated with the pre-hybridized membranes at 43°C on a rocking shaker overnight (~ 12 h). 
The membranes were then washed three times for 30 min each with 2X SSC (300 mM sodium 
chloride and 30 mM sodium citrate), 1X SSC and 0.5X SSC, respectively, at 43°C on a rocking 
shaker. All SSC wash buffers contained 0.1% sodium dodecyl sulfate (SDS). The membranes 









Table 4.1. Bacterial strains used in this study. 
Bacterial strains Description or genotypea Reference 
or source 
IB101 B. fragilis, Clinical isolate 638R, Rifr (75) 
ADB77 B. fragilis, strain 638R, ∆thyA,, Rifr, Tpr (14) 
DH10B E. coli, F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 endA1 
araD139 Δ(ara leu) 7697 galU galK rpsL nupG λ– 
Invitrogen 
HB101::RK231 E. coli, HB101 containing RK231, Kanr, Tetr, Spr (79) 
IB558 B. fragilis, strain 638R, donA overexpressed on pFD340, Rifr, Ermr This Study 
IB559 (∆donA) B. fragilis, strain 638R, ∆donA, Rifr This Study 
IB560 (∆donB) B. fragilis, strain 638R, ∆donB, Rifr This Study 
IB561 B. fragilis, strain 638R, DonS silenced by promoter sequence mutation, Rifr This Study 
IB563 B. fragilis, strain 638R, DonS overexpressed on pFD1244, Rifr, Ermr This Study 
 
aRifr, rifampin resistance; Tetr, tetracycline resistance; Spr, spectinomycin resistance; Ermr, 













Table 4.2. Plasmids used in this study 
Plasmid Descriptiona Reference 
of source 
pYT102 P15A ori, RP4 oriT; B. fragilis suicide vector, thyA+, (Cmr), Tetr (14) 
pFD340 Bacteroides-E.coli expression shuttle vector, (Ampr), Ermr (114) 
pFD1243 
(pFD340_donA) 
B. fragilis expression vector, generated by inserting the cloned donA gene 
with ahpC ribosomal binding site downstream the IS4351 promoter on 
pFD340 
This Study 
pFD1244 B. fragilis expression vector, generated by replacing the IS4351 promoter on 
pFD340  with an 82 bp 16s rRNA promoter sequence and the donS gene 
This Study 
 
aCmr, chloramphenicol resistance; Tetr, tetracycline resistance; Ampr, ampicillin resistance; 
Ermr, erythromycin resistance. For Bacteroides-E. coli shuttle vectors, parentheses indicate 





Table 4.3. Oligonucleotides used in this studya. 
Name Sequence ( 5’ → 3’) Tag Description 
sigOK+2kL AGTC GGATCC CCGATGGTTACATCTACGATC BamHI Designed to amplify a 1283 bp 
upstream fragment of donA 
gene 
sigOK+2kR AGTC CTGCAG CGCTTTGACTTTGGGATAAGTC PstI 
sigOK-2kL AGTC CTGCAG CACATCTATTTGGCACTAATCG PstI Designed to amplify a 1231 bp 
downstream fragment of donA 
gene 
sigOK-2kR GCAT AAGCTT TAACGCAAAGAATTC   HindIII 
Omp117rtL GGTGAAGGCATTTCCGACTT  Designed to amplify a 140 bp 
fragment of donC gene for 
quantitative PCR 
Omp117rtR TTGCCTTCCTGCCCTTTCTT  
16srL GATGCGTTCCATTAGGTTGTTG  Designed to amplify a 127 bp 
fragment of 16s ribosomal RNA 
gene for quantitative PCR 
16srR CACTGCTGCCTCCCGTAG  
anti-sigOK+2kL CACG AAGCTT GCGTACAGTA HindIII Designed to amplify a 1393 bp 
upstream fragment of donB 
gene 
anti-sigOK+2kR AGTC CTGCAG GGCAAACAGACGGATGATTC PstI 
anti-sigOK-2kL AGTC CTGCAG GTTGTGGGAGGATTCAGTCAT    PstI Designed to amplify a 1296 bp 
downstream fragment of donB 
gene 
anti-sigOK-2kR AGTC GGATCC CTCCGTATTGTTGGAGATCGA     BamHI 
sigOK-340L AGTC GGATCC AAATAAGAAACAATT 
ATGATTTTAAATAACGAGTCTAATAAGAAG    
BamHI Designed to amplify the donA 
gene with the ahpC gene 
ribosomal binding site 
upstream 
sigOK-340R AGTC GAGCTC AGGTGTGACTGATTACTCAA    SacI 
sRNA117+L AGTC GGATCC GTCAGCCATTCATTGTCAGA BamHI Designed to amplify a 693 bp 
DNA fragment including donS 
sequence with its -7 “TTTG” 










 Designed to amplify a 679 bp 
DNA fragment including donS 
sequence with its -7 “TTTG” 
change to “AAAC 
sRNA117-R AGTC GGATCC CTGCTGAACACTGTAACTCA     BamHI 
sRNA117-L TTGTCTCTTATCTCCTAATGCCTTACTTTTGCATCCCGA
ATTTTAGTGTTAAATCATAATATTTATTTC 
 Designed to amplify the donS 
sequence with an 82 bp 16s 
rRNA promoter fragment 
sequence tagged upstream. 
sRNA117-R1 AGTC GAGCTC GGATTCAGTCATGAACTGAAG     SacI 
16sPR-36-82 AGTCCTGCAGTTTACGTTTTTATTCAAAATATTTTCAAA
AAAATCCCCTTTTATATTTGTCTCTTATCTCCTAATGCC   
PstI 
 











Table 4.3. Oligonucleotides used in this study (continued). 
Name Sequence ( 5’ → 3’) Tag Description 
DonSP GCCACCTGATTCCGGATATGAAATCTGAAT  Probe for small RNA DonS 
0549P GGTGGCACACTTCCGGCTCCGGGTTAACAA    Probe for small RNA 0549 
1041P CCTTGTGAGCTTGTTTGGCGACAAGCTGAGA  Probe for small RNA 1041 
1270P GGTCTGGTACACCTTTCCCTCCCGATAAAGTCAA       Probe for small RNA 1270 
1469P TGAGAATGCCGATAGGTGTTCCCGCACCTA  Probe for small RNA 1469 
1035P ATTGGCGTATCTACCTGTATGAAAGTCCACCGTC       Probe for small RNA 1035 
2917P ACATATTGGGGTATGTCCTCCGATTCAGAA     Probe for small RNA 2917 
3123P CACCCATTTCCGATCCCCGAAATCAATCAA     Probe for small RNA 3123 
3597P CTGAGTTTTTTTAATCACGTCTCTTGCAGGAGGCGC     Probe for small RNA 3579 
3604P CCTCATATCATCCAACCCCTGATTAGATTAAACTACG     Probe for small RNA 3604 
4145P CAGATGCGCCAACACCTGCCAACCTCGGGT  Probe for small RNA 4145 






4.3   Results 
4.3.1   BF638R_3437 and BF638R_3438 encode regulators of the don operon 
                The typical genetic organization of the Bacteroides PULs includes regulatory genes 
adjacent to the susC orthologues. In the case of the don PUL, there is an ECF sigma factor 
homolog BF638R_3437 (donA) and an anti-sigma factor homolog BF638R_3438 (donB) which 
appear immediately upstream from donC (Fig. 4.1A), suggesting that they are the regulators of 
this PUL. To confirm their roles in regulation, in-frame deletion mutants for both donA and 
donB were constructed, and a donA overexpression strain was made by cloning the gene on an 
expression plasmid, under the control of a constitutive promoter. The relative expression level 
of donC was determined for the wild type strain and genetically modified strains in glucose 
defined medium (non-inducing medium) and mucin glycan defined medium (inducing medium). 
The expression of donC in the wild type strain under non-inducing conditions was as low as 
background levels and used as the baseline against which the expression in other strains and 
conditions was compared.  As shown in Fig. 4.1B, donC expression was highly induced in the 
wild type when grown in mucin glycan medium. When donA was overexpressed on the plasmid, 
donC levels were high even in the non-inducing medium compared to the wild type, and it was 
induced to the highest levels observed when grown in the inducing medium. When the sigma 
factor homolog was deleted from the cell, induction of donC expression was abolished even 
when grown in the inducing condition. The anti-sigma factor deletion mutant, ∆donB, was able 











Fig. 4.1. Relative expression of donC in different B. fragilis strains under non-inducing and 
inducing conditions. A) A schematic diagram of the B. fragilis don operon. B) qRT-PCR analysis 
of donC expression. RNA samples were obtained from mid-logarithmic phase cultures of the 
wild type strain (IB101), the donA overexpressing strain (IB558), donA deletion mutant (IB559) 
and donB deletion mutant (IB560). qRT-PCR were performed in triplicate. The donC expression 
level in the wild type strain under non-inducing condition (glucose defined medium) was used 












there was about an 80-fold up-regulation in the non-inducing medium compared to the wild 
type strain. From these data it is clear that the sigma factor homolog donA and anti-sigma 
factor homolog donB act as an activator and a repressor respectively and work coordinately in 
the regulation of the don operon expression in response to the presence of the substrate 
nutrients. 
 
4.3.2   A small non-coding RNA is divergently transcribed from the donC gene. 
                As described in chapter 3, when analyzing the primary transcriptome data of cells 
grown under standard growth conditions in BHIS medium, a group of putative sRNA signals in 
14 PULs were identified, including one in the don PUL. Based on the primary transcriptome 
map, all these putative sRNAs are located immediately upstream from, and divergently 
transcribed from the SusC orthologues of each of the 14 PULs (see chapter 3 Fig. 3.3). To verify 
the existence of the sRNA in the don PUL, northern hybridization analysis was performed using 
an oligonucleotide complementary to the putative sRNA sequence shown in the primary 
transcriptome map as the probe (Fig. 4.2A). As shown in Fig. 4. 2B, a sRNA species about 125 










Fig. 4.2. A small, non-coding RNA is divergently transcribe from the donC gene. A) A schematic 
diagram of the sRNA location and orientation in the don PUL. The probe used to detect this 
sRNA is indicated by the green arrow. B) Northern blot confirmation of the sRNA species. 10 µg 
of total RNA from a B. fragilis mid-logarithmic phase culture grown in BHIS medium was 
electrophoresed for analysis. Lane 1, γ-32P labeled low molecular weight DNA ladder. Lane 2, 
sRNA detected by the γ-32P labeled probe. C) Sequence analysis of the sRNA region in the don 
PUL. The TIS and -7 promoter sequence of the sRNA are underlined and indicated by “+1” and “-
7”. The DonC coding sequence is in blue and the sRNA sequence is in Red. The sRNA sequence 













                This sRNA is divergently transcribed and located immediately upstream from donC. 
The TIS ( from primary transcriptome data) of the sRNA is only 9 bases from the donC start 
codon and is adjacent to a consensus primary sigma factor recognition sequence (Fig. 4.2C). The 
location and orientaton of this sRNA suggests that it is a cis-encoded antisense RNA that plays a 
role in regulation of the don PUL. Since this sRNA is in the don PUL, it was designated DonS. 
 
4.3.3   DonS is a cis-encoded antisense RNA that negatively regulates the don operon. 
The location and orientation of DonS suggests that it is a regulator for the don PUL. To 
explore this role, a DonS silencing strain (IB561) and a DonS overexpression strain (IB563) were 
constructed. As shown in Fig. 4.3A, the sRNA northern blot confirmed that DonS expression was 
abolished in IB561 and DonS was highly overexpressed in strain IB563. To test the effect of 
DonS on don expression, qRT-PCR was performed to check the donC transcript level. As before, 
the expression of donC in the wild type strain under non-inducing condition (glucose defined 
medium) was used as a baseline control. The results in Fig. 4.3B show that expression of donC 
was up-regulated further in strain IB561 in the inducing condition (mucin glycan defined 
medium) compared to the wild type. In contrast, donC expression in strain IB563 decreased to 
background levels even for cells grown in the inducing condition. Gene expression microarray 
analysis (Fig. 4.3C) showed similar trend as the qRT-PCR analysis. Taken together, these results 








Fig. 4.3. DonS is a negative regulator of the don expression. A) sRNA northern blot. DonS 
expression is abolished in IB561, and highly overexpressed in IB563. 5s rRNA was used as a 
loading control. 10 µg of total RNA was analyzed for each sample. γ-32P labeled probes (Table 
4.3) were used for detection. B) qRT-PCR analysis of donC expression in the wild type, DonS 
silencing mutant and DonS overexpression mutant. qRT-PCR reactions using donC primers were 
performed in triplicate. The donC expression level in wild type strain grown under non-inducing 
condition (glucose defined medium) was used as a baseline. Results are the average of two 
biological repeats. Error bars represent the standard deviation. glu, cells grown in glucose 
defined medium; mcn, cells grown in mucin glycan defined medium.  C) Gene expression 
microarray analysis result of donC expression in wild type, DonS silencing mutant and DonS 
overexpression mutant. The donC expression level in wild type under non-inducing condition 
(glucose defined medium) was used as a baseline. glu, cells grown in glucose defined medium; 














4.3.4   DonS-like sRNAs are found in other PULs of B. fragilis 
                As mentioned in chapter 3, a group of putative sRNA signals in 14 PULs was identified 
when analyzing the primary transcriptome data of B. fragilis. To confirm the existence of the 
other sRNAs in this group, probes were designed for 10 of these (Table 4.4) and northern blots 
performed. As shown in Fig. 4. 4, 10 sRNAs with size range from 75 bases to 130 bases in this 
group were confirmed by northern blot analysis. These sRNAs have been named according to 
the SusC-like gene they are adjacent to. The other three putative sRNAs in this group 













Fig. 4.4. Northern blot confirmation of the DonS-like sRNAs in B. fragilis. 10 µg of total RNA 
from mid-logarithmic phase cultures grown in BHIS medium was loaded each lane for analysis. 
The left lane of each panel is γ-32P labeled low molecular weight DNA ladder. The right lane of 
each panel shows the specific sRNA species to that PUL using γ-32P labeled probes specific to 
that sRNA (Table 4.3). The numbers above each panel are the BF638R gene designation of the 














                This group of DonS-like sRNAs have several common features. First, they are all 
divergently transcribed from the susC homolog of the PUL. Their orientation and proximity to 
the susC homolog makes it likely that these are cis-encoded antisense sRNA that will negatively 
regulate that PUL expression like DonS. Second, they all have the B. fragilis primary sigma factor 
-7 promoter recognition sequence “TAxxTTTG” 5 to 9 bases upstream of their TIS and they are 
relatively abundant as estimated from the primary transcriptome data and the northern blot 
results. Third, many of the PULs in which they are located may be involved in utilization of host 
glycans as shown for Don. The evidence for this is that some of these PULs contain genes for 
glycoside hydrolase that target glycosidic linkage specific for host derived glycans. For example, 
donC in the don PUL encodes an endo-beta-N-acetylglucosaminidase homolog which 
specifically hydrolyzes the glycosidic bond between the two N-acetyglucosamine residuals on 
the host complex N-linked glycoproteins such as transferrin. A summary of these DonS-like 












Table 4.4. Characteristics of the  DonS-like sRNAs in B. fragilis. Except DonS, these sRNAs have 









* Laminin G is a protein domain which specifically binds to some type of glycosaminoglycans 




4.4   Discussion 
                This study clearly showed that the ECF sigma factor and anti-sigma factor genes, donA 
and donB, encode regulators for the downstream outer membrane complex genes in the don 
PUL. Constitutive over-expression of donA in the absence of inducing substrate significantly 
induced transcription of the donBCDEFG operon. In contrast, deletion of donA completely 
abolished expression of the operon regardless of the presence of inducing substrate. In the 
anti-sigma deletion mutant ∆donB, there was an 80 fold increase in donC expression compared 
to the wild type in non-inducing condition. This level of induction is significant but it is not 
comparable to induction in the wild type under the inducing condition (several hundred to 
several thousands). This low induction could be due to the fact that the anti-sigma factor DonB 
is a FecR type regulator which interacts with its cognate sigma factor to fully activate the sigma 
factor’s function in a process called sigma factor maturation (116). Notably, donC expression in 
the anti-sigma deletion mutant was induced to the same level as the sigma over-expression 
mutant under the inducing condition, seemingly like the presence of substrate can overcome 
the lack of sigma maturation. The increased expression of donC in the presence of substrate in 
all of the three modified strains, the sigma factor deletion strain, anti-sigma deletion strain and 
sigma factor over-expressing strain, suggests a possibility that the substrate is involved in 
second pathway to boost the Don complex expression. 
                The existence of a group of cis-encoded antisense sRNAs associated with some of the 
Sus-like PULs in B. fragilis was demonstrated in this report. Each of these sRNAs is divergently 




the don PUL, named DonS, was used as a model and we found this sRNA is likely a cis-acting 
regulatory sRNAs that negatively effects the expression of the downstream outer membrane 
complex genes. Small regulatory RNAs can affect gene expression in many different ways, 
including transcriptional and translational regulation (107-110, 117). As showed previously in 
chapter 2, donBCDEFG are transcribed in one operon. When antisense sRNAs are organized 
between two genes on the same messages such as donS in don, they usually repress 
downstream gene expression by transcriptional termination in which the sRNA binds the 
nascent mRNA and forms a termination loop, causing RNA polymerase to stop further 
transcription of the message (117, 118). It is very likely that DonS represses the don operon 
expression through a similar mechanism, since our microarray analyses showed that under 
inducing conditions, donCDEFG expression was completely abolished in the DonS over-
expressing strain the while the donB gene was still normally induced. This could be tested by 
using northern blot analysis to check the effect of DonS on the donBCDEFG message. 
                Evidently, the presence of the sRNA DonS adds another layer to the regulation of the 
don PUL expression. Different from the ECF sigma/anti-sigma pair DonA/DonB, DonS expression 
does not respond to the presence of the don PUL substrate and it appeared to be constantly 
expressed at a relatively high level during logarithmic growth phase. However, we observed a 
significant decrease in DonS expression when cells were grown into stationary phase in defined 
glucose media (data not shown). This differential expression of DonS could be a response to the 
varieties of stresses when cells enter stationary phase. It has been well-known that sRNAs can 
be implicated in integrating environmental stress signals and regulating a plethora of stress 




proteins (OMPs) stress, oxidative stress, iron deficiency stress and anaerobic stress (119). Here 
we suspect these DonS-like sRNAs respond to metabolite/nutrient starvation or perhaps 
envelope stress. The reason for this is that the genes under control of these sRNAs are PULs 
which are involved in nutrient uptake and they contain multiple OMPs.  
                It is also interesting to notice that many of this group of sRNAs may be specialized to 
regulate PULs which are involved in host derived glycan utilization. This hypothesis is supported 
by the presence of host derived glycan hydrolases in these PULs. As shown in Table 4. 5, among 
the PULs which contain a DonS-like sRNA, two encode sulfatases, two encode arysulfatases, and 
one encodes a laminin G. Sulfatases and arysulfatases has been implicated in hydrolysis of the 
sulfate linkages on various types of glycosaminoglycans (GAGs) (120), while laminin G is a 
protein globular domain which possess heparin binding activity (115). One PUL in this group 
encodes a chitobiase homolog, which specifically hydrolyzes oligomer, trimer and dimer of N-
acetyglucosamine molecules into monomers (121, 122). Another PUL in this group encodes two 
sialidase/neuroaminidase homologs, indicating its substrates are host glycoproteins or 
glycolipids rather than plant derived glycans (123). The potential substrates of these glycosyl 
hydrolases, as well as the confirmed glycan substrates of Don (chapter 2), suggest that these 
DonS-like sRNA regulated PULs are specifically involved in host derived glycan utilization. 
Notably, by enabling B. fragilis to utilize different host glycans, this group of PULs may indirectly 
affect the body site-specific colonization and growth of the bacterium in its host. For example, 
we demonstrated in chapter 2 using a rat model that the Don PUL acts as an extraintestinal 
growth factor by enabling the bacterium efficiently utilization of N-linked serous glycoprotein 




divergently transcribe from the BF638R_3604 gene (Fig. 4.4; Table 4.4). A recently study 
showed that this PUL allows B. fragilis to establish a resilient colonization in a specific niche 
within the colonic crypts that serves as a reservoir for stable gut colonization, so it has been 
named the Commensal Colonization Factor (CCF) (98). 
                Future directions for this project will be, first, test the hypothesis that DonS has an 
effect on the donBCDEFG message using northern blot analysis. Second, characterize another 
sRNA-PUL system to support our idea that actually these DonS-like RNAs are regulators of their 
adjacent PULs, and these PULs are involved in host glycan utilization in B. fragilis. Third, explore 
the possible stress conditions that these DonS-like sRNAs respond to. Forth, since these DonS-
like sRNAs have the same -7 promoter sequence, we would like to explore if there is a master 
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APPENDIX 2: INDUCTION AND REPRESSION OF B. FRAGILIS 638R PUL 
GENES IN VIVO AND IN VITRO 
 
*All values were calculated from the expression microarray data deposited at the NCBI GEO, accession # 
GSE53883.  B. fragilis 638R wild type cells were grown in vitro in defined medium with either 0.4% 
glucose (DM-G) or 2% mucin glycans (DM-M).  B. fragilis 638R cells were grown in vivo in the rat tissue 
cage for 1 (D1), 4 (D4), or 8 (D8) days.  Values given in columns C-F are the ratios (induction or 











BF638R0283  exported alpha-galactosidase 0.84 0.90 1.70 2.85 
BF638R0284 conserved hypothetical exported protein 0.84 0.60 1.28 2.08 
BF638R0285 SusC-like 0.61 0.82 2.58 4.84 
BF638R0286  regulatory protein 0.80 0.61 19.93 15.68 
BF638R0287  ECF-type sigma factor 1.10 0.74 0.83 1.09 
BF638R0288  exported alpha-galactosidase 1.63 0.94 1.18 0.86 
BF638R0345 SusC-like 2.29 0.85 0.17 0.16 
BF638R0346  lipoprotein 1.96 0.70 0.38 0.34 
BF638R0347  exported protein 2.14 0.40 0.23 0.24 
BF638R0348  exported protein 2.18 0.91 1.03 0.75 
BF638R0349  exported endo-arabinase 0.79 0.69 0.75 0.65 
BF638R0384 conserved hypothetical exported protein 1.99 1.61 0.40 0.33 
BF638R0385  beta-galactosidase 2.23 2.29 0.24 0.18 
BF638R0386  exported beta-hexosaminidase 5.52 3.61 0.35 0.32 
BF638R0387 conserved hypothetical exported protein 5.99 4.49 0.44 0.78 
BF638R0388  exported hydrolase 5.17 4.79 0.86 0.80 
BF638R0389 conserved hypothetical protein 4.17 6.56 4.08 3.39 
BF638R0390  exported protein 20.14 12.38 4.37 3.01 
BF638R0391 SusC-like 37.20 21.85 6.25 3.07 
BF638R0392 
 two-component system sensor histidine 
kinase 1.22 3.45 3.54 2.64 
BF638R0393  two-component sensor histidine kinase 1.78 11.73 3.31 2.65 
BF638R0394 conserved hypothetical exported protein 1.41 8.51 4.32 3.41 
BF638R0395 conserved hypothetical exported protein 1.27 2.73 1.72 1.52 
BF638R0397  exported protein 1.28 1.92 1.39 1.40 




BF638R0406 SusC-like 0.03 0.04 0.10 0.18 
BF638R0407  outer membrane protein 0.06 0.10 0.21 0.30 
BF638R0421  exported protein 4.32 3.75 1.32 1.30 
BF638R0422  exported protein 5.70 4.33 1.56 1.23 
BF638R0423  outer membrane protein 10.43 6.80 1.52 1.50 
BF638R0424 SusC-like 15.08 8.96 2.96 2.29 
BF638R0425 
 two-component system sensor histidine 
kinase/response regulator fusion protein 1.82 16.18 2.42 2.01 
BF638R0444 
possible exported xanthan lyase/N-
acetylmuramoyl-L-alanine amidase 4.30 2.57 0.83 0.69 
BF638R0445  cation symporter 4.23 18.45 12.65 12.29 
BF638R0446 conserved hypothetical exported protein 4.93 6.79 11.61 14.21 
BF638R0447 conserved hypothetical lipoprotein 44.85 25.01 10.22 16.46 
BF638R0448 SusC-like 55.44 30.24 14.86 22.53 
BF638R0546  melibiase 1.65 0.86 1.79 1.94 
BF638R0547  glycosyl hydrolase, alpha-xylosidase 2.40 0.86 0.91 0.89 
BF638R0548  outer membrane protein 2.16 0.99 1.19 0.85 
BF638R0549 SusC-like 2.97 2.36 7.81 4.60 
BF638R0550  anti-sigma factor 1.40 0.73 18.21 6.61 
BF638R0551  ECF-type RNA polymerase sigma factor 1.42 1.62 0.50 0.63 
BF638R0555 
 ATP-binding component of ABC 
transporter 0.42 0.23 0.13 0.27 
BF638R0556  ABC transporter 0.47 0.32 0.25 0.51 
BF638R0564 SusC-like 21.32 25.78 9.83 5.33 
BF638R0565 conserved hypothetical protein 9.58 13.48 4.87 3.46 
BF638R0566  arylsulfatase 6.60 6.71 2.58 1.69 
BF638R0582  RNA polymerase ECF sigma factor 0.91 0.66 0.92 1.08 
BF638R0583  anti-sigma factor 1.18 0.79 2.15 3.34 
BF638R0584 SusC-like 3.30 18.29 14.87 23.79 
BF638R0585  outer membrane protein 2.65 8.11 8.98 14.03 
BF638R0586 conserved hypothetical protein 2.50 5.69 4.39 6.85 
BF638R0614  RNA polymerase ECF-type sigma factor 1.54 1.30 2.48 3.91 
BF638R0615  anti-sigma factor 1.33 0.43 1.62 1.24 
BF638R0616 conserved hypothetical protein 1.32 1.77 6.72 6.50 
BF638R0617 SusC-like 2.19 2.80 24.96 29.00 
BF638R0618  outer membrane protein 2.06 2.16 9.34 14.91 
BF638R0619  beta-galactosidase 1.44 0.71 1.71 3.31 
BF638R0620  glycosyl hydrolase 1.32 0.64 0.84 1.39 
BF638R0621  glycosyl hydrolase/xylanase 1.30 0.83 0.86 1.32 
BF638R0636 conserved hypothetical protein 0.52 0.64 0.12 0.08 
BF638R0637 SusC-like 0.57 0.60 0.11 0.07 




BF638R0639 SusC-like 0.58 0.91 0.32 0.31 
BF638R0641 SusC-like 0.70 0.77 0.23 0.17 
BF638R0642  lipoprotein 0.65 0.85 0.30 0.23 
BF638R0643  GTP-binding protein 0.69 0.30 0.48 0.38 
BF638R0644 conserved hypothetical protein 0.62 0.52 0.28 0.24 
BF638R0645  aminopeptidase 0.96 0.41 0.16 0.16 
BF638R0703 SusC-like 3.60 1.94 1.04 0.55 
BF638R0704 conserved hypothetical protein 2.61 1.39 0.66 0.36 
BF638R0705 conserved hypothetical exported protein 2.20 1.31 0.80 0.59 
BF638R0706 conserved hypothetical exported protein 1.66 0.94 0.43 0.23 
BF638R0722 conserved hypothetical lipoprotein 3.17 6.13 1.76 1.95 
BF638R0723 SusC-like 3.85 7.41 2.15 2.09 
BF638R0724  alpha-1,2-mannosidase precursor 2.84 6.11 2.05 1.62 
BF638R0725  alpha-1,2-mannosidase precursor 3.03 7.13 3.62 3.16 
BF638R0726  anti-sigma factor 0.77 2.23 3.46 4.25 
BF638R0727  RNA polymerase ECF-type sigma factor 0.59 1.17 0.65 0.43 
BF638R0728  alpha-1,2-mannosidase precursor 0.64 1.17 0.96 0.85 
BF638R0816  glycosyl hydrolase 1.68 0.74 2.88 3.75 
BF638R0817 SusC-like 1.96 0.96 1.47 1.24 
BF638R0818  outer membrane protein 1.13 0.69 1.06 0.83 
BF638R0819  lipoprotein 1.08 0.51 1.00 0.97 
BF638R0858  secreted sulfatase 1.50 2.38 0.31 0.26 
BF638R0859 possible alpha-galactosidase 1.34 2.98 0.32 0.24 
BF638R0860 conserved hypothetical protein 2.02 2.38 0.66 0.43 
BF638R0861  sulfatase 4.55 2.10 2.88 2.00 
BF638R0862 conserved hypothetical protein 3.68 3.97 3.52 4.19 
BF638R0863 SusC-like 4.95 4.21 3.53 4.12 
BF638R0864 
 two-component system sensor histidine 
kinase/response regulator fusion protein 0.99 0.87 0.57 0.43 
BF638R0920  beta-glucosidase 4.59 1.69 1.59 1.37 
BF638R0921  cytochrome c binding protein 2.95 0.71 0.47 0.40 
BF638R0922  transmembrane protein 2.41 3.45 1.04 0.81 
BF638R0923  outer membrane protein 6.39 1.63 0.80 0.62 
BF638R0924 SusC-like 7.44 0.78 0.18 0.13 
BF638R0925 conserved hypothetical protein 1.14 1.45 0.32 0.38 
BF638R0926 SusC-like 1.16 1.01 0.14 0.18 
BF638R0927 possible outer membrane protein 2.34 1.34 0.31 0.37 
BF638R0929 SusC-like 2.80 1.21 0.27 0.22 
BF638R0930  RNA polymerase ECF-type sigma factor 0.62 0.58 0.52 0.63 
BF638R0931  anti-sigma factor 5.77 0.82 11.63 6.73 
BF638R0932 SusC-like 3.68 0.64 0.17 0.14 




BF638R0949 conserved hypothetical protein 3.16 2.27 0.54 0.35 
BF638R0950 SusC-like 4.16 2.69 0.33 0.25 
BF638R0951 conserved hypothetical protein 1.43 0.82 1.04 1.61 
BF638R0952 SusC-like 2.06 0.69 1.01 0.74 
BF638R1032  RNA polymerase ECF-type sigma factor 0.80 1.33 2.93 2.41 
BF638R1033  anti-sigma factor 1.65 1.13 5.94 3.39 
BF638R1035 SusC-like 1.12 0.39 0.34 0.23 
BF638R1036 conserved hypothetical protein 1.10 0.37 0.12 0.10 
BF638R1037 
 endonuclease/exonuclease/phosphatase 
family protein 1.25 0.47 0.18 0.16 
BF638R1038  exported protein 1.93 0.39 0.32 0.37 
BF638R1039  RNA polymerase ECF-type sigma factor 1.47 1.12 3.34 2.11 
BF638R1040  anti-sigma factor 7.58 0.94 15.74 9.82 
BF638R1041 SusC-like 29.69 5.19 5.89 3.69 
BF638R1042  outer membrane protein 18.88 3.83 3.75 2.63 
BF638R1043  arylsulfatase precursor 14.97 4.08 4.27 2.98 
BF638R1045  arylsulfatase 1.77 0.48 1.58 1.74 
BF638R1264  alpha-glucosidase, glycosylhydrolase 2.19 1.49 1.18 1.11 
BF638R1265  ECF-type RNA polymerase sigma factor 1.17 0.34 0.22 0.23 
BF638R1266  xylosidase/arabinosidase 2.18 0.16 0.33 0.39 
BF638R1267 beta-lactamase 0.73 0.49 0.68 1.14 
BF638R1268 hypothetical protein 0.80 0.46 0.60 0.53 
BF638R1269  anti-sigma factor 0.56 0.39 3.33 2.04 
BF638R1270 SusC-like 0.79 0.74 2.71 0.93 
BF638R1271 conserved hypothetical protein 0.77 0.68 1.24 0.51 
BF638R1272  phosphohydrolase, Icc family 1.14 1.23 1.33 1.24 
BF638R1273 
possible phosphodiesterase/nucleotide 
pyrophosphatase-like protein 1.67 0.51 1.08 0.87 
BF638R1274 
 endonuclease/exonuclease/phosphatase 
family protein 1.94 0.62 0.43 0.37 
BF638R1323  RNA polymerase ECF-type sigma factor 0.76 2.33 5.17 7.21 
BF638R1324  anti-sigma factor 2.00 2.03 13.65 13.92 
BF638R1325 SusC-like 20.82 21.43 16.60 20.89 
BF638R1326 conserved hypothetical protein 20.04 17.86 12.88 17.23 
BF638R1327 
possible endo-beta-N-
acetylglucosaminidase 19.35 17.54 11.15 16.70 
BF638R1329 conserved hypothetical protein 20.68 15.05 9.62 13.49 
BF638R1330 conserved hypothetical protein 13.81 13.37 8.34 10.29 
BF638R1494  RNA polymerase ECF-type sigma factor 1.07 7.96 6.75 13.31 
BF638R1495  anti-sigma factor 1.20 1.83 11.32 4.29 
BF638R1496 SusC-like 1.07 1.47 1.04 1.05 




BF638R1498 hypothetical protein 0.96 1.08 0.97 0.79 
BF638R1499  alpha-galactosidase 1.03 1.68 0.99 1.04 
BF638R1620 SusC-like 1.14 1.99 0.97 0.79 
BF638R1621 conserved hypothetical protein 1.25 3.01 1.24 1.05 
BF638R1720 SusC-like 5.94 62.70 12.82 8.02 
BF638R1721 conserved hypothetical protein 5.43 74.43 16.70 11.68 
BF638R1722 conserved hypothetical protein 21.28 188.38 63.00 75.48 
BF638R1723 SusC-like 47.55 195.37 67.18 76.87 
BF638R1724 conserved hypothetical protein 13.49 163.55 7.43 4.49 
BF638R1725 SusC-like 16.81 152.89 5.42 2.61 
BF638R1726 SusC-like 3.38 7.18 0.44 0.25 
BF638R1727  exported protein 2.52 7.96 0.71 0.52 
BF638R1728 neuraminidase precursor 9.81 37.60 12.63 12.98 
BF638R1729 beta-N-acetylhexoosaminidase 19.66 128.60 15.90 15.22 
BF638R1730 sialate-O-acetyltransferase 11.99 75.34 4.85 7.61 
BF638R1731 sialate O-acetylesterase 2.60 3.43 1.19 1.28 
BF638R1732 beta-mannosidase 1.38 1.84 0.45 0.61 
BF638R1733 beta-N-acetylhexosaminidase 1.63 2.12 0.42 0.48 
BF638R1734  lipoprotein 1.29 2.37 0.27 0.40 
BF638R1735 beta-N-acetylhexosaminidase 1.28 1.18 0.52 0.43 
BF638R1736  outer membrane protein 1.09 1.27 0.37 0.38 
BF638R1737 beta-galactosidase 0.99 1.32 0.43 0.50 
BF638R1738 SusC-like 6.81 21.16 14.41 10.74 
BF638R1739 conserved hypothetical protein 5.40 6.36 3.37 1.96 
BF638R1740  outer membrane protein 4.59 3.95 2.57 2.02 
BF638R1751 SusC-like 23.68 6.85 0.81 0.62 
BF638R1752  outer membrane protein 19.34 6.23 0.68 0.67 
BF638R1753  alpha-1,2-mannosidase precursor 13.55 3.03 1.06 1.28 
BF638R1754 
 endonuclease/exonuclease/phosphatase 
family protein 4.03 1.65 0.55 0.58 
BF638R1755  Alkaline phosphatase 2.41 0.70 0.23 0.24 
BF638R1756 conserved hypothetical protein 2.22 1.03 0.29 0.29 
BF638R1757  exported protein 2.47 0.71 0.21 0.21 
BF638R1758  exported protein 1.83 0.92 0.23 0.18 
BF638R1928 SusC-like 1.01 0.85 0.26 0.29 
BF638R1929 conserved hypothetical protein 1.01 1.10 0.32 0.36 
BF638R1960 
 TonB-dependent outer membrane 
receptor protein 0.53 0.31 0.44 0.39 
BF638R1961 SusC-like 0.34 0.65 0.19 0.28 
BF638R1962 conserved hypothetical protein 0.32 0.42 0.09 0.15 
BF638R1963 conserved hypothetical protein 0.33 0.34 0.06 0.07 




BF638R1965 hypothetical protein 0.37 0.54 0.09 0.14 
BF638R1966 hypothetical protein 0.43 0.59 0.14 0.17 
BF638R1967 conserved hypothetical protein 0.42 0.46 0.10 0.14 
BF638R1968 conserved hypothetical protein 0.46 0.51 0.07 0.09 
BF638R1969  polysialic acid capsule transport protein 0.52 0.82 0.16 0.21 
BF638R2253 SusC-like 0.13 0.31 0.02 0.04 
BF638R2254  lipoprotein 0.15 0.28 0.04 0.07 
BF638R2329  lipoprotein 0.07 0.08 0.06 0.07 
BF638R2330 SusC-like 0.07 0.05 0.03 0.03 
BF638R2916 conserved hypothetical protein 2.63 1.04 0.73 0.95 
BF638R2917 SusC-like 3.23 1.30 0.83 0.70 
BF638R2918  membrane protein 3.26 0.78 1.83 1.64 
BF638R2920  ECF sigma factor 1.90 3.73 13.53 10.60 
BF638R2946  exported protein 15.80 3.53 8.07 1.32 
BF638R2947  membrane protein 18.11 3.53 7.19 1.50 
BF638R2948 SusC-like 34.43 8.37 12.90 2.29 
BF638R2949 conserved hypothetical protein 15.35 1.25 12.24 3.46 
BF638R3029  glutamine-dependent NAD+ synthetase 0.64 1.25 1.39 0.97 
BF638R3030  exported protein 0.39 1.59 1.85 0.87 
BF638R3031 SusC-like 0.37 0.46 1.07 1.09 
BF638R3032  exported protein 0.50 0.21 0.40 0.53 
BF638R3033  exported protein 0.67 0.77 1.70 1.00 
BF638R3120  sulfatase 1.48 0.63 0.39 0.24 
BF638R3121  exported hydrolase 1.64 0.50 0.60 0.33 
BF638R3122  lipoprotein 1.47 0.34 0.59 0.24 
BF638R3123 SusC-like 1.20 0.82 2.34 0.52 
BF638R3124  anti-sigma factor 1.81 1.40 3.64 2.52 
BF638R3125  sigma factor 1.15 1.73 0.78 1.22 
BF638R3167 conserved hypothetical lipoprotein 8.14 7.10 2.76 4.31 
BF638R3168  lipoprotein 2.90 3.23 1.60 2.29 
BF638R3169  membrane protein 4.07 3.93 1.86 3.07 
BF638R3170 SusC-like 4.23 4.61 2.72 3.57 
BF638R3226 SusC-like 5.03 3.82 1.24 0.67 
BF638R3227  lipoprotein 3.44 3.90 1.43 0.81 
BF638R3228  lipoprotein 3.73 5.26 3.18 2.70 
BF638R3290  exported protein 7.72 1.67 0.27 0.20 
BF638R3291 SusC-like 8.76 2.17 0.29 0.22 
BF638R3331 hypothetical protein 0.90 0.56 0.27 0.32 
BF638R3332  lipoprotein 1.08 0.42 0.53 0.44 
BF638R3333  exported protein 3.34 2.11 1.27 0.87 




BF638R3437  RNA polymerase sigma factor 3.60 23.33 14.85 22.79 
BF638R3438  regulatory protein 33.84 223.63 597.79 532.11 
BF638R3439 SusC-like 559.54 2146.72 933.46 1161.15 
BF638R3440 conserved hypothetical protein 505.26 1907.71 700.53 918.12 
BF638R3441  exported protein 334.26 1494.32 443.63 631.07 
BF638R3442  lipoprotein 233.61 765.28 367.94 438.35 
BF638R3443  exported protein 90.69 1227.85 235.37 363.24 
BF638R3466 SusC-like 0.50 1.92 0.96 0.68 
BF638R3467 conserved hypothetical protein 0.50 1.90 0.28 0.38 
BF638R3468  lipoprotein 0.51 0.82 0.08 0.12 
BF638R3469  peptidase 0.51 0.88 0.10 0.10 
BF638R3470 hypothetical protein 0.41 0.70 0.12 0.15 
BF638R3593  exported phosphatase 1.48 1.37 1.03 1.13 
BF638R3594  exported protein 1.69 0.99 0.49 0.38 
BF638R3595  exported phosphoesterase protein 1.81 0.89 0.72 0.48 
BF638R3596 conserved hypothetical protein 6.21 4.97 3.34 3.16 
BF638R3597 SusC-like 7.16 6.41 3.45 3.47 
BF638R3598  anti sigma factor 2.46 1.60 17.35 14.63 
BF638R3599  RNA polymerase sigma factor 1.76 1.46 0.82 0.69 
BF638R3600  lipoprotein 8.64 0.67 0.20 0.15 
BF638R3601 SusC-like 9.98 0.49 0.14 0.11 
BF638R3602 conserved hypothetical protein 6.63 0.82 1.21 1.83 
BF638R3603  membrane protein 10.52 0.87 1.31 1.01 
BF638R3604 SusC-like 17.96 1.22 1.82 1.44 
BF638R3605 
 regulatory protein (possible anti-sigma 
factor) 5.53 0.74 10.18 7.99 
BF638R3606  RNA polymerase sigma factor 0.87 0.49 0.83 1.81 
BF638R3783  transport related, membrane protein 2.67 1.65 1.55 1.22 
BF638R3784  sialidase 3.29 1.67 0.67 0.60 
BF638R3785 hypothetical protein 3.64 2.55 2.00 1.42 
BF638R3786  lipoprotein 2.56 1.55 1.31 1.32 
BF638R3787 SusC-like 2.70 1.54 1.41 1.28 
BF638R3788 
 N-acetylneuraminate lyase (sialic acid 
lyase) 1.90 2.57 1.51 1.69 
BF638R3789  GntR-family regulatory protein 1.29 0.38 1.12 1.22 
BF638R3796  exported sulfatase 1.59 0.76 1.08 0.84 
BF638R3797  exported uslfatase 2.21 1.11 1.20 0.82 
BF638R3798 conserved hypothetical protein 2.31 1.70 2.66 2.92 
BF638R3799 SusC-like 2.99 2.90 3.90 4.01 
BF638R3800  membrane protein 1.37 0.66 15.37 9.87 
BF638R3801  RNA polymerase sigma factor 0.59 2.08 3.20 4.32 




BF638R3820  membrane protein 4.68 4.53 12.17 6.41 
BF638R3821 SusC-like 2.13 2.18 2.17 1.33 
BF638R3822  liporotein 1.80 0.94 0.60 0.35 
BF638R3823  lipoprotein 0.95 1.39 1.07 0.74 
BF638R3824  exported protein 0.08 0.12 0.07 0.06 
BF638R4102 SusC-like 4.38 4.27 0.97 0.69 
BF638R4103  outer membrane protein 3.60 3.57 0.51 0.37 
BF638R4104  endo-beta-galactosidase 3.00 3.34 0.74 0.66 
BF638R4105  beta-hexosaminidase precursor 2.15 1.40 0.18 0.17 
BF638R4106  beta-glucanase 1.99 1.88 0.49 0.44 
BF638R4107  beta-galactosidase 1.92 2.37 1.23 0.59 
BF638R4108 SusC-like 2.63 2.12 0.42 0.36 
BF638R4109  outer membrane protein 2.44 1.50 0.46 0.42 
BF638R4142  glycosyl hydrolase 2.02 1.68 0.52 0.52 
BF638R4143 conserved hypothetical protein 1.71 0.96 0.30 0.28 
BF638R4144  outer membrane protein 2.27 0.84 0.48 0.42 
BF638R4145 SusC-like 2.75 1.19 0.37 0.23 
BF638R4146  anti-sigma factor 1.58 1.07 1.26 0.75 
BF638R4147  ECF-type RNA polymerase sigma factor 0.80 0.72 0.33 0.36 
BF638R4192  Transcriptional regulator 1.02 3.06 3.10 2.59 
BF638R4193 SusC-like 42.41 4.08 3.66 4.58 
BF638R4194  lipoprotein 32.61 3.23 1.83 2.95 
BF638R4207  RNA polymerase ECF-type sigma factor 2.17 7.16 12.22 11.38 
BF638R4208  anti-sigma factor 8.54 2.29 5.73 2.32 
BF638R4209 SusC-like 57.11 32.97 8.14 3.80 
BF638R4210 conserved hypothetical protein 24.09 9.37 2.59 2.31 
BF638R4247 conserved hypothetical protein 1.41 2.26 2.58 2.10 
BF638R4248 possible xylosidase/arabinosidase 1.71 2.17 2.75 2.22 
BF638R4249 conserved hypothetical exported protein 2.03 1.70 4.03 4.00 
BF638R4250  outer membrane protein 1.59 1.20 3.79 2.11 
BF638R4251 SusC-like 2.29 1.88 4.90 2.51 
BF638R4258 hypothetical protein 1.46 0.52 0.20 0.19 
BF638R4259  outer membrane protein 2.76 1.06 0.73 0.46 
BF638R4260 SusC-like 3.79 1.46 0.83 0.70 
BF638R4261 
 two-component system sensor 
kinase/response regulator fusion protein 0.89 5.25 3.59 2.53 
BF638R4328 SusC-like 1.91 1.69 0.17 0.19 
BF638R4329 conserved hypothetical protein 1.69 1.29 0.18 0.19 
BF638R4330 SusC-like 8.45 1.79 0.35 0.17 
BF638R4331  outer membrane protein 6.52 1.39 0.40 0.17 
BF638R4332 hypothetical protein 5.68 1.11 1.07 1.36 




BF638R4339 conserved hypothetical protein 2.18 1.09 0.12 0.14 
BF638R4348 conserved hypothetical protein 0.93 0.86 1.30 1.18 
BF638R4349  arylsulfatase 1.14 0.52 1.32 1.63 
BF638R4350 
conserved hypothetical protein; 
lipoprotein 1.24 0.53 1.10 1.81 
BF638R4352 SusC-like 1.24 0.42 1.10 1.61 
BF638R4353  anti-sigma factor 1.21 0.28 12.51 9.78 
BF638R4354  ECF-type RNA polymerase 0.95 1.05 2.02 3.62 
BF638R4443 SusC-like 2.59 2.06 0.41 0.36 
BF638R4444  lipoprotein 0.65 0.46 0.15 0.21 
BF638R4478 hypothetical protein 2.23 2.84 1.45 2.03 
BF638R4479  outer membrane protein 4.48 4.32 0.95 0.72 
BF638R4480 SusC-like 4.99 5.82 1.57 1.04 
BF638R4481 hypothetical protein 2.09 1.35 1.07 0.70 
BF638R4482  transmembrane sugar transporter 2.19 0.83 2.38 1.95 
BF638R4442  outer membrane protein 1.00 1.00 1.00 1.00 
 

















716 + bf638r_0002 omp 0 
AAATAGAAATAGTAATATTATTCTATTT
ATATGGTTTTTATGATATTGCAAA 0 
3187 + bf638r_0004 sugar transferase 0 
CCGTTATCTTGGCTTTTGCGCGAATAA
AAAATTTCCTTTACTTTAATAACTT 0 
14658 - bf638r_0012 hypo 0 
TTTGCAAAAATAAAGGATTAAATTTAT
ATTAATGGTTTTCCTTGCAGCATTT 1 
14734 + bf638r_0012 hypo 0 
TATTAATGGTTTTCCTTGCAGCATTAAC
CTATTTAAATTATCTTCGACAAT 0 
16811 + bf638r_0014 SAM superfamily 0 
AAACGGATGTACAAATGCAGCTGCGT
CTAAAGTTTTAGTAATTTTGTAGAA 1 





24900 - bf638r_0019 sulfate permease 0 
TTGCAAAATTACATAAAATAAATGGCA
ATATTATGTTTTTGAACATCTTAT 1 
25042 + bf638r_0020 rubreythrin 0 
TAATGGATAAAGTTCCGTGTTTTTTGA
ACTAAATCCTTATATTTGCGTTAT 1 
27348 - bf638r_0021 nadB 0 
ACCGCAAAGCTACAAAATAAGTTTTTT
CGTTGTGCTTTTCGTTGCCATTAA 1 
27425 + bf638r_0022 mem prt 0 
TCGTTGTGCTTTTCGTTGCCATTAATTC
ATAAATTTACTAACTTTCCGCCAA 1 













34441 + bf638r_0028 alpha fucosidase 0 
TATGACTGCACCTTGTTTGTTATATGG
CTACATTGTTTTATCTTTGTGCGT 1 
41129 + bf638r_0033 mem prt 0 
AATCTATGAGGGAACTTTGAGATAATA
TTGTAAAGTATTACATTTGTTTGC 1 
42445 + bf638r_0034 hypo 0 
TAATGCAAAAAATGGTGTTATATTGAT
CAATAGCTTTTAACTTTGCTGTGA 1 
44349 + bf638r_0037 hypo 0 
AATAAAATTGATAGCAGTTTATCCAAA
ATCTCTTTTTACCTTTGCTGCCAG 1 
44748 -     1 
GGCACGAAGATAGCGAAAAATTTATT
GGAATGAGTAAATGTAGCATTTACT 1 
46745 + bf638r_0040 mem prt 0 
ATTTTTTCTATATTTTAGCTTCTTGTTAG
GAAATAATATTATTTTTGTCAG 1 
















48461 + bf638r_0042 hypo 0 
TTCTACGGAGGAGGTGGCTACCCGAG
AGAGAGACACGGCAAATAAGAAAATA 0 
49845 + bf638r_0044 hypo-pseudo 0 
AGATGTGGATTGTAATATAGAATCTGT
CGATTTGGCAGAGTTGTGGAAGCA 0 
50914 +     1 
CTCTGCCTGATGACAAAGGAAACGGA
TGGTGGAGAAGAGCGTTATCATTAT 0 
52178 + bf638r_0049 hypo 1 
CTGTGATGCTCCGTGGTGAAAAGAGT
TATATGAATATGAAAATTATGAAAT 0 
54233 + bf638r_0050 hypo 0 
CTCCTTAAGGAAATGCCTATTCGTCAC
TTTTTATTTGTTATTTTGCACCAA 1 








59671 + bf638r_0058 metK 0 
ACGAAGCAAAAGTAGCAATAAATTCA
AAATATTATCTACCTTTGTCCCTGA 1 





61284 -     1 
AAGTACAAAAATAGACCAGACTTATTT
TGATGCAGCCATGAAATTAGGGCA 1 
62588 + bf638r_0061 
uroporphyrinogen 
III synthetase 0 
TCCTGTAATATTTATGGGGTTTTCCTTT
TAATTTTATACTTTTGTGCCCTT 1 





69533 - bf638r_0066 peptidase 0 
AAGTACAAAGGTAGCAATTCGCTTCG
GCTAACGAGACTTATTATACAAAAA 1 
69635 + tRNA-gln tRNA 0 
GTCTAAAAATATTTGGAAAATAGCTTG
CATGGCATTATCTTTGCATCGCTT 1 










































92778 + bf638r_0087 TCS-sensor 0 
AAGTAGTACGTTTGTTATCGAATTTAA
AAAAAGGATGTATTTTTGTTGGGT 1 
95605 + bf638r_0089 hypo 0 
CGCGGATTCTTGAAAGAACTACAAGA
GCGCTTTTGTATAATTTGAAGTTTTT 1 
95716 + bf638r_0089 hypo 0 
CAGATAAAAAAGGGTTGCTATGCTTTT
ACTTTGATTGTATCTTTGTGAGGTA 1 








99476 - bf638r_0091 polA 0 
AAAAAAATACCGTATTAACCGTTTTAT
TATTACTTTTGTGCTCAAATAGTG 0 












107716 - bf638r_0101 gidA 0 
CGCGCAAAGTTACGAAAAAGTTGCCA
GTTGCGGGTTTTATGCAATAAGTTT 1 
108414 + bf638r_0102 lipoprotein 0 
TCCTTTGAAAAATTTGGAAGTGGCTGA
AAAGAATCGTAAGTTTGTCATCAT 1 
110223 + bf638r_0103 exp prt 0 
ATTGCTTTATATCTGTTAATCTGCTATT
TACAATGTTTAAGATGTTATCTC 0 
113100 - bf638r_0107 hypo 0 
AAGACAAAGATAAGAATTTTAATTGA
GGATAAGCGCAAATTGCAGTAATAA 1 
113416 + bf638r_0109 hypo 0 
TACTATCTTTTGAGACCGTAACTATTTT
GTTTTTTATATATTTGCAAATGA 1 





















120062 + bf638r_0115 ruvB 0 
CTCTGTGAAACTCTGCCTTACTATGTA
GCGAAATCTATATCTTTGCTACCT 1 
124037 + bf638r_0118 hypo 0 
ATTGTTGAAGAGTGACGGTAAGCGTG
TCGCCAGAGAAAAGAAGATGAATAA 0 
127175 - bf638r_0119 transmembrane prt 0 
CACGCAAAGGTAGCACTTTTAAAGACA
ATAATAAAGAGGGGAAGGATTTTT 1 
129826 - bf638r_0121 RNA helicase 0 
GGGTGCAAAGATACGCATTAATTGTG
AATAATGAATGATAACAATAAATAA 1 













133258 + bf638r_0126 peptidase 0 
ATCTGCAATTTTCTATAAACGACAATA
AGTTTTATTGTATTTTTGTGTCCT 1 
135073 - bf638r_0127 exp prt 0 
GGCGGCAAATGTATGGATTAATATGG
CTCTTTGGTCCGGGTGACTCTGCTT 1 
135279 + bf638r_0128 acetyl transferase 0 
AATGTTTAAAGACTGCTGTCTTCCGGC
TTATTCAGCTTATCTTTGCTCGAA 1 










142158 + bf638r_0136 hypo 0 
ATATCCAAAATATTAGTCGCAAAGATA
AGATTTTTATTACATTTGTCGAGC 1 
146534 - bf638r_0139 hypo 0 
GCTGCAAAGGTAAGGAAATCATCTGA
CTGACCATAAAAAAGGAGATCCGA 1 








157550 + bf638r_0146 hypo 0 
TTAGTGTAAAGTATAGCATTAATTAAT
GGATAAGGCTTATTTTTGCAGCAT 1 


















163813 + bf638r_0151 transmembrane prt 0 
TTTTTCTTTATTTTCTTTAAAATCAGAA
ATAAATACACGATATTTGTATAA 1 








170318 + bf638r_0158 TCS-regulator 0 
TTTCTGTCCGCATGACATTCAGGATAG
GAAAAAAGTCTTAACTTTGTGCCGT 1 
172531 + bf638r_0160 mgtA 0 
TAATTTGTTTCTAACTACCTTCTCATAA
GGTGGTTTGTACCTTTGTGGCGT 1 
176570 + bf638r_0162 lipoprotein 0 
TAATTTGTTTCTAACTACCTTCTCATAA
GGTGGTTTGTACCTTTGTGGCGT 1 
180505 - bf638r_0163 SNF family helicase 0 
GGATCAAAGATACGGGATTTTATGTA
ATTTTGCGGTATGATGGAAAAAAAC 1 






183278 + bf638r_0166 
pfkA2; 6-
phosphofructokinas
e 2 0 
TAGTCGTGCAAAAATAGCCTTAATTAT
CTTTTTTTTCTATCTTTACGACGG 1 
186844 - bf638r_0169 

















188689 + bf638r_0172 hypo 0 
AAAAGCAGGAAAGATTGGCTATATGG
AAAATATTGCATAGATTTGCCCGGT 1 
192995 - bf638r_0176 glycosyltransferase 0 
GATACAAATGTAATACTTATTTTGAAA
TAAAGGACTTTTATATTGCTCTTA 1 
194171 - bf638r_0177 glycosyltransferase 0 
GTGCAAAGATAGAACGTTTATATTAGA
ATGTTACTAAAAAATGGAGAAAAG 1 
194521 + b638r_0178 
transport ATP-
binding protein 0 
TATGCGATGATTTATAAATTCACTAAA
GATTTTCTGTTATCTTTGTGCCCT 1 





198324 + bf638r_0181 hypo 0 
GGTACGAATATATTCCATTACCGAACA
ACTTTCGTTTGTCAGTTGTTTTAA 0 
199787 + bf638r_0184 shikimate kinase 0 
TACCATGTGGGTCATTCGGTGTTCTCT
CAATAAATATCTATCTTTGTGCGAA 1 





208769 + bf638r_0190 ecf sigma factor 0 
AAATAGGAGTACTTCTGTAACTTTTCA
CCAGCTCATCCGTCAACTTAATAG 0 
212007 - bf638r_0194 lipoprotein 0 
ATTGATTTAGACGTAAGTCGGCTATGA
AAAGTTGCATCTATCTTTCTTTTT 1 
212088 + bf638r_0195 hypo 0 
TTGCATCTATCTTTCTTTTTTATGCAAA
ATAATCCGTTTATTTGTATTTAT 1 
213391 - bf638r_0196 transmembrane prt 0 
GTGATAAAGATAGTGATTTGTTTTATT
CATTACAAGAATAACGATACCTTT 1 
213447 + bf638r_0197 transmembrane prt 0 
AAAGATAGTGATTTGTTTTATTCATTAC
AAGAATAACGATACCTTTGCTGAA 1 











229623 + bf638r_0211 tetR regulator 0 
ACCATTTTTAGGGATTGATTATGTAAA
GAGATATTGCGAACTTTGCAAACG 1 
240103 + bf638r_0219 peptidase 0 
TTAGGAGAAAATCTTA1GATGTTTTAA
AATAAATTCATTTATTTTGCATTAT 1 
243575 - bf638r_0223 exp prt 0 
TATAAAGATACTTTTGTTTTAAAATTTC
TGCAATACCTAAAAAAGGGTATTT 1 
245937 - bf638r_0227 ecf sigma factor 0 
CCAAATATACGAAAAGTTTATAATCCT
TCCAAGAAACCGCAGTGCGTTGTG 1 








271932 + bf638r_0200 hypo 0 
AATTTGGAGAAAATTCTTTTTTTTCACG
ATATACTCTTATCTTTGCAACAG 1 
284377 + bf638r_0273 hypo 0 
TTTTCTCTAATATTTTGTAGTCGAACAG
ATTATTTATATCTTTGCACCCGA 1 








305077 - bf638r_0287 ecf sigma factor 0 
GCTGCAAAAATATAAAATATAAACTTC
TTTTCTTAATATTTATTACATTGT 1 





307666 + bf638r_0289 lipoprotein 0 
TCATTCCGGTACTTTGTTGTTACATAAA
TAAAAATATGTAATTTTGAGGAT 1 










312450 - bf638r_0292 cationic transporter 0 
AGCGCAAAAATAAGGAAATCATTTCA
AATCTGCGGTATTTTTTCTTCCTTT 1 
312573 + bf638r_0293 
gpmI, 
phosphoglycerate 
mutase  0 
AACATAGATTAAACGTGTTCGTAATTA
ACTTTTTTGTACCTTTGCACCCGA 1 










tRNA glu 0 
GAGTGCAAAGGTAGGGCTTTTTTTGA
AACTACCAAACTATTCGCGGAAAAAT 1 
324087 + bf638r_0300 recO 0 
GATAGTAGTATTCGATTGTCTATTTCCT
CTTTTTTTGTAGCTTTGTTACCG 1 
341181 - bf638r_0314 mraZ 0 
GACCGTAAAAGTAGGTATTTCCCCACA
ATTCCCCACAATTTTCCACCAAAA 1 
341951 - bf638r_0316 hypo 0 
AGACAAAGGTATGTGAAATAATGGAG
ATATACAAGGAAAATAAGCTGGAAA 1 
342168 + bf638r_0317 exp prt 0 
ATGCAGGAAGTAATGCTATTTATTAAA
AAATATGTTATATTTACGATTTAG 1 
346772 - bf638r_0322 sigE, ecf 0 
GATGCAAGTTTACGGCATTTTTTAGAC
AGTGACGGGGGAAAATTAAGCTTT 1 
346916 + bf638r_0323 mem prt 0 
TGATAGTTTTTGGGTGTTTTTGGGACG
CTGGGTTTTCTATCTTTGCGTCGG 1 
350251 + bf638r_0326 hypo 0 
TTCTACCGATTTATTGCGATTAATAAA
AAAGAACAGTTAATTTTGCGCAAT 1 

















362986 - bf638r_0334 exported hydrolase 0 
ATTGCAAATTAAATACGTTTTGGGACG
AACGGAGACACGTCCGGCTCAAGT 1 
366957 - bf638r_0336 glycosylhydrolase 0 
GATTTGCAAAATAATAAAATAGCAGAT
AACAGTTGAAAGCCTCCCTTTCAT 1 
373369 + bf638r_0340 lipoprotein 0 
TGAGCAGTATTTATCCCTTTATTCAACG
AAAATGTTTTTTCTTTGTAGCAT 1 
385493 + bf638r_0345 omp 0 
TGAACGAAAATTATCGTCTTATTAGTT
AAAAATAACTTTCCTTTGCAATGT 1 
394047 + bf638r_0352 glycosyl hydrolase 0 
TGAATAATAATTATCCTCCTTTCTCCAA
TATTTCCCCAATCTTTGTAACAT 1 





403846 + bf638r_0357 




405168 + bf638r_0358 mem prt 0 
CAAATTTTCGGTAGATAACGGAAAATA
ACACAAGCGTTTTTTTAGTTGT 0 
413636 + bf638r_0367 hypo 0 
TATTGTTATTTTCTTTTAAGGATATGTT
TGTAGTTATTATCTTTGTCAGAC 1 




417039 + bf638r_0371 exp prt 0 
TTAACGCCTCTATGTGCTTATATTCAGA
CCTTTCCGTTAACTTTGTCTGAA 1 
419595 - bf638r_0372 regulator 0 
GCTGCAAAGATAGGATAAAAAACGTA
AAAGGGTACAGCTACTGTCCGGATA 1 
419723 + bf638r_0373 hypo 0 
ATACATACCAGTTCGTATCAGTTACGA
TAGGTTTCATTATCTTTGCACTGT 1 





428365 + bf638r_0377 





431468 + bf638r_0379 hypo 0 
TTTTATTTCCTTTCTTTGTCCGTCATTTT
ATTCTCTATATTTTTGGCAGGT 1 
431496 + bf638r_0379 hypo 0 
TTATTCTCTATATTTTTGGCAGGTTAAA
AGATTTGTTCTTACTTTGTTAGC 1 


































471795 + bf638r_0406 exp prt 0 
GCTTACTTCACCAGTATTTTTTGAGGTA
TAATTATTGGAGTATAAATGCAA 0 






481258 + bf638r_0411 glyS 0 
TGTGCAGGCAAAAATACGAATTTAATT
GAAAAAAATCATTTACTTTGCAGAT 1 












496921 + bf638r_0425 TCS-sensor 0 
AAGTATCAAAAATAAAGTGTCAATCAT
TAAAATTTCTAACTTTGCTAATAC 1 





529869 - bf638r_0446 exp prt 0 
GTAGCAAAGATACTTTTTATTTTAATAT
CAAAAACAATTATTTAGAAATAT 1 
536453 - bf638r_0449 hypo 0 
GATACAAATATATAATATTTTTTGTAAT
TTGATTTGTTTTGATCGGAAAG 1 
537804 - bf638r_0450 asd 0 
GCTGCAAAATTATAACATTTTGCAATA
TAATCAGCATTTTAGAGAGAAGAT 1 
537921 + bf638r_0451 Na+/H+ antiporter 0 
CTTTCCTTATGAATTGGCGGTGTGATA
ACTTTTTTGTTATTTTGCAGATAA 1 





543798 + bf638r_0456 mem prt 0 
TTTCTCGCTTTAAACGTGCAAATATAG
AAAATGTTCCTTATATTTGCGATTCA    1 
545537 - bf638r_0457 murF 0 
GGGTGCAAAATTACATTTTCTATTTCA
GATTATCATTAAACAAGAAAGAAT 1 
546820 - bf638r_0458 transporter 0 
GTGTGAAGAACAAACGATCCGTTAGA
ATGTTCGGCACACAAGCAGCAGAAA 1 
546999 + bf638r_0459 gadB 0 
ATAATGTAAAACCGAAGAACTTTCATA
TCCTCTCACTGTTGTTGTGGGAA 0 
551597 - bf638r_0461 TCS-sensor 0 
AGCTGCAAAGATAACTTTATTTTTAGT
GTGCTGATAGCATTAGGACATTTA 1 











554213 + bf638r_0466 mem prt 0 
GAAAAATAATATTTTATTTGTTACCAA
CTCTTTTTTTGATTTTCTTTGCAG 1 


















558843 + bf638r_0473 exp prt 0 
ATCAGTCTTTCTCACTGGCGGTGGGCG
GGATAAGCCATACCTTTGCAATAA 1 
561707 + bf638r_0477 exp prt 0 
TTTTATGAACTCAAATAGTTTAAATCTT
ATTACTTTTTTATATTAGTACAA 0 
567895 - bf638r_0481 acetyl transferase 1 
TCAGCAAACAACTCGTTGATATACGAG
CTATCATCGTGTTTATAGACAACA 1 
569507 - bf638r_0482 hypo 0 
TTATATATAACAAAGATAAAGCTATTT
TGTTAGAGAATTCCTAATAATCGC 1 
570593 - bf638r_0484 LrgA, holin 0 
GTTGCAAAGTTATGAAAAATAGAGTTA
GGGTAGCAACTAATAAGGCACGAA 1 
570724 + bf638r_0486 hypo 0 
AAAATAAAGAAAAAGTAAACGAAATG
GATTACTTTATATATTTTTGCAAAG 1 













577928 + bf638r_0492 hypo 0 
ATTTATCCTCAATATTCTCTATCTTTCA
AAGAATTTCTTTAGCTTTGTCTT 1 
579113 + bf638r_0494 radC1 0 
ACCCAACTTTAATTTTTCCGGATTCCAA
TCGTTATGCCGGTCAGATAAGCC 0 








581907 - bf638r_0496 
efp, elongation 
factor P 0 
GGGTGCAAAAGTAATCTAAATCGGCA
AAAAACACAAAATGTTTTGACTAAA 1 
582006 + bf638r_0497 




582402 + bf638r_0498 mem prt 0 
ACTCGGTGAAAGTCTGTGATACTGTGT
AACGAAAATAGTATCTTTGTCCGC 1 
589373 - bf638r_0505 hypo 0 
GGCGCAAAGATACGGATTTCTATTCCA
AAACAAAAATAATTGTCTCATTTA 1 








593264 - bf638r_0508 proB 0 
CACAAATATATGGATTTTTGTCGATAT
GTTACCTCTCCCATACGGATATC 1 
593625 - bf638r_0509 hypo 0 
ACAAATATAACAAAAAGAACTTAGATA
AAGTTGTTTTACCGATAGATTATT 1 
595165 - bf638r_0511 ompH 0 
GGGTGCAAATGTATGAAATTAATTTGA
ATATCCTAATTTCGCCAGCACTTC 1 
600505 - bf638r_0515 hypo 0 
GTTGCAAAAATAGGAACATTTTTCTCT
ATATTGAACATTGAAGGGAAGTTT 1 
601701 + bf638r_0517 hemK 0 
TCTTTCATCTTTTAGGCTGATAGCTATA
TTATTTGTACTTTTGCACCCCA 1 











606731 + bf638r_0523 hypo 0 
TTGAGATTCTTCTTCTTTTTTATACCTA
AAAAAGTACTACTTTTGTAATAA 1 
609522 - bf638r_0524 hypo 0 
GGATGCAAATATAGCAGGTTGTTTGTT
CATTTAAGAACAATTTCTGTTCAG 1 
612732 - bf638r_0527 proC 0 
GACAAAGGTATAAGTAAAAAGTGAAA
ATACGAGCAAACGTGGCAGGTATTT 1 








618074 + bf638r_0534 TCS-sensor 0 
AACGTTTGTCTTTATTATATGTATAATG
CTATTTCCTTATCTTTACCGCAA 1 
621107 - bf638r_0535 gadC 0 
AGTGTCTATAACAACGTTTAACGTGAG
ATGTTTTAGTTTACTAACGTCAAA 0 
621257 + bf638r_0536 ion transporter 0 
AATCCGGGTGGGTATCAAACAAATCG
TGTAGGACTCTTGTTCCTTCTGCAT 0 
623324 + bf638r_0538 hypo 0 
TTTCGGCGGCTAATCATTCTTACGTCT
GTTTTTTATTTATCTTTGCAGTAA 1 
624256 + bf638r_0539 hypo 0 
ATAGATAGAATCATTAGGGTGGGGAG
TTTCCTCACCCTATTTTTGTGATAT 1 
628607 + bf637r_0544 mismatch repair prt 0 
TCGGCTGCAAAGTTATACAATTCCCGG
AAAAATATTATATCTTTGGGAAAT 1 










642105 - bf638r_0551 ecf sigma factor 0 
GCCGCAAGGTATGAAAAAAAAAGCAA
AAGAGGATTAATAGTTGTGAGTATT 0 
648454 + bf638r_0558 glcK repressor 0 
TTTTAAAAAAAGATTTTGTAGACTCAA
TCTTCTTTACGTAATTTGTGTGCAA 1 
650664 - bf638r_0559 50s ribosomal prt 0 
GGTGCAAAGTAACGAATTATTTGCCG
GATAGCCAAATGTTTTTGTATATTT 1 





667489 - bf638r+0568 hypo 0 
CAGAAAATAACAAGACTCTTGTTAAAA
GGTTCGCAAAGAATAATGTTAAAA 0 













673856 + bf638r_0575 atoC, TCS-regulator 0 
TCAGCAGTCCGATCATTTGCGTTGTAG
CAGAAAACCATTATATTTGCACGC 1 
683597 + bf638r_0582 

















690348 + bf638r_0586 frrI 0 
CATTCAGAATGAAGGATACTAATGCTT
CTTAAGAGATTATTATAAATTAAT 0 













699282 + bf638r_0591 hypo 0 
AGTGAATTAATTATGCCTTGTAATTAG
AAAAAAGTATTTATCTTGGCACAC 1 
699749 + bf638r_0592 permease 0 
TCGACCAAAAATTTTTCGCACTCCTTTT
TTTGTGCTAATTTTGTATCTTAA 1 













707429 + bf638r_0596 metA 0 
TGTTTTAATTTGTATATCTTCTAAATAA
GGAAAACACTATTTTTGCATTGA 1 
713726 - bf638r_0599 tonB receptor 0 
GTTTGCAAAGATGCAGCAAAAAATGTT
AAACGGCAATCCTCATTTATTAGG 1 
717864 - bf638r_0603 radA, dna repair 0 
GTCTCAAAGTTACGCATTTCGTCTTTTT
CTGCCAAACAGAATATAGCTTTT 1 








720032 + bf638r_0605 aspartokinase 0 
ATCAACAAAGATGGTTTTGTATGCCTG
AAAGAGCGTACAAGGCATTCCATT 0 





725544 + bf638r_0608 mem prt 0 
TCGTCCTTCTTTCTCCGAACTTTCCGTC
TCCCTCTTTTGTTGTACGGGAAT 0 
729969 - bf638r_0611 tonB receptor 1 
GGCGGCAAATTTACGCTTTTTGCTTGT
GTAAAGCAAGAAACACTTCGCTAT 1 
730050 + bf638r_0612 mscS, ion channel 0 
AGCAAGAAACACTTCGCTATTTGATAA
AAACATTGTAGCTTTGTCCGCTGT 1 
731322 - bf638r_0613 hypo 0 
ACAGTTAAAACATTCTCAAAGAGGATA
AGGTTCAAACTGTTTTTTCTTATC 1 
731383 + bf638r_0614 ecf sigma factor 0 
ATTCTCAAAGAGGATAAGGTTCAAACT
GTTTTTTCTTATCTTTGCCATTTC 1 
748134 - bf638r_0622 hypo 1 
CTTTCAATCTGTGGCGATTTCAGGTAT
ATGGCACATTTACCAGAACTTATT 0 
748367 - bf638r_0622 hypo 1 
GGCTGCAAAGATACGGTAACTCTGTG
TATCCTGCAAGAGCACTTCTTTCTT 1 


















755863 + bf638r_0631 hypo 0 
TTTATTGGCTTCTCAGTGTTTTTTCATT
ATTTATTTCTACATTTGCCAAGT 1 





764405 - bf638r_0637 surface prt 0 
AATATGATTATTACAAATTCAGATTGA
ACTTAGTGTAGAAAGAAACTGTAT 1 
769529 - bf638r_0639 tonB receptor 0 
TGCAAATATATTAAGAAATATGAAACG
GACAATCATTTTTATAAAAAAATC 1 
769904 + bf638r_0640 integrase 0 
TAAATCTTATTCAATTCTAATATAGTAC
CCAAGCACGTCTTATTTGTCCAT 1 
771721 + bf638r_0641 tonB receptor 0 
AAACTCTTATAATAAAGAAGTTATGAT
ATAATTGTAGTTCTGCAAAGACTT 0 
776167 + bf638r_0643 gtp binding prt 0 
GGGCGATTTTTTCTTTTAGTATGTTACG
AAAATAGCTATATTTGTCGCCAT 1 
779487 + bf638r_0645 pepN 1 
TAACCGCATCGGGCAATTGGCGTGAG
AGAGGGTACGAGTTATATAATATTTA 0 













800289 - bf638r_0657 hypo 0 
TTGTTTCTTGACTTTTTCGTGAAGCAGT
ATTTTTTGCTTTTCGACCTGTTG 0 
803347 - bf638r_0659 hypo 0 
TTTGTTAATATATGACTTTTTTTATATG
AACATCCTCCAAAAAGATTTTTT 0 
805903 - bf638r_0662 
frr, ribosome 








816122 - bf638r_0669 pyrH 0 
TGCAAAGATACGCGATTCCTTTTAATG
GACTATCTTTTTTGCTAAAAAAG 1 













819068 + bf638r_0673 hypo 0 
AGTGAGTATGTGACTTGGGAATACAC
AATATAAATACTATCTTTGTAGGGA 1 
821139 - bf638r_0674 hypo 0 
CAGGGTCAAAGATAATGGTTTAAACTT
TAAATCTCAATTTTAAAGAATGTAT 1 
822720 - bf638r_0677 hypo 0 
TCTGCAAATTTACTCTTTTTATTCTTTG
AAATTACAGAAGTAAAAGTAAAT 1 
822779 + bf638r_0678 hypo 0 
TTACTCTTTTTATTCTTTGAAATTACAG
AAGTAAAAGTAAATTTGCAAAGA 1 
823794 - bf638r_0680 hypo 0 
GTAGTACAACAAACGTGCCAGAAGGA
TTGTTTATTTATTTTTTCTTGTTAA 0 







825373 + bf638r_0683 dnaE 0 
TTTTGATGTTTATCTTTGTTAGTAGCTG
TAGACATTGTAATTTTATGGCTT 1 
829203 + bf638r_0684 trxA 0 
AAGGAACGTCCCGAACTTGCGTTTCAT
ATAAATTGATTATCTTTGCCGCAT 1 
830906 - bf638r_0686 mem prt 0 
GCTGCAAATATATCATAATTCTCTTACT
TTTGCTTCCGGTTTCGGACAAAA 1 
831785 + bf638r_0688 mem prt 0 
TTTTTAGTTTTGGTTGCAAATATATCAT
AATTCTCTTACTTTTGCTTCCGG 1 
839899 - bf638r_0697 hypo 0 
GCAAAGGTACTTATTAATTTGTATTATT
CCGTATATTTGTCCTTGCAATGTG 1 
839944 + bf638r_0698 amino peptidase 0 
TTTTCGCAAAGGTACTTATTAATTTGTA
TTATTCCGTATATTTGTCCTTGC 1 








860500 - bf638r_0708 aroA 0 
GGTTGCAAAAATAGGAAATCTATTCTT
TTTTGCCTCTATCCTCTTCCTAAA 1 
860742 + bf638r_0709 araC 0 
AAAGACTTGTGTAGTTACGGGGTTAAT
GTAGTTATTTTACTTTTGTATCAA 1 














868576 - bf638r_0714 aroB 0 
ACTGCAAAGATAGGAGTTCGGAGATA
AATAGTGAAACTTAGCACTTAAAAA 1 
868674 + bf638r_0715 mem prt 0 
AAATGTAAAACATGGGGTTCTGTTTGT
GAGAAAAAGCTATCTTTGTGACAT 1 





875823 - bf638r_0720 hypo 0 
AGCGGCAAATTAAGGAAAATTTTTCTT
ATCAGCCAACTTTTGAGCAAGAAA 1 












882584 - bf638r_0723 tonB receptor 0 
GTTAATAAAACAAGTGTCCCGAAAGA
AACACTTACTTCAGTTACTAACTTT 0 






891307 - bf638r_0728 alpha mannosidase 0 
TGTGCAAAGGTAGAGAATATAAATGT
AAAACGAAAGAGCTTGTGTGCTGAT 1 
892980 - bf638r_0729 efflux transporter 0 
GGTTGCAAAATTACTCCATCTGTTAGG
AATCGAATATAGGCTAATCTGTAC 1 
893093 + bf638r_0730 araC 0 
TTTCAGAACAAAATAGCCCGAATATCA
AAAATAAACCTACATTTGTTGCCT 1 










900602 - bf638r_0734 relA 0 
GCAAAAATAATCAAATTTAAACATCAG
GCAAGCGAAAGGCGATTTATTTGT 1 
904646 - bf638r_0739 parA 1 
CTTGCAAATATACGTATTAAAATTGAA
TATCGATTCCTTTTTTTACTCACT 1 
904970 + bf638r_0741 
surE, stationary 
phase phosphatase 0 
TCCTATTTGGTTCTGTTGTCGATACAA
GTTCTTTTTGTTACTTTTGTGCAT 1 










tRNA gln 0 
AAGAGCGAAAAGTATTTGTGATTAAA
AAAAACTTTGTACCTTTGCAACCGC 1 
913715 - bf638r_0747 hypo 0 
AGATCACAAATTAATGAAATAAAATGA
TTACTTCATACTATTTTCCTTTAT 1 






916077 + bf638r_0750 membrane prt 0 
TTAGGCTTTACTAATTTCATTTATCAAC
TAAATAACTACTTTTGCAGCAGA 1 
917231 + bf638r_0751 
pepD, aminoacyl 








925763 - bf638r+_755 hypo 0 
ATTACAAAGATACCCGAAAAAGTTTTG
CTATTTTGATTTTTGTGTTAAAAG 1 
925915 + bf638r_0756 hypo 0 
TTTAAGCTAAAAAGAACAAATCTTTAA
ACTTTAATTTGTTACTTTGTTAAT 0 
931873 + bf638r_0757 hypo 0 
TATTTTTATTAAAATGGTTTTTGTTGCA
AATAAAACTTATCTTTGTAGGAT 1 
934037 + bf638r_0760 hypo 0 
AATATGTAATCAATGGCAGAATCTCAC
TGAAAACCCCTATTTTTGTACTCT 1 
937225 - bf638r_0762 permease 0 
GATGCAAAAGTAACCAATTTATCGTTT
GAATTTTCTATATTTGTTTAATTT 1 
937272 + bf638r_0764 ABC transport 0 
ACTGATGCAAAAGTAACCAATTTATCG
TTTGAATTTTCTATATTTGTTTAA 1 
940399 + bf638r_0766 araC 0 
TTCGGGAGTGGAATAGAAGAAATTAA
AAAAGTGTGTTATATTTGTGGCTAA 1 










972143 + bf638r_0814 hypo 0 
ATTATGGTTAGCAAAACCGATAATTAA
GAATAATCTTGTATATTTGTGAGT 1 





974928 + bf638r_0816 glycosyl transferase 0 
GGATAAAATAATACTGGATGGTTTGAT
GGAATCCCGATAATTTTGCATTAT 1 
1002481 + bf638r_0833 membrane prt 0 
TGTTTCCTGTTTCGTTAGATTGTTTTCC
AAACTTTTTGTACTTTTGGGCAC 1 





1026321 - bf638r_0851 hypo 0 
GGTTGCAAATATAGAATTTAATTTTAT
CTCTTTTGCAAACTCCACGTGACA 1 
1031290 - bf638r_0854 
dxs, 1-deoxy-D-
xylulose-5-
phosphate synthase 0 
AATGCAAATTTAGTAAAAGAAAGCGG
AAGGAGCATCTTTTTGATTGGAAAT 1 
1033461 - bf638r_0856 transmembrane prt 0 
TTCACAAACTTAAAATATTTTCTTTGAA
AAAGGAGCTTTTCGGACTGATTC 1 











1040843 - bf638r_0861 sulfatase 0 
GCTGTAAAGTTACTCTTTTTTGGGTAG
AATACAATTTTTATTGAAAATAAT 1 
1046307 + bf638r_0864 TCS 0 
TTTTTTTTGAATCTCTTTTGTATGTTTAG
GCTTTATTTCGTTCTTTTGCAA 1 








1058848 - bf638r_0868 hypo 0 
ACAGCAAAAATACATGATAATTCCCGG
ATTTTCATGCGGACGGATGAAAAT 1 





























1071124 + nf638r_0881 hypo 0 
CTGATCGTGGAAATCGATCTGGAGAA
TCTGGAAAAATAAAAGAGAGATAAC 0 
1074268 - bf638r_0884 hypo 0 
GGCGTAAAAGTAATAAAAAACCGAAA
GATTGCAAATAAGATGGCTGGGTT 1 
1077613 - bf638r_0887 lpxD 0 
ACGCAAATAACGGACTTTTTTTTTATAT
ATCCTTACTCTTTGATGAATATT 0 
1079735 - bf638r_0889 pyrF 0 
TTACAAATTTACGATTTACAATTGAAG
TAACCGTCCGTTACAATTCACTCT 1 








2999613 + bf638r2545 sodB 0 
AAGTTTGGACAACTCCGAACATTTGGG
CCCTATATCCTGTTATATATTCAG 0 










3007877 - bf638r2554 hypo 0 
GGGCGCAAAAGTATATCATATTCATTA
ATTAAACAACTATTTCGATCATT 1 











3020332 - bf638r_2565 ppdk 0 
TTCGCAAATCTAAGGATATTTCGCAAA
CCAGAAAACTTTTATATGAAAA 1 





3023961 - bf638r_2569 













3032671 - bf638r_2576 Unkown fuction 0 
ACTGCAAATATAGTTATAATTATGTTA
TATAACAGATTATTAGTAACTT 1 





3033272 + bf638r_2578 Unkown fuction 0 
TTTATATTTTTTTATTTCTTGCAAAATTA
TTAAAAAAGTATCTTTGTCGG 1 







3035844 + bf638r_2581 Unkown fuction 0 
CAAGCGAGAACCTTGTTCGGTTCACTT
TTAACAACTATCTTTGCCCAA 1 
3039986 - bf638r_2584 
phenyalanyl tRNA 
synthetase subunit 0 
CCGCAAAGTTAATAAGATTTTTTGGTT
GATGGGGAATGAATGGTTATAAAAAA 1 







TGTGCAAAATATTTTTAGATGAAAAA  1/2 
3062979 - bf638r_2603 DnaB 0 
AGGCAAAGATAATTCTCTATTATCAAT
TTTCCATTATCAAATCTGAATTATT 1 
3063049 + bf638r_2604 
4-diphosphocytidyl-
2-C-methyl-D-
erythritol kinase 0 
ATCAATTTTCCATTATCAAATCTGAATT
ATTTATTTAACTTTGCGTCCA 1 
3067983 - bf638r_2607 galE 0 
TTGCAAATGTAACAAAATTAATTTAGA
TAAATGCACAAAAAACGAATATT 1 
3075909 - bf638r_2616 Unkown fuction 0 
GGGCAAATTTACATTAAATAGTTTAGA
TTACATAAAATTTGCTCGATTTTA 1 
3076222 + bf638r_2618 CTP synthetase 0 
TTTGTTTTGTAGAAAGCATCCGTTCTTC
CCCATTTTTTTGTAATTTTGCGGT 1 
3081229 + bf638r_2621 Peptidase 0 
AACTGGCAGAAAAAGCAGATTTGACC
TGATTTTTGCTTATCTTCGCAGCA 1 





3086197 + br638r_2625 acyl transferase 0 
TTAAGTCCCTTTCACCTTATTATAAATG
CAAATTATCACTATATTTGCCGT 1 
3088526 - bf638r_2626 transmembrane 0 
GCAAATATATACTTTTTACTGAAATTA
AACAGTATATAATACACAAA 1 
3092131 - bf638r_2628 uvrA1 0 
GCTGCAAAATTAATGTTTCCGCCCGAA
ATATAGTTTTAAAAAACACAATA 1 
3092240 + bf638r_2629 Unkown fuction 0 
TTAACTCAATATATTATGTGAATGTAT
GACATTATTCGTACCTTTGCCGTAA 1 
3096575 - bf638r_2633 YfiO 0 
GCGCAAAGTTAAAGATTCGCGCTGAA
TAAACCAATTAATCAATGTTTTTTAAG 1 
3098526 - bf638r_2635 paak1 0 
TGTGCAAAGTAAAGGATTTATTTTAAA
ATTTGATTTGTTTATCTCAACTATT 1 
3100804 + bf638r_2637 Unkown fuction 0 
GGTTTTCTATGAAACATTTGCCAAGAT
CTCAAAAATCTGTATCTTTGCATT 1 
3103067 + bf638r_2640 Chaperone 0 
 
0 





3114151 - bf638r_2647 with signal peptide 0 
ACTAACAAATATACGAATAGTTCGTAA
CTCCGGATTGTTTGTACGGATAAA 1 
3114438 + bf638r_2648 Unkown fuction 0 
TTATATCGGGCCTGCTTATAAATCGTA
TATTTTACCTAAGTTTGCCGT 1 














3126766 + bf638r_2655 Unkown fuction 0 
TCAAAACCAAGTCTTCCAATATTTCAA
ATTAATTATCTACATTTACGGTCAT 1 
3128434 - bf638r_2655 Unkown fuction 1 
AATGCAAAGATAGACTTTTTCTGCAAT
GTATGGTAGATTTTATGTAGAATA 1 





3139492 + bf638r_2669 Unkown fuction 0 
CATTCCTCCCGTTTTTCGAGGTTATTCC
AGAGATTTCTATATATTTGTAC 1 
3140799 + bf638r_2670 dapF 0 
AAGACATGCTTTTTATAAAAACAAAAG
TCAAAAAGACATATCTTTGTGCGG 1 
3143704 - bf638r_ 2672 Unkown fuction 0 
AAAAAGAACAAATGAATTTTGTAATAA
GTTCATAGCAAGATTGTAATATCT  1/2 





















hypo or  sRNA 1 
CCCTAAAAAGGGGATTGTGGCAACCG
CCGAAACCGCCTATCTTTGCAGTAT 1 
3165387 - bf638r_2693 Unkown fuction 0 
GGGTGCAAAGAAACACAATATTTTAAT
GGTATACAATCACTATAAATAGGT 1 
3165554 + bf638r_2695 Unkown fuction 0 
AAATCACAGATTATTATTCATCGTTCAC
CACTATTTTTTACCTTTGCACAAT 1 
3166855 + bf638r_2696 Flavodoxin 0 
TTATAAATGGGGATTTTCTATTTCTGCC
GGACCGCCTATCTTTGCCGTAT 1 
3171242 - bf638r_2702 









3175499 - bf638r_2705 hypo 0 
GGCAAAGATAAGAAGTATTCCATAAT
GGAACAATCCCCATTTATAGGGATA 1 
3176938 - bf638r_2707 Unkown fuction 0 
GGACAAAAGTAATAAAATGAATCTGA
ACCGGGAAAAATAAAGTCAATAAA 1 
3181057 - bf638r_2710 permease 0 
GTGCGCAAAGGTACGTAAAAAACTGT
TTTCGACTATAGCAAAAGAAGAAG 1 
3183026 - bf638r_2713 hypo 0 
GGCACAAAAGTACGCAGATCACCAAG
TGAAGGCAATACCTACTAATATCT 1 

















3202906 - bf638r_2728 
cabohydrate kinase 
pfkb family 0 
GACACAAAGATACGTAAATTTTCAGGA
TTACAAAAATTGTTATATATTTGT 1 
3202962 + bf638r_2729 
Sugar transporter 
or lacI regulator 0 
AAGATACGTAAATTTTCAGGATTACAA
AAATTGTTATATATTTGTGTCCAT 1 





3205261 + bf638r_2732 
hybrid Two 
component 
regulatory system 0 
TTTAGTCTAAACAAGAGGTACAATCCA
TTTATTATTAATACTTTTGTACAC 1 








3213343 + bf638r_2738 Na+/H+ antiporter 0 
ATGCAAAATTACCGTTTTTCTCCCTATC
ATTCACTATCTTTGCACCTC 1 
3216662 - bf638r_2739 Unkown fuction 0 
AGCAAATATATGCTATTTGTGCGAGAA
GAGAACCAACCTCAAAGCGG 1 
3216816 + bf638r_2740 Unkown fuction 0 
CTATCGTCTTTTCTACCGGACAACTCTC
TTTATGTGTACTTTTGCCCCCAT 1 
3217306 + bf638r_2741 rpsp 0 
AAGAACCGGAAGTCTTTGTCAATCAAA
ACAAAACCCTTATCTTTGCACCCG 1 
3220346 - bf638r_2744 RNA binding protein 0 
GCGGTAAATATAGACATTTACAACAGA
CTGAGAAACAAAATCATCATTTTC  1/2 
3224938 - bf638r_2748 ABC transport 0 
GGTGCAAAGGTACACATTTATCCGATT
CGTACATACATGTTAATCTAATAT 1 
3225036 + bf638r_2749 Unkown fuction 0 
ATAACAGAGAAATTCTATCCGGAATTA
AAAAAACACCTATCTTTGCATAA 1 
3231341 - bf638r_2752 glycogen synthase 0 
AGGTGCAAAAGTACGCATTATTTATTG
AAAAATAATGCTTTATGCAAAAAA 1 








3247835 - bf638r_2760 NagA 0 
GAAACAAAATTAGACACTTCTGTTGAG
ATAGAAAAATAAAATAGCTTTT 1 





3250209 + bf638r_2763 Unkown fuction 0 
GGAGAGAATTCCCAATTCTTTTCAGAA
TCGACCTTCATCTTTGCATTAT  1/2 
3253291 - bf638r_2766 Unkown fuction 0 
TTCGCAAAGATAACAAAAAAAAACGC
CCACCAAAAGATGAAGCGTTTTTT 1 
3254252 - bf638r_2767 Sigma 70 0 
AGTGCAAAGTTACGACTATTTATTTGT
TAACGTATAAATTTTCACAACTT 1 
3260170 - bf638r_2773 Unkown fuction 0 
GCAAAGATAGAAACTCTTTCCATTTTA
GATATATATTTTCAGAAACAT 0 
3260493 + bf638r_2774 ribonulase 0 
AATCCTCCCTTCCGTTTGCTCAAACAAA
ATAATTCTTGTACTTTTGCTGAC 1 
3263698 - bf638r_2776 ribE 0 
AGGGGTCAAAGATACAAAGAAAATGG
GATTGGATAAAGAATCAACATAAAA 1 
3264732 - bf638r_2777 phoU 0 
AGCAAATATACAATATTAAATGATACA
TCGAGCTGCATGCCGATCAA 1 
3267816 + bf638r_2781 Unkown fuction 0 
GCGGCACGTTTTGAAACAGGAATGTA
ACACGCTATTGCTTTATTTGCACAT  1/2 
3268828 + bf638r_2782 glns 0 
TATACCCGTGAAATAAGGATATACAAA
AAAAATATCCTACTTTTGCAGCAA 1 
3273158 + bf638r_2785 Unkown fuction 0 
TTTTCGTCCTCCATGCAGTACCTTTATA
TTTTCTGCATTTACTTATTGT 0 
3274559 - bf638r_2786 tpx 0 
ATATTCTAAACAATCGGTGCAAGAACT
TTGTTCACGATGGACAATAATCTA 0 





3277147 - bf638r_2788 mpi recombinase 0 
GCTGCAAAAATAGAGATAATAATTGA
AACTCCACAAACAAAATGATAATT 1 
3303474 + bf638r_2816 glycosyl transferase 0 
TTTTTAATAAATACTTTCCTCTTTATCG
GAAAAAGCATACCTTTGCAAAGA 1 
3318366 - bf638r_2830 phosphoesterase 0 
CCACAAAGGTAAAAAAAATATATCCAA
AAGCAACGCACCACAAATAAAAGT 1 
3320356 + bf638r_2832 Unkown fuction 0 
CTTTCTCCATTTTCTCAACCTTTCAGATT
TTCTCTTTATCTTTGTAGTAG 1 





3345064 - bf638r_2856 
polysaccharide 
biosynthesis protein 0 
GGTGCAAAGATACACTATTTTCACTAA
CACGTGCGTTTTTATTTGACAA 1 
3346594 - bf638r_2857 PhoH like 0 
GCAACTAAGATAACAAATAAAAAGGC
AAACAAAGGAAGTTGCCCGTTA 0 
3346560 + bf638r_2858 folC 0 
TTCTTTGTTCCCATGATTCTTAGATTTA
AATGTTGATATTTGCAATCA  1/2 








3356145 - bf638r_2865 DNA pol III 0 
AGCACAAAGTTACAAAAAAGATCGAG
GCAGCACAATAAAAGAGAAGAAAAA 1 
3356247 + bf638r_2866 Unkown fuction 0 
ACAGGGGAATATTCGTCGGATATCCCT
AAAAAATTGTAACTTCGCCGCAC 1 
3358377 - bf638r_2867 Unkown fuction 0 
AGTGCAAAAATAATAATTTCTCCAAAT
AAAACAAAATATACTTAAAGAAAG 1 





TTATACCAAATATATGTTGTTTA  1/2 







3377844 + bf638r_2887 Unkown fuction 0 
ACAATCCCCGGGACGATATGCTATACT
CTTTTTGTATATCTTTGCCGATC 1 
3380201 - bf638r_2888 AAA-ATPase 0 
AAATACAAAGATAACATTTTCTTCTGT
ATTTTACGTGTTGTACTACAAAA 1 
3380971 - bf638r_2890 Unkown fuction 0 
CCTACAAATATAAGTTTTAAAAAAGAA
CTATCCAAGCATACGGCGGAAG 1 
3382635 - bf638r_2891 ftnA 0 
ACTACAAAAATAACAATTTTAAAAGAA
AGGTTGTTCGGAGAAAGTGAAA 1 
3386917 - bf638r_2896 hisI 0 
GGCCGCAAAGATACGATTTTAATTCGG
GAATTTTAATTTCTCCGAAGTG 1 
















3394604 - bf638r_2903 regulator 0 
GGGCAAATATAGTGAGAATCACTCAC
ACCTGCTATTTATCCGAATACAAA 1 














3417475 + bf638r_2921 Unkown fuction 0 
AAAAGTTTTGAAGATGAATTTTATCAG
TTTTTATATTTATATTTGCATTGT 1 













3420527 + bf638r_2925 methytransferase 0 
TAATCAGGCCCGATTTGCCGGCCGGA
AGATTCTCCGTATCTTTGCCACAT 1 








3431279 - bf638r_2932 ion transporter 0 
GAAAGGCATATAGCCAATATCGTGCC
AAAACGGAAAGAAAAAGTACAAGTA 0 
3432310 - bf638_2934 HTH regulator 0 
CTGAGCAAAGATAAGCGATTCTACCG
GAATAACGCCCTGCTTTTGGTTA 0 
3432428 + bf638r_2835 transporter 0 
ATGATATCGGACGAAATAGTATGCAA
AAATAACGGCAACTTTGCAACCGGA  1/2 
3433714 + bf638r_2936 dehydrogenase 0 
CTTTCCACATTCCGTACCTTGTCTTATT
TTTATTTCTTATCTTTGCCTCAA 1 




TATGAAAGAAAATGATGATTTT  1/2 




TTTGTTCTCATAAAAGACTTCAC  1/2 
3453113 + bf638r_2951 Sigma Factor 0 
CTTGTAGAAATCGCAGCAATTTAGAAC
AAAAAGATTACTTTTGCACCTCT 1 
3459543 - bf638r_2954 efflux transporter 0 
AGCTACTTTACAAATCAGATACCAAAT
TATACCTGAACCGATCTTTTCAAC 0 
3459804 + bf38r_2955 phospholipase 0 
ATGGCATTCGCTACTTATTTATCAAATA
ATAGTATAAATTTGTAGTAA 1 
3462245 + bf638r_2956 Unkown fuction 0 
TTTCAAATTTATTACTCAGAACCAAAG
AAAGTCATTATCTTTACCGAA 0 
3463976 + bf638r_2959 NagA 0 
TCTCTTGAATTATAGTATATAAATGCA
AAAAAGTATCTAATTTTGCCAGAC 1 












3472373 + bf638r_2965 Unkown fuction 0 
ATCCTTGCCACTTACTCCATTCTTCATT
TTAAATTCTATCTTTGCTCCTAG 1 
3473780 + bf638r_2969 Unkown fuction 0 
TGCTTTATCCGTGCCCTCGTATAGCGA
AATTATCCGTATCTTTGTCCCCAT 1 
3479137 - bf638r_2970 
Transcription-repair 
coupling factor 0 
ACCGCAAAAGTACTAAATTATCCTTAG
TTTTAATGCGCTATCTTTGGTTAG 1 
3479216 + bf638r_2971 glycosyl transferase 0 
TTAATGCGCTATCTTTGGTTAGTAGCG
GAAAAGCATTACATTTGTCTTCAA 1 
3482707 + bf638r_2976 
tonB like outer 
membrane protein 0 
CTGGCAGCAAACTTGCAATAAAAGTTT
TCTTTCGATATATTTGTAACTG 1 





3487070 + bf638r_2982 Unkown fuction 0 
GCCCCCCGGAATAATAAATATTCAATA
TTATCTCCCTATATTTACAGACAG  1/2 
3488259 - bf638r_2983 Unkown fuction 0 
GGCTTCCAAATTTAATAAATATCCGGA
GACGAACCCCAATTACCACCAATT 1 
3488351 + bf638r_2984 Sigma Factor 0 
CACCAATTTTCACTCTTATTCTGTGATT




3499225 - bf638r_2990 exonulease 0 
AAACAAAGTTAGCAATTATTCAGGACA
GCAATATTATTTTGTTTATTTTT 0 





3513159 - bf638r_2999 Unkown fuction 0 
ACTCGCAAAAATAATACATTTTAAATT
ATAAACACATCTTATTCGTAAAAA 1 
3523831 - bf638r_3010 Unkown fuction 0 
CAGCAAAGATAAGCGAGTGCATAGAA
GCATGCAAACATTCTATGTCAACA 1 





3526034 - bf638r_3013 Unkown fuction 0 
TTCGTCAAATGTAGCGCATATTTTTCA
GACAGCCAAAGAAATTACCCGGA 1 
3528733 - bf638r_3015 Unkown fuction 0 
GACGACAAAGGTACAACGGATTCGTA
TGCAAATGAAACATTTTATCAAT 1 





3536911 + bf638r_3022 thioredoxin 0 
CGGGACTTCTCTGTTATTATAATAAAA
CAAATAACTATATTTGCCCCCTGT 1 





3539922 - bf638r_3026 fur 0 
GATGCAAAGATAAAGAGTTCTTTTATT
TTCGCAAACAAAATACGAATATT 1 
3540452 - bf638r_3027 Unkown fuction 0 
GCCACAAATATACTAACTACTATTTATA
TTTTTTATATTTTCCGCATTTA 1 













3555788 - bf638r_3037 hisG 0 
GCGACAAAAATAAAGTATTAGTTCTGA
ATCACCAAACAATTATCAGAAA 1 
3556364 - bf638r_3038 thioesterase 0 
GCTCAAAGATATAAATCTTTTCGCAAA
ATGCACCCATCTCACCACCAGAA 1 
3556445 + bf638r_3039 pirin 0 
CCATCTCACCACCAGAACTTTATCTATA
ATTCGTTTGTTATACAGATGT  1/2 





3559709 + bf638r_3042 udk 0 
GTTTTACCATTACGTTGTTATTTTAATT
ATTTGTTTTTATATTTGTCAGCC 1 
3563533 - bf638r_3044 symporter 0 
TGGTGCAAATGTAAGGAATTTATTGAA
ATAGAGAAACAAAATGCAGAAAT 1 
3567122 - bf638r_3046 metH 0 
GCTTTTTACCTTTAGCCAAAGCTACAA
CCACTTTGGCCAAACCTCTTTCAT 1 
3568907 - bf638r_3049 Unkown fuction 0 
GTTTGCAAAGATATAAATTCTAATTCA
CAATAAGTAAATGCAGAGACTT 1 
3569517 - bf638r_3050 Unkown fuction 0 
AGGAAACAAAAATACGGAAATATATG
GTTCAGAAAGGCTTTTTGATAAG 1 
3570482 - bf638r_3051 Unkown fuction 0 
TCAGAAGAAACAAAGAATCAGAGTAA
TAGTTCAACAAAACAAAGATTATC 1 
3570601 + bf638r_3052 
ion-sulfer cluster 
scafford like protein 0 
TAATAAAACCCGATTTGCAAAAACAAA
TAAAACGACTACCTTTGTGAGCGA 1 
3587164 + bf638r_3070 Unkown fuction 0 
AACAACCAAAGCATTGCTATTAAAAGA
GGAATGATTACCTTTGTCTTAA 1 
3588559 + bf638r_3073 
Ketoacyl-acyl carrier 
protein synthase III 0 
AGATTACAAGATATTGAATAAATCTTT
CTTTTCTGTATATTTGCGCCCGG 1 
3589749 + bf638r_3074 alpha amylase 0 
TTTGGGTAAACACAAGAAACCTTATCA
TACACTTCTTTGTTATTTTCCGAT 0 






3593756 - bf638r_3077 Unkown fuction 0 
GCAACAAAGGTACACTTTTATGAAGAA
AAAAAGAGTAAACGAAGACAAA 1 
3593785 + bf638r_3078 Rho 0 
AAGAGTAAACGAAGACAAAAACCAAA
ATTATTTATTATCTTTGCGGCGT 1 
3596101 + bf638r_3079 histidine kinase 0 
AGTGAGATTCTGTTTGATTCTCACTCTT
TTTATTTAGCTTTGCACTAC 1 
3600007 + bf638r_3081 
Na+-driven 
multidrug efflux 
pump  0 
TCCCCTATCCGCTCGTCTACTTCTACAG
AAAGTTGTATCTTTGCAACCTG 1 
3601382 + bf638r_3082 ffh 0 
AGAACAAAAAGATATAAAGTACGAGA
GATTTTTGTACATTTGCGGCTGA 1 
3603206 + bf638r_3083 lpA-like family 0 
TACTCTTGACAAAAAACAGGGGATGG
TAAATGATATTACTTTTGCCCGATA 1 
3608099 + bf638r_ tRNA 0 
AGTTCGCAGAATGTTTGCAGATTCAAA
AAGAATCGTTACCTTTGCATCGC 1 
3617859 - bf638r_3094 porin 0 
TAGCTCGCAAAAGTATAAGATATCCGC
AGCAGAGGCAATACCAAAAATTA 1 
3619219 - bf638r_3096 Unkown fuction 0 
AGCTATTAGACGTTACAACAACACAAA
ACGTTGCATGGCCGATCCTCTTTT 0 
3621169 - bf638r_3097 DNA pol III 0 
TTGTGCAAATGTACGCAAAAAAGTGC
AAGGATAAAAAAGGAAGCGAAATAA 1 





3626394 - bf638r_3104 Unkown fuction 0 
GGGTGCAAATATAGACTTTTGTACTGA
CTAAGCCTCCTTTTTTACCATA 1 
3626399 + bf638r_3105 
pepD, aminoacyl 
histidine peptidase 0 
AACAGAGTTATCAGTATTGTATAGAGC
ATTTCTATTAATTTTGTGGGTGC 1 
3630415 - bf638r_3107 ion channel 0 
ATCCAAATAACACCTAAACAGGCTTTA
GGTTTAGTCCAAATAAAAAAGG 0 
3640227 - bf638r_3112 sulfatase 0 
GGTGCAAATATAAAGAGTTTTAACAGT
CCGTCGAGTTCAAAAACAACTA 1 
3640403 + bf638r_3113 sulfatase 0 
AGCCTCTAACTAACAAGTCTTAGCTGA
AATTTGTATATTTGCAGACAT 1 
3643936 - bf638r_3114 Glycosyl hydrolase 0 
AGTGCAAAGATAGGATTTTATTTCCAT
TTTTTTGGTCACGTCTATGCAA 1 
3644004 + bf638r_3115 
 periplasmic ligand-
binding sensor 0 
TTCCATTTTTTTGGTCACGTCTATGCAA
ACTGTTACTTTTGCCGGTAA 1 
3649006 - bf638r_3117 gpmA 0 
ACTATAGAACATTTGTACTGAGTACAA
AGTTCACGAAACTTTTTCTAAAT 0 
3649099 + bf638r_3118 Unkown fuction 0 
CTAAATATCTATGCTGAAGTATGCTGA
TAAAAGTTACCTTTGTACACTGT 1 
3653095 - bf638r_3119 ABC transport 0 
AGGGCAAAATTATACCAAAATCCGCAC
AAAGAGACGGAATAATGCTAAAA 1 
3656331 - bf638r3121 Glycosyl hydrolase 0 
GTCCAAAGATAAGATTTTCTCCGGACA
GTTTTTTATCACACGGTTAAAA 1 
3661732 + bf638r_3124 FecR 1 
TAATCAATTAATACTGTTTAAAGTCTCT
AAAGGTTAAAAAGTTTTTGATTG 1 








3668975 + bf638r_3130 
phenyalanyl tRNA 
synthetase subunit 0 
TATTTCTTTCTATCCTCTTTGATTGCAAT
ATTATTGTTACTTTTGCAGCAA 1 
3672059 + bf638r_3133 pgk 0 
ATAACGATTTCATAGCAAAAAAGAGA
AATTAATACTAACTTTGCGGTCAT 1 
3680816 - bf638r_3140 laminarinase 0 
TAATAAGCAACAAACCGTATATTTATT
TAGTTCATCGTCCCCCATTGTT 0 
3681092 + bf638r_3141 
Acyl-protein 
synthetase, LuxE 0 
TAATCGATTGTGCGTAGGGAGATCAG
ACCATTTCACTGTCATCTTAATAA 0 





3689639 - bf638r_3149 Carbonic anhydrase 0 
GACAGCTCAACAAAATAAGCCCTGCA
AATGTTGTAAAGAGAAATAAAAAA  1/2 
3689705 + bf638r_3150 Unkown fuction 0 
GCCCTGCAAATGTTGTAAAGAGAAAT
AAAAAATGTAAATTTGTCCCGAT 1 




AAGAATTGATTTTCTTTGTGCTGT  1/2 
3698825 + bf638r_3158 amylase 0 
AAGAAAGAAAACGGAAAACAATCCGA
TGATTTACCCTATATTAGCAACAT  1/2 




AGAATATTCCTACCTTTGCAGCGA  1/2 











AGAATACGACTTTTTTTCCAAAAC  1/2 
3706476 + bf638r_3164 rpmE 0 
TTTCCAAAACTTTTTTCCTAAGAAACAA
AAAAGCATTATCTTTGCAACCT 1 
3708371 + bf638r_3166 Peptidase 0 
ATAGGAGAAAAAACAGCGCTGTAGGA
AACTTCTTTCGTATCTTCGTAACAT 0 
3719369 - bf638r_3170 OsuA 0 
GTAGCAAAAATACTATTTAAACAACAG
TCGCTTATTTAAATTCAAACAAA 1 
3719517 + bf638r_3171 OsuR 0 
AACATACTATCACTGAACTTTTCAGTCT
CCTTTACACTATTTTTGTGACAT 1 




TTTTTTGTATCTTGGGTGCCGT  1/2 
3724800 + bf638r_3174 efflux transporter 0 
ACAAACCGGAAAACTGTTTTTGGTTTT
TTAGTTTTATATCTTTGCGCCCTC 1 
3726055 + bf638r_3176 efflux transporter 0 
CTGAAATAAGAGTGCCCGTTCAACGCA
ATAATTAATTTCACCACAGATTA 0 






3736041 + bf638r_3180 Unkown fuction 0 
TCCTTTCCTAAAGTTTGCACTTCTCCAC
TCTTTTTATTAATTTTGTAAAAT 1 
3742924 - bf636r_3183 Unkown fuction 0 
GGTGCAAAGATACAATTTTGCTCCTCA
TTTGCAACGGTTAAGCAAGCAATT 1 
3743054 + bf638r_3184 uvrA2 0 
GTTCCTTCCACTGTTAGGTTAAACGTT
GCTGACTCACTATCTTTGCAGTCC 1 
3748206 - bf638r_3187 
Carbon starvation 
protein CstA 0 
AGCGCAAATGTAACATAATCTAAGGA
AACTACACAACTTTACGAAGGGTTT 1 





3753750 - bf638r_3190 Unkown fuction 0 
CTGCAAATATATGCACAAAAACGCATA
TAAAACCGGGAAACAGGTCACTT 1 
3754057 + bf638r_3191 ATPase 0 
TACCGGCAGAAACTACCGAAAACAAA
AAACAATATTTATATTTGCAAGCAA 1 
3764091 - bf638r_3198 opuAA 0 
AATTAAGTAAACAAGCCGAACGTTCAA
ATGGTTCATCGCATTATTTCCGG 0 
3767308 - bf638r_3200 sensor kinase 0 
GGAGGCAAATATAACAATTTCCCTCCG
GAATCTCCCACCTGCTTGGTTTA 1 





3773920 - bf638r_3204 
outer membrane 
receptor protein 0 
GCCGCAAAGGAACGCGGAATCCCATT
TCCCAACTAAAAGATTTGTTTCAAA  1/2 
3777198 - bf638r_3207 Unkown fuction 0 
GAAGCAAATGTAGATATTATAATTATA
CTAAGCAAGAGTTAAGAGAAAAAA 1 












TGTTATCTTGCTAACCGGAGTTT  1/2 
3784358 - bf638r_3212 ion transporter 0 
AAAGATAAAACAAACCAAAATAAAAA
ATAGTTTTAGAGTAAGTTTAAATC  1/2 
3794891 - bf638r_3220 efflux transporter 0 
ATATGCAAAGTTATTGGGAAGGGAGG
AGATAGAAAGGTTGAAATGAATGA 1 
3794890 + bf638r_3221 regulator 0 
CCTGTCAGAATAAGATAAATCTGTTTC
ATAATTTGCGTACTTTTGTATTTC 1 
3795981 + bf638r_3222 Peptidase family 0 
GATAGACGTTCATTTCCATATTTGGGG
ATATTCAGCTATCTTTGTCGCAT 1 








3805958 + bf638r_3228 Alpha-L-fucosidase 0 
TTAGTTAGTCCCCGGAACGAGTTTCCG
GGGATTTTTTTATCTTTGCACCAT 1 





3812026 + bf638r_3232 glycosy hydrolase 0 
ATGTCAAATGATTTGGCTATGTGGCTG
GTTTTTACGAATATTGCAACAA 0 
3817577 - bf638r_3234 CbpA 0 
ATACAAACAACACGCCAACCTGAGTTT
TAGATTCAAATTTTAGCACAAAT 0 
3819498 - bf638r_3235 NtrY 0 
GACAGTAAATATAGATATTATTCTCCT
ACTTTCAACACAAAACACAACAAA  1/2 













3823407 + bf638r_3238 Unkown fuction 0 
AAGTAACGTTCCGTAAGGTTTTTACCG
ACAAATCTTTATCTTTACAGTCT  1/2 




GAAAAAGAAAGGATTTCACCACAG  1/2 
3827875 - bf638r_3242 Sigma factor 0 
AGTGCAAAGAACGAAATTATTCACTTA
AAAACATACGATCATGATGGATT  1/2 
3827881 + bf638r_3243 Unkown fuction 0 
TATTTTTTTCTTTGTAACCTTTCCGCAG
CCTGCTGCGTCAAACAGTGCAA 0 
3828731 - bf638r_3244 Unkown fuction 0 
GCGGTGAAAGTTAACAAAATTATGCA
CGCATTGTTATTACAAAGACACTAA  1/2 
3828898 + bf638r_3245 poxB 0 
GCATACGTTAAATATACAACTTTTTATC
ACAACTACCTGTTATTGCAACAT 0 
3831486 - bf638r_3246 
NADPH-dependent 
FMN reductase 0 
AATACAAATATAATCAGTTAAATATGC
GATGGTTAAAGTAATATTGTTTCC 1 
3836168 - bf638r_3251 groES 0 
GCTGCAAATGTATGGATTCTTTTTAAT
GTAACCAAAATATTTCATTTCTTT 1 
3836387 + bf638r_3252 Unkown fuction 0 
TATTCATTCCTAATTAAAGATACGGTTT
CAGGTCAGAATCATTTGCATAG 0 
3846074 - bf638r_3259 
Polyphosphate 
kinase 2 0 
GTAATAAAGATACAAAAAATCGGGCA






3848580 - bf638r_3262 integrase 0 
AATGCAAAGTTAACTAATCATGAGGA
GATTTCGGTCTCCTCTTTCTGTTT 1 
3851660 - bf638r_3264 glycosyl transferase 0 
TTGCAAAGAAACAGCTTACGTATTACA
ATTGTTTGACGGAAGTATGACGA  1/2 
3851838 + bf638r_3265 glycosyl hydrolase 0 
CTTCCTTTATCCTGTGCGATACTGTCAG
TTTTTTCCTTATTTTTGCCCGAA 1 



















3862393 - bf638r_3272 Unkown fuction 0 
ATTTACAAAGATATATATAAAAAGAGA
CTATCAACATTTAGAACATAAAA 1 






3866541 - bf638r_3276 Fur 0 
GCCAACAAAGTTAATTGTTTTTTGCGG
AAAGCAAAAATATATCTGTAAATT 1 











TACACAACTTTTTCGTATATAT  1/2 
3871871 + bf638r_3282 recQ 0 
AAGAATATTTAACTTTTAATAACCCGA
AAATAAAGCGTACCTTTGCCTGAA 1 
3875996 - bf638r_3285 cysteine synthase 0 
GCGCAAAGATAAAGAAAAGAATCGTA
CCTTTGCGACCGTTCAATCTTTTTA 1 






















3892265 - bf638r_3297 Glycosyl transferase 0 
CCCGCAAAAGTACAAAAAATATGAAA
TAAAATAGGATTATTGAAACAACAA 1 
3898940 - bf638r_3302 leuA 0 
GATGCAAAGGTAGAGATTATTTCTTAG
CCTCCAAATAATACGTTACTTTTT 1 








3905953 + bf638r_3305 ferritin 0 
AAAATCACCCTTTCAGAAAACAAAATC
CCCTACCCCATGTTACATAACCAA 0 
3906703 + bf638r_3306 sspA 0 
TATGCGACTTATGGGATGAATTTCAAC
TCAATTATTTATCTTTGTTAGCTT 1 





3918867 + bf638r_3322 HTH protein 0 
AAAAATAGTAAAAATTGCACAACTAAT
AATTAATCAATATATTTGCAATAT 1 





3924672 + bf638r_3327 HTH protein 0 
ACTTTTCGTTATATCGGTAAAATTACGT
TTTTTAGACTATATTTGTCTTAT 1 
3929635 - bf638r_3328 
periplasmic ligand-
binding sensor 0 
TTCACAAAGATAATACATGCCGGACAA
ATAATTCTCAAGTGCATGATAAA 1 
3931805 - bf638r_3329 Glycoside hydrolase 0 
ATTTGCAAAATTAGCACATAAATAGAA
CATTCTGTTCTGCATTTGTGACAT 1 
3931948 + bf638r_3330 Unkown fuction 0 
GTCATGTATTTGGGTGCGTTTTTAAGT
ATAGATTTCTATCTTTGTACAAA 1 






3943669 + bf638r_3336 Acetyltransferase 0 
AAAAATGAATAAATATCACCCATTGGA
AATAAAATGCCATATTTGCACAAT  1/2 
3945766 - bf638r_3337 efflux transporter 0 
GGAACAAAAGTATAAAAAAGAAGCGG
ATAAACAATTTTCTCCCTCAAACGT 1 







ATCCATATCCTAATCCGGGACAAT  1/2 
3948124 + bf638r_3342 Unkown fuction 0 
ATCGTAATTCATAGTAATAATTATATTA
ATAACACTAGTTTTGTTATCAC 1 
3950211 + bf638r_3343 Unkown fuction 0 
TTCTTATCATCCGAATAGGGAATCTTCT
TATTTTTTCTGTCTTTATAATCAA 0 
3952547 - bf638r_3346 Unkown fuction 0 
CCACAAAGATATATTTTTTTTAGATAA
GTTAAAATTAATCTGATCTTTTAG 1 








3954752 + bf638r_3349 hdhA 0 
AGAGGGTTTATTCGAATAACAAATTCT
GAAACAGACTGTTTATGTAAGTAT 0 
3970745 - bf638r_3360 phage integrase 0 
GTTGCAAATAAAAGATTCCTCCAGCAA
TTGCGCAAAAGATCGATACCAAAT  1/2 
3972026 - bf638r_3361 HTH regulator 0 
AAGTTTTAAAACTAATAAAAAGATAGA





AGATCTTTTTTTGTTTTTAATATCA  1/2 
3972214 + bf638r_3362 pncB 0 
ATGAACCGATACGGAATGGATTACTAT
AGAATATTTTGTATCTTTGACGAG 1 












GTAGTCCGTTTGTGTTCCGTATAT  1/2 
3977850 + bf638r_3365 
acetyl-CoA 
carboxylase biotin 
carboxylase subunit 0 
TCGTGCAAAAAGTATCCATCCTATTCA
ATATTTCTCTATATTTGTCGCCGA 1 
3982904 + bf638r_3369 beta-lactamase 0 
TGTGATATCGCTATTTCCCGTGAACTA
AAAGCCGCCTATCTTTGCAACAT 1 
3986462 - bf638r_3370 impDH 0 
CATGCAAAATTACATCTTTCTTTTTAAT
TATGTGACTGGGGAAGGGAGATT 1 
3986982 - bf638r_3372 Unkown fuction 0 
CCCGCAAAGGTAACACAAATCGGCCT
ACGTTAGGCTTTTCTTATAAATTTA 1 
3987118 + bf638r_3373 Unkown fuction 0 
AAACAACACTACTTGGCAAACACTTTC
ATACCTCCGGTGTTATACATCAAC 0 








3995708 - bf638r_3378 
Cys/Met 
metabolism PLP-
dependent enzy 0 
GACGCAAAAGTAGAGAAAATTATTGG
TTTAAAAGGCTATCTTTGCGAGCGA 1 
3995758 + bf638r_3379 
N-acetylmuramoyl-
L-alanine amidase 0 
GACGCAAAAGTAGAGAAAATTATTGG
TTTAAAAGGCTATCTTTGCGAGCGA 1 





3999019 - bf638r_3381 Unkown fuction 0 
CCGCAAAGATAGTCATTTATCAGGAG
GCATCCCTCCCGAATGGCTACCGGA 1 












4004740 + bf638r_3388 Unkown fuction 0 
TTCTTTTCCGGATTCAAGAACCAACAC
ATACGGCTTTTGTTATTACCGCAT 0 
4007483 - bf638r_3390 his kinase 0 
TGAAGTACAACAATCGGGAAAAGAAA
AGGTTCGGTAGCGGTCCTCTACTTT 0 








4015534 + bf638r_3397 transglycosylase 0 
AACGTATGAACATCCTTTTTGGTTTAAT
CCTTTTGGTTATCTTTACCCCAC  1/2 
4023430 - bf638r_3399 helicase 0 
GTGGCAAAATTACATATTTATTTATAA
AGGAGACCTCTTTAATTTAAAGAA 1 
4023966 - bf638r_3400 Unkown fuction 0 
ACTGCGAATATACGTTATTTCTAAAAA
ACTATTGTATCTTTAGGTAATGAA  1/2 
4024012 + bf638r_3401 MgtC 0 
TTTGACTGCGAATATACGTTATTTCTAA
AAAACTATTGTATCTTTAGGTAA  1/2 









ACGATCTTCGTTTGTTATTTATAA  1/2 










4029414 + bf638r_3406 Unkown fuction 0 
AAATCAGCAAAAAAATAAGGTTTAGTC
TTTTTTATCTACTTTTGCAGGCAT 1 
4031545 + bf638r_3408 Unkown fuction 0 
TCCGTGTAATCTGTAGTAATTTAACAA
CTTATTTAGTAAATTTGCAACCTC 1 
4032306 + bf638r_3409 radical SAM family 0 
ATAGCAAAGCGGAGGTTTTCTACCTCC
GCTTTTTTTGTTATATTTATGCAA  1/2 
4036590 - bf638r_3411 Unkown fuction 0 
AAGGCGCAAAAGTAATTAAAAATCGT
GGGAGTACGTTTCTATCAAATAGAT 1 














4048448 - bf638r_3424 Unkown fuction 0 
ATTACAAGAACAAGGCTGAAGGAAAA
AATGTTCGGCGGGAAGTTGTTCATA 0 
















4050271 - bf638r_3428 phosphorylase 0 
GCTGCAAAAGTAATCAATTAAAGCCAA
ATTGACCAGATATTATCTTTAAT 1 
4055339 - bf638r_3434 Unkown fuction 0 
ACACAAAAATACGATTAACTCTGATAT
TACAAAAACTTTTCGGCGGAAAAT 1 
4055632 + bf638r_3435 maeB 0 
TATATCAGATAGACTACGATTTCGAAC
TTTTATTCCTACATTTGCGGGCAA 1 











4070909 + bf638r_3445 HTH regulator 0 
TAATATTCATTTTATTCATCTTATTCCAT
TTTTTCGTATATTTGCTTCGAA 1 
4071946 + bf638r_3446 Unkown fuction 0 
CAATTAATAGGTATTTTTCTGACAAGA
AAAAACTTGTAAATTTGCATAAAC 1 
4075207 - bf638r_3448 Unkown fuction 0 
CATTCAAATATACTACAAAAATACATT
ATTAACCCGTTTTCTCACAAAAGT 1 
4075218 - bf638r_3448 Unkown fuction 0 
ACTACAAAAATACATTATTAACCCGTTT
TCTCACAAAAGTTAATAAAATAA 1 
4084876 - bf638r_3456 Unkown fuction 0 
AACGCAAAGTTATAGTTTTCCTTTATTA
TAATAAATGCACAACATGCGATT 1 
4088052 - bf638r_3457 ppdk 0 
ACAGACAAAAGTCGCTGTTTTTATTGG
GAAAAACAAGAAAAAACAATTCAC  1/2 
4088395 + bf638r_3459 gdhB2 0 
AATACGCCATTCCGAATGACATCAGAA
AACTTTTCTTATATTTGCATATGA 1 
4089928 + bf638r_3460 aminopeptidase 0 
TTTTTATAAAAAGGTTTCATTTTCAACT
AAAATCGCCTAACTTTGCATCTC 1 
4096176 - bf638r_3462 Unkown fuction 0 
TTTGCAAAATAAGCACTTATTCCGCAA
TCTATCACTAACAGAAACTCCTTT  1/2 





4098005 + bf638r_3465 Unkown fuction 0 
TTTCGCTCTTCACTTTCCACTCTTCACTC
TAAATTTGTATTTTTGCCCTCT 1 
4099216 + bf638r_3466 TonB-linked OMP 0 
TATGTGTAGCGATTACACAGACTATTC
ATAGTATCTATCTTTGTCCCCCGA 1 
4109706 - bf638r_3471 Cold Shock protein 0 
AACGGCAAATATACACATTTTATTCGG
TTATTCCTAATTCTCCGGCCCCAA 1 
4126588 - bf638r_3489 NusG 0 
TGAAACATCATTTTTGATGAAATTCAG
AACCGGACAAAAAGAAAAATTCAA 0 
4126772 + bf638r_3490 Unkown fuction 0 
ATTTATAAAAATATTTTGCTATAGTAAA
AATACTGTTTACCTTTGTTCCAT 1 





4131450 - bf638r_3495 Unkown fuction 0 
AGCATAAAGATAACAAAAACAAACGA
CATATCATAGCAGAAGTCATACTAT  1/2 
4134236 - bf638r_3499 Unkown fuction 0 
GGAAACAAATGTACTTCTTTTCTGATA
AGATTGGCTACATTTGCACCAATT 1 
4134284 + bf638r_3500 Unkown fuction 0 
ACGGAAACAAATGTACTTCTTTTCTGA
TAAGATTGGCTACATTTGCACCAA 1 
4134959 + bf638r_3501 HTH regulator 0 
CGTGTGGCAATATTTGTATATACAAGA
AATTATCGGTACTTTTGCCACAGA 1 
4137300 - bf638r_3504 ruvA 0 
GAACGCAAAGATAATAAATATTGTGCT
TCACGAACCTTGAATAACAAAAAC 1 












4142550 + bf638r_3510 transporter 0 
CACTACCTCCCCCAACCGAAGAAGTCC
GATTTTGTTTATTTTTGTAGCACT 1 
4146200 + bf638r_3513 Unkown fuction 0 
GTAACATTCATATCATGATTATATAATC
CAAAAGTCATATATTTGCAATGT 1 
4150646 - bf638r_3516 peptidase 0 
ACGACAAATGTAAGCATTTCGCTTTAC
TTGCCGTCTGTTTCTTTATGCTAT 1 
4154017 - bf638r_3520 protease 0 
GACGCAAATTTACATGATTATTTTCAG
ATTACCACACCGAGATATAAATAA 1 
4155697 + bf638r_3523 Unkown fuction 0 
TTTTATCCATTTACAGCGATTATCTTAA
AATTATCCCGTATTTTTGCACAA 1 






4158244 + bf638r_3527 ubiA 0 
AGATAGACAAAAAAGCAAAAATATAC
GTTTTTTGCCCTATCTTTGTTCTCT 1 







4161877 - bf638r_3530 Unkown fuction 0 
TCTGCAAAGGTAACTATATTTGGGCAA
ACCTTACGTGCAAATGGAAAACAA 1 
4161903 + bf638r_3531 ppk 0 
TTTGTCATACTTTCTTTGTTTATCTCTGC
AAAGGTAACTATATTTGGGCAA 1 





4166963 + bf638r_3534 ABC transport 0 
AGCCCGCAAGGTATAAAAAAAAATCA
TAGATTTGATTATCTTTGCGGCTAA 1 
4169215 + bf638r_3537 efflux transporter 0 
TTAAGTAACACTGTTTGTTTTTTATCCA
ATGATAGACTATCTTTGCTTCGC 1 
4179445 - bf638r_3543 Unkown fuction 0 
ACCTGCAAATATCAAAAATATTTCGTC
TCTTTGCAACTTTCTGTGGCATGA  1/2 
4179483 + bf638r_3544 Unkown fuction 0 
TTGTGTATTAATACCTGCAAATATCAA
AAATATTTCGTCTCTTTGCAACTT  1/2 
4180444 + bf638r_3545 sigma factor 0 
TGGCTTTACAGAATTGCTTATAACGTA
TTTTATGATTATATTCGCAGCCGA  1/2 
4181485 + bf638r_3547 Phospholipase D 0 
GCTCTTGACAAAAAGAAGGCAAGAAC
AGAGATGTTGTATCTTTGTTTCCTT 1 
4182817 + bf638r_3548 thyB 0 
TTCACACCATTCCTGTAAGTTATTCAG
GCTGTTTTTGTAACTTTGGCAGGA 1 




























4192582 - bf638r_3560 tonB 0 
GGCACAAATATAACGCAGATATTTTAA
AAATACAGTATATTTGGCGAAAAA 1 
4192629 + bf638r_3561 cytidylate kinase 0 
TGTGGCACAAATATAACGCAGATATTT
TAAAAATACAGTATATTTGGCGAA 1 
4194406 + bf638r_3563 
6-
phosphofructokinas
e 1 0 
TTAACGTTATTTAATCATACAGGGCAC
TCCTTTTTGTTATCTTTGCAACGT 1 
4198359 - bf638r_3566 Unkown fuction 0 
AAGGACAAAGTTAAAAGAAAAACTTT
AAAGGGACAAATAGTTTACGAAAAT 1 
4203528 - bf638r_3569 aconitate hydratase 0 
ATTTATTATAACCAATAATATGAAAGA
AAGGTTTAACAAATTGAAATGTTT 0 
4203616 + bf638r_3570 DNA helicase 0 
AATTGAAATGTTTATTCCAACCCGGAA
ACAGAATTGTTATCTTTGCGGGAA 1 
4207725 - bf638r_3571 Unkown fuction 0 
GGCACAAAGATATATATTAAACTTGAT
TTATCTACCCAAACAATCTATCTA 1 
4214693 - bf638r_3578 ilvD 0 
GCTGCAAAGGTAAGTGCTTTTTTATAA
ACTCCAAACAAATTGAAGAAAAAA 1 
4225284 + bf638r_3585 
peptidyl-prolyl cis-
trans isomerase 0 
TCCCCACCAGTCCATAAATCTCTGACG
ATTAATTCGTATATTTGTCCCCAC 1 











4229313 + bf628r_3589 Unkown fuction 0 
GTAGGCATTCAAATGTATCTTTTCAAA
AAAGAAACTTAACTTTGCAGCCAA 1 
4233575 - bf638r_3592 Unkown fuction 0 
GGAGCAAAGTAACAGCTTTATTTCCAT
CCAAACAAGGTCTATCTTACGTAT  1/2 








4245766 - bf638r_3599 sigma factor 0 
ATTGACAAAGTAACAAATAATAATAAT
















4261212 - bf638r_3606 sigma factor 0 
AGTTGCGCAAAATAAATAAAAAATCAT
CAAATGTAGTTAATGCAGCTCTCT  1/2 
4261423 + bf638r_3607 aroC 0 
AAAACTCGAGAGAACAACTCTTTCCTG
AATTTTATTGTTATATTTGCATAT 1 





4268938 + bf638r_3614 fructosidase 0 
GGAAGGGAGAAGTAGTAATCCGTCTC
CATTTATTTTGTAGCTTTGCTTCGT 1 
4274596 - bf638r_3616 mutA 0 
GACTTGCAAATATACTGAAATACTCTA
AACCTCACGCTTTTTTAGGGAAAA 1 
4274737 + bf638r_3617 permease 0 
GGCAGGCAAATATTTGATTACCTCCGA
GGTTATAGCTAATTTTGCACCCGT 1 
4277168 - bf638r_3618 Cytidylate kinase  0 
AATAGCAAACATACACATTATTTCCGA
AAGAAGAAAATAAATAATGTACCA 1 
4277290 + bf638r_3619 matE 0 
TTATCAATTGGTAACTTTTATCCATTTT
CAGAGTCGTATCTTTGCAGCCGC 1 
4278683 + bf638r_3620 transcription factor 0 
TACCTGAAGGACTCTTTCGCCGTTCGC
CGATGATATGTATCTTTGCATCAT 1 
4282508 - bf638r_3622 Unkown fuction 0 
AGATAAAAGACAAATGCCGACTGCAA
TTTGTTTAGCCCACCGGCATGAAAG 0 
4284044 - bf638r_3623 vmrA 0 
GGGTGCAAAGATACAAATCTATTTAGA
ATTAAAGGTGAAGAATAAAGAATA 1 
4284144 + bf638r_3624 lysU 0 
AAGAGTTACAATGCCGTATTTCTAAGA
AAAGTTTCGTATTTTTGCCTCCAA 1 
4288988 - bf638r_3627 Unkown fuction 0 
TTTGCAAAAATACATATTCTGTTCGATT
CACCAAAATAATCGTATCTTTGC 1 






4290005 + bf638r_3629 phage integrase 0 
TGTTGTGCAATATTGCATATATGTTGT
GCAAAAGCCTTATATTTGCACAAC 1 
4293965 - bf638r_3630 EpsE 0 
AAAAGCAAAGGAAGTGAAAATATCTT
















4314841 - bf638r_3651 Unkown fuction 0 
ACTACAAATATAATAACATTATTGTTAT
TAAGCAAATATTCCAATAACTTT 1 
4325279 + bf638r_3676 phage genes 0 
TTTTGGTCACGAAATTTGTTGTTTCCAT
AATTTAATATTATAATTGTTGAT  1/2 
4329161 - 
 





4329348 + bf638r_3681 asnA 0 
TTAGCCTATTATTCATACAGATATAGA
TATTATTCATATCTTTGCCGACAA 1 
4333939 - bf638r_3683 ostA 0 
AGGGGCAAAAGTACACAATCTTCACC
AAATATACTTGAGAATCTTCATTTT 1 
4334917 + bf638r_3685 glycosyl hydrolase 0 
TTTTAATACGGAATGAAGATAATCAAA
AGAATTGATTGTATATTTGTGCAT 1 




AAACTTAACACTAAATAGTGAGTTT  1/2 
4339189 + bf638r_3688 
N-acetylmuramoyl-
L-alanine amidase 0 
ACTTAACACTAAATAGTGAGTTTTCAA
CAAATTTCTGCTACATTTGCACAT 1 
4341665 + bf638r_3690 dnaA 0 
AGAAAAAGGAGATTTGTTTTTCTCGAA
TAAGATTCCCAATTTTGCAACCGT  1/2 














ATATTTCTATACTTGCAAAATCATT  1/2 










4353861 - bf638r_3697 mgsA 0 
TGCACTAAGATACTACTTTTTATCCGTT
CGGGAATAAAGTGTGAGGAAGTT 0 
4357458 + bf638r_3701 luxE 0 
TTAACACCTAAAGGTTTCTTAATCCGG
AAGTTTATACCTACTTTTGCACAA 1 
4347070 - bf638r_3700 Unkown fuction 0 
AGCGCAAAGTTACACATTATTATTAGG
AGTAAAGAGGTGAAAGGAGTTAAA 1 
4359263 + bf638r_3702 Unkown fuction 0 
AGTTGGGCTTAGGAGTACAACATATA
CAAAAAGTACATACCTTTGCAGCGT 1 
4360971 - bf638r_3705 rpsF 0 
GGTGCAAAGGTAGGCATTTTATTTTGA
ACTGCAAACATTTAATCTTTTTTT 1 







AATTATGCGTTAATTTGTGACTGG  1/2 
4364326 - bf638r_3709 rprX 0 
GTTTGCAAATTTAATAAAAAATTAAAG
ATTTCTCTTCAGAAAATCTACTTT 1 





4369380 + bf638r_3716 FecR 0 
TTGCACACTTCCGATAGGGAGATTCTT
CAAACGCTCTGTCTTTATCCATGA 0 
4374489 + bf638r_3719 Unkown fuction 0 
GTTCCCCCAATGGTACCGGATTTATAA
AGAAACCACTATCTTTGTGCCCTA 1 
4375537 + bf638r_3721 Unkown fuction 0 
TTTCTTTCTTTGCGCTTTTATGTTGAAT
AACATATTTGTATATTTGCATAG 1 
4377286 - bf638r_3722 ATPase 0 
ATTGCAAATATAATAATTATCTTTTAG
GTAAAAGATGCAAGTGAAAATATT 1 
4379407 - bf638r_3724 Unkown fuction 0 
AAGGCAAATATAACTACTTTTGTCGTC
GCAAAGAAAGAAATGATGAAAGAA 1 
4379381 + bf638r_3725 
Queuosine 
biosynthesis protein 0 
TTACCATTTACAATCTACAAATTAAGG
CAAATATAACTACTTTTGTCGTCG 1 
4384298 - br638r_3728 mannosidase 0 
ATGCAAAGATAGTTTTTTTTCAGCTATT
CCAATTCACTTCATCTCCACATT 1 












4403054 - bf638r_3740 Unkown fuction 0 
CGTACAAATGTATTTTAAATTAGTCGA
ATCTTTAGATTTAAAAGCAGAAAG 1 
4404229 - bf638r_3741 DHH 0 
GTTGGCAAAAATACGATAAATCTTTGT
ACTTAGAGCAAAAACCTCACAGAA 1 





4410631 - bf638r_3746 Unkown fuction 0 
CGTGCAAAAATACTAATTTTGCCCAAT
AATAACAAAGGTTAAGAGAAAACA 1 
4410657 + bf638r_3747 
4-hydroxybenzoyl-
CoA thioesterase 0 
TTGATCTATTTCTTGTGAGAATAACGT
GCAAAAATACTAATTTTGCCCAAT 1 








4441521 - bf638r_3775 updY 0 
GAAACACACTTTTTTAAAGATCCAGAC
AATTAAAATACATATAAAAGCAGA 0 
4441706 + bf638r_3776 Unkown fuction 0 
TTTTATTAAACATTTTGCAGTTATGAAA
ATACCCTCTATCTTTGCGTTCAA 1 





4444726 + bf638r_3780 recJ 0 
TTTTTCAGTATATCCCCCACACTTCCGG
TTTTTTTCGTACTTTTACAGCTT  1/2 









GTAATTTTTCTCATCTTTGTATGC  1/2 




GAAAAACTAGCATCTTAAGAACTGA  1/2 













4477406 - bf638r_3801 sigma factor 0 
GCGGCAAAAATAGATAACTATAACTAT
ATAACCAAACTAAAATATAAGTAA 1 
4481300 - bf638r_3806 Unkown fuction 0 
TGTGCAAAGGTAACAATAATTAAAGTA
AAAAGAAAAGAGGGCACTCTAAAT 1 
4482805 - bf638r_3808 
Nucleoside 
diphosphate kinase 0 
CCCCAAAGATAGCATTTCCAGACGAAA
GAGAAGGCATGTTCTTAACTATTT 1 
4489173 - bf638r_3815 pdx 0 
GCGCAAAAGTACAAATATTAGCGATA
AGATAACAGCAATACCGAAAAAAAT 1 
4489240 + bf638r_3816  ATP-NAD kinase 0 
TTAGCGATAAGATAACAGCAATACCG






4497233 - bf638r_3818 Unkown fuction 0 
AAGTACAAAGATAAAAAAAAATCAAA
TATCGGTTCTTCAATCTAAAGTATT 1 













4514138 - bf638r_3828 mdh 0 
GACGACAAAAGTACAACGATAATCGA
AATTAAAGAAATTTTTCCATAATAA 1 
4514252 + bf638r_3829 Unkown fuction 0 
AAAGTGAATAGACTGTGTTACTCTGTA
TTGAAATGATTACTTTTGCAGCGT 1 






4519813 + bf638r_3833 efflux transporter 0 
AAAAATTAAATCGTTTTGCTTTTTAAG
ATTAACCCTTTATATTTGCATCGT 1 





4536718 - bf638r_3846 aminotransferase 0 
GCAACAAAAATAACCTTTATTCTTCAG
ATAGCCTCTTTTCTTGCAGTAATT 1 





4541682 + bf638r_3853 Unkown fuction 0 
ATAGCTAAAAGCATTTGCCTTCTTCAA
AAAGAATCAGTATATTTGAAGTAT 1 
4545414 - bf638r_3857 Rex 0 
GATTGACAAAATTACACTATTTTTTCCG
AAATGCCATAAGGATGTCATAGA 1 





4549158 - bf638r_3862 rplM 0 
GCTTGCAAAAGTACGGCTTTTCTTTGA
ATTGGCAAACTATTTCTGTCTTTT 1 
4549899 - bf638r_3864 Unkown fuction 0 
GTCACAAATATAAAGATTTCTTTTATA
AAAATAGCAATCTAAAGACATAAA 1 
4554377 - bf638r_3867 purB 0 
AGGCTGCAAAATTAACTCTTTTTCCTG
AGTTATAAGGCATAAGGGGAGAGA 1 
4556488 - bf638r_3868 beta-gal 0 
GAAGCAAAGTAAAGAAATAAATCACT






4558490 - bf638r_3870 Unkown fuction 0 
AAAGGAACAAAATTAATAGAAAAACG
GCAGTATGCACTTTTTTTCTTATTT 1 






4573047 - bf638r_3879 aapA 0 
AAATTCCGAGATAAAGAAGTGTCTTTA
AAGGAGTTGTTTTTACTAAAATGA 0 








4574992 - bf638r_3882 Unkown fuction 0 
ATTACAAATATAAGTTAATTATAAGAC
AGGCAGAAAAAAAGACGGGAAAAT 1 
4578554 - bf638r_3883 carB2 0 
TTGTGCAAAGTAACGACTTATTTCTAT
AATTACAAAGGAATCTGGTAAGAA  1/2 
4578654 + bf638r_3884 trpS 0 
ATATTCGTTTTATTTGTTACTTCTGCCG
ATTCTGACTATCTTTGCCCATTG 1 
4581111 - bf638r_3885 ompA 0 
ATTTAAATAACACCAACGAAACTAAAA
GGTTTTGGATAAATAGAAATTTCC 0 
4601065 - bf638r_3903 Unkown fuction 0 
TCCTCAAAAGTACAATTATATTTTTAAA
TATCAACAATAAGTAAAATAAAG 1 
4608419 + bf638r_3913 
two component 
regulatory systme 0 
TACAATAATTCTTTCCATAAAAATCAAA
TACAAAAACTATCTTTACAATAT  1/2 
4619354 + bf638r_3923 ubb 0 
TACTGTAATATATAATAATAAAGAAAA
ACAGATAACTTATATTTGTCCCAT 1 
4632883 - bf638r_3932 recQ 0 
CTAACAAAGTTATAAACAACTTCTTAA
ATATCAAGCATAATCAGACTAATA 1 
4634929 - bf638r_3934 clpP 0 
AACTGCAAAGAAACAAAAAAGAACAC
AGAGACACAAAAAAACACAGAGTTA  1/2 
4636439 - bf638r_3935 trigger factor 0 
GGGTGCAAAATTAGTGCTAATCTTTCA
AATTTCAAAAAACATTGCAGAATT 1 
4637475 + bf638r_3937 RNA binding protein 0 
AAAGAGAAAAAGTTATTGCAATTCCG
GTTTTTATGCGTTTCTTTGCTGCGG  1/2 
4638771 - bf638r_3938 ABC transport 0 
GCGGCAAATGTAGCAAAAATAAGCCG
AAAAAACGTACATTTGCAAACAAAT 1 























4653034 + bf638r_3947 
Methylenetetrahyd
rofolate reductase 0 
CAGGTTCTACAACGATTTCGTTTCATCT
TTTTTTCGTATTTTTGTCCCAAT 1 
4664440 - bf638r_3956 purH 0 
GCGCAAAGTTACGAAATATTGTTTATC
GTACGTAATAAATAAGGTGTGAAT 1 
4668598 - bf638r_3958 ABC transport 0 
GCAGCAAAGATACTCATTTATACAGAC
TGCGAAAAAAGAAACGGAATAAAT 1 
4671218 - bf638r_3959 Unkown fuction 0 
ATTTCAAATATAAACACATATTCTGAA
ATAAGCAACGAAAAGAATATAAAT 1 
4673013 - bf638r_3960 glycosytransferase 0 
GTTGCAAAAGTACAAAATAGAATGAA
GAATGAAGAACGAAGTATGAAGAAT 1 
4680045 - bf638r_3962 Unkown fuction 0 
GATACAAAGGAAACAAAATTTTCCGG
AAAAAGATTAAAGTGACGACGATTT  1/2 
4685872 - bf638r_3966 cyclophilin 0 
CTGCAAATATACGACTTTACCTCAAAA
CCTCTTACCTTTGTAGCTCACAAA 1 







unknown transcript 0 
ACTACAGGAACGTAAAATACGCCCTGT
TGGTTCAAACTCAGAAATTACTGT 0 
4687443 + bf638r_3969 unknown function 0 
CAGATTAGTTCACACGTATTCTTTTTGG
CACAAGATTTGGGAAATACTCAA  1/2 










4690526 + bf638r_3973 unknown function 0 
AAGATGTAAATTGTGGTGACTCTATGC
AATTAGTTACTATTTTTGTCCCGA 1 
4696773 + bf638r_3980 ABC transport 0 
ACATTGCCAATTCGGTTGTAATATTCA
TATATTTATCTACTTTTGTGGTGT 1 


























4725389 - bf638r_3997 cas1 0 
GTTGCAAAGATAGATAAAACCCATAA
AAAGAGAGGAGAATCTGCATGAAAT 1 





4738880 - bf638r_4007 hutU 0 
CTTCGCAATATAGAAAAAAGGTGGGA
ATCTACCAAGATTTCAGCAGATTTA 0 
4739687 - bf638r_4008 unknown 0 
GGCGGAAAGGTACACCTTTTAACGAA











4743127 - bf638r_4012 unknown 0 
GTCTGCAAATATAACAGATTATTCAGT
CCGACTGTTCACCTTCAAATGTTT 1 
4751778 - bf638r_4027 rpsN 0 
GTTACAAAGGTAATATTCATTCCGAGA
ATTCTGGTAATACTATCGATATTA 1 
4756629 - bf638r_4039 rplW 0 
GCTGACAAATATACATTTTTATTTGCTT
CTGGTAAAACTACAAGCAGTTTT 1 
4761422 - bf638r_4045 rpsL 0 
GCTGCAAAAATACGAATAATATTTGAA
TAATCAATGCACTACATCTTTTTT 1 
4762828 - bf638r_4048 unknown 0 
ATATAGGAACGCTGCAGGCACAGGAA
TGTTCGGTAAATAAAGAGGGAATTA 0 
4779516 - bf638r_4063 ribosomal protein 0 
GCCGCAAAATTACACATACTTTCTTTAT
TCACAAAACTTTCGGCAATTATT 1 
4784988 - bf638r_4067 gltX 0 
ATTTCTCAAAATCAATGCAAAAGGTAC
AGAAAGTAGTTATCTTTGGAGAGT 1 




GTTTTTTTTTGTACTTTTCGCAA  1/2 
4791982 - bf638r_4071 priA 0 
GAGGACAAAGATACAAAAAATCCCCG
ACGCAAGCGCCGGGGATTCGTTTAT 1 








4794538 - bf638r_4074 unknown 0 
GACGGGAAAGATACATATTATTACTGA
AACCGATGTACTACTATACCCTAA  1/2 
4796142 - bf638r_4075 aspA 0 
AATAACCAAACTTAAGCAATATTGTTT
TGAAAGCATACATATTCGCAATTT 1 




















4850609 - bf638r_4125 ATPase 0 
GCAAAGATAGGGAAATAGTTTATGAA
TCATATAAATTGCAACACAAATTTG 1 
4857615 - bf638r_4131 phage integrase 0 
GAGAAGCAAAGGTAATGTATTTTAGA
CAAACAAACCCAGTTTTTGAGAAGA 1 
4858053 - bf638r_4132 unknown 0 
CGGCAAAAGTATAATAAAATATTTCAC
TTGCAACTATTATTCCAAAATATT 1 
4859342 - bf638r_4134 unknown 0 
AACGCACAAAGATATATAAAACCATTT
GAGAAGTAAAGTGTTATATGCAAG 1 













4879513 - bf638r_4147 sigma factor 0 
GAATGCAAATATAGCTGTTTATTTGTT
AATAATACCAATCGGCATCTAATT 1 
































4895091 + bf638r_4159 
two component 
regulatory systme 
for cell autolysis 0 
AAAAGCCTTGGAGCGTAGGGAGTTTC
TCATCGGGTGTTGTCTTTATAGGAA 0 











4906398 - bf638r_4169 unknown 0 
GATACAAAGGTAAGTAGTTTATAATCA
TCTAGCAATAAGGTACTTCTATGT 1 
4906691 + bf638r_4170 Unknown 0 
TAAGTGACAAGGAAGAACAATATTGG
CCGGAACATCCTATCTTCGCAGGAA  1/2 
4911085 + bf638r_4174 unknown 0 
TCCGTTCTATATAATACAAAAGATCAA
TTAAATAGCTAATTTTGTATTCGG 1 




































4927859 - bf638r_4190 transposase 0 
GCCTAAAGATACAAAAACTTTGGGTAA
TAACAAAGCCCGGGCTTGTGAAAG 1 





4930194 + bf638r_4193 TonB-linked OMP 0 
GGTGTATCGGATATTTGTAAACTCCGA
ATATTGTCGTATATTTACATCCGT  1/2 















AGAATAAACCGTATTTTAGCAGAA  1/2 
4942141 - bf638r_4204 greA 0 
TCGCAAAGATAACCTTTTAAATGACAT
GTGTCAAGCAAAAAGCAATGCTAT 1 
4943403 - bf638r_4205 unknown 0 
GCTGCAAATATACTTCTTTTCAAGATTA
GTCAAAGCATTTTGCCGCGTTCT 1 





























AGTACATCATGGAATACTGAAAAAA  1/2 
4960242 + bf638r_4219 Laminarinase 0 
TCATTTCTACGGATGCAGGTAATTTCG
TTTTTTAATGTAAATTTGTGTCCT 1 
4962079 + bf638r_4221 Unknown 0 
AACCCTCCTATCTGACTCACCCTACAGT
GAAAATCATTAATTTTGAGGCTT 1 
4965410 - bf638r_4225 protease 0 
GTACAAAGATAACGGTTTTAATTGACT
ACCGCTTCGGTAGAAGAGCTATTT 1 







4972459 - bf638r_4230 
Two component 
regulatory System 0 
ACAGACAAAGGTAGTGCTTTATTAATG
AAAAAAGAAAAAATAAATGAACAA 1 
4972538 + bf638r_4231 Rubredoxin 0 
AAAAGAAAAAATAAATGAACAATACG
TCCGATACTTTTGTTATATTTGCAT 1 









TTATGTGATATATTTATCCGTAC  1/2 
4976476 + bf638r_4235 BaeS 0 
AAGAGGGGGAAATGAGAGGTTTCTAC
AAAGATTTTTTAACTTTGTCACTGT 1 
4980424 - bf638r_4236 unknown 0 
TATATTTTGAGTTATTAAATCTGAATAA
TAGCACATATACTGTCTCTTCCT 0 
4984080 - bf638r_4238 unknown 0 
AACGGACAAAAGTAGTGTATCGATGC
ATAAAAAACAAGAATTATCAGAAGA 1 





















5009116 - bf638r_4254 peptidase 0 
GACGTAAAAGTAACTCATTGCCTGCTT
ACTCTGACAGAACTTCGTTAATAT  1/2 














5036313 - bf638r_4269 suhB 0 
TTCGGCAAAGATAAATGATTCTTTTGA
AAAAACATTGCAGCATTCGGCATA 1 
5041092 - bf638r_4274 unknown 0 
GTATACAAAGATACATTTTCAATTTGA
AAAATCACTTAAAATCAATCATTT 1 





5066578 + bf638r_4300 unknown 0 
AAAGATTCCTGAAAGAGAGGTAAAAT
ACATAAAAACAAGTACTTTTGTCAA 1 
5071560 + bf638r_4302 topA 0 
TTCTCTCTATATTATAAGGTAAAGAAA
ACGTTTTTTTCTACTTTTGCGGGC 1 






5077479 - bf638r_4305 hup3 0 
CTCACAAATATAAAGTAACAAAACAAT
ATATCAAATAAAAACATCAAAAAA 1 
5077611 + bf638r_4306 unknown 0 
TAGATTATTTTTCTGTTGTAGAACAGA
ATTTATTCGTATTTTTGCGTTCAT 1 













5100923 + bf638r_4321 porA 0 
AATCAGAAAAGATTTTGTTAAGTCACT
TAACTTTGCGAACTTTGCCTGCCA  1/2 
5107036 - bf638r_4324 ugpQ 0 
AGCGGCAAAGATACACAAATCTCTCCT
TGCTTGTTTACCTTCAGAAAGCAT 1 




TTTGCAACGTTCAGTTTGCAGATA  1/2 
5108005 + bf638r_4326 pckA 0 
TTTCTCTAATATATTCTTTGTTTCCAAA
GAAAGCATTACTTTTGTAGTCGA 1 








5129750 + bf638r_4337 unknown 0 
AACGTCACATAGTCTGCACAAGATTCA
AGGTTTTTCTTTATCTTTGTGCAG 1 
5140713 - bf638r_4340 typA 0 
GCGACAAAGGTACAAAAATTGGATTA
GAAAAAAGGGATACTATAGAAAATA 1 
5140814 + bf638r_4341 rpsO 0 
TTTCCTGCAATTCATTGTGGGATAAAA
GATAATGCCTATCTTTGCACGCTC 1 
5141232 + bf638r_4342 
transcriptional 
repressor puuR 0 
TTTTATCTTTCTCCCTTGCTTGGATATA
AAATTTCATTAATTTTGCAGCAA 1 
5145212 - bf638r_4344 arcB 0 
ACTTGCAAATATAATACATATATCCAA
AAAATATCCTACAAATCGAAGTTA 1 
5158644 + bf638r_4354 sigma factor 0 
TTTTCGGCTTTTTTTCTGTTTTATAAATT
GAGTATGCTATATTTGTAATTC 1 





5163945 - bf638r_4360 aroQ 0 
GGTGCAAAGGTAGAAAAAAGAAATGA
AATTAGAGGAAAAAACAAAAAAGAA 1 
5163930 + bf638r_4361 xerD 0 
ATTTGTATCCTCATAACACAATCCTGCT
ATTTTTAATACCTTTGTCTTCGA 1 
5164953 + bf638r_4362 unknown 0 
AAAAAGCCGTTTCGGTAAACAATAGA
GGCTGATTTGGTGTTGTTTAAGAAG 1 
5178847 - bf638r_4371 unknown 0 
GGTTTCAAAATTACGGAAAAGAGTCAT
AATTCTGATAACTTTTAAGAAATA 1 
5209276 + bf638r_4408 unknown 0 
GAGCTGGAATGAAAACATGTGTTTTTG
AATAAATTTCGATTTTTGCAAAAT  1/2 


























5259326 - bf638r_4449 







5260928 - bf638r_4450 unknown 0 
TTCCAAAGATATATCGTTTTTTGCAATT
ATCCGGAGAAAATACAGCCTTTT 1 
5264408 + bf638r_4456 metG 0 
CATCCATCTTATTTATAAAGAATTCCTC
AGAAAGTCGTTATCTTTGCACGT 1 
5271471 + bf638r_4461 unknown 0 
TTATGCAGTAAAAATGGAGTACGACC
AAAAAGAATGATTATCTTTAGGCAG  1/2 






5274678 + bf638r_4464 Glycosyltransferase 0 
AATATGTGACTTTGTACGGTTTCTCAC
CGAAAACCACTACTTTTGCCAAAA 1 
5277774 + bf638r_4467 fklB 0 
TTTAAAACCAAAAAGTAAAATCATTCA
AATAAAACACTTACTTTTGCCGCT 1 








5282309 - bf638r_4472 
Two component 













5305199 - bf638r_4482 Sugar transporter 0 
GCAACAAAGATAAGACGCTTTTTTCAT
ATGTGCAAATATTTCTACATTATT 1 
5305317 + bf638r_4483 unknown 0 
ATCTCTTCTTCTTATATTCAGTGCACAG
AGCCAAAACAGTGTTTCAAAAAA 0 
5320761 - bf638r_4491 unknown 0 
GTGCCAAACATACAGATTGTTTTTGAC
ATAGCATAGATCGAAATCATTATA 1 
5320822 + bf638r_4492 
calcium/sodium:pro
ton antiporter 0 
ACAGATTGTTTTTGACATAGCATAGAT
CGAAATCATTATATTTGCACCCGA 1 
5321874 + bf638r_4493 unknown 0 
TTAGTTTTCGTACGTGGTAATTTAAAG
ATTATCACGTATCTTTGCCCCCTC 1 
5322922 + bf638r_4494 parE 0 
TTTTCCGATTTAATTCCGGTTTATCAAA
AATTAGGTTTTATCTTTGCAGAA 1 
5327728 - bf638r_4497 unknown 0 
CAGCAAAGATAGATTAAAAAGACAGA
GTTTTCGCAAAAAAAACCTATCTTT 1 














5337717 - bf638r_4504 TonB-linked OMP 0 
AGTCCGCAAAGGTACGTATATCGACAC
CGGACGACAATCACCATATTTAGG 1 










5345706 - bf638r_4512 unknown 0 
AGGTGCAAAGGTAGGGGTTTTTTCCG
TACTTTTGCAGCCAAATAATGAATA 1 





5348043 - bf638r_4514 unknown 0 
GCGAGCAAAGATACGACTTTTAGCAC
AATTAACGGACATTTGACGTGAATA 1 
5349803 - bf638r_4516 cation efflux pump 0 
GAGGGGCAAATGTACATGAAAATCTT
GAATTATTAATATTTAATCGCTTAC 1 
5349863 + bf638r_4517 ribonuclease R 0 
ATGTACATGAAAATCTTGAATTATTAA




5353979 + bf638r_4522 
Pyridoxamine 5'-
phosphate oxidase 0 
ATGCCCTGTTGCTGCACGGATATCTAA
AATAAATTTCCATCTTTGTAGTTC  1/2 
5356501 - bf638r_4524 Esterase/lipase 0 
TGGGCAAATATACTACAATAACGACAC
TGTTTGAAAAATAATGCGTTCCTT 1 
5356622 + bf638r_4525 unknown 0 
AGTATAGAGAAATAACTGTATTAATCC
CAATTTAATTACCTTTGTCAATAT 1 
5358148 + bf638r_4526 YchF 0 
GAGAAAGCAGATGACTGCATTAGCCT
AAAATTGATTATCTTTGCACCCCAA 1 
5359613 + bf638r_4527 apbA_panE 0 
CTCCCGGTTTTCTACTACTATCTTCAAG
CAAATCATTATCTTTGCGACCGG 1 























5365389 + bf638r_4531 unknown 0 
TTGGTCGGTTAATGATTTCCCGATAAT











5366760 + bf638r_4532 leuS 0 
TTTAGCTATCTTCGTGGTTATCTGAAA
ATAATCATGTAAATTTGCTCCCTC 1 
5372929 - bf638r_4535 nadA 0 
AAAGTGCAAAGTTAAAAACTTTATGGA
TATAAACAGGCTAATTAGTACTGA 1 
Appendix 4: INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE 
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